U.S. patent application number 15/588933 was filed with the patent office on 2017-11-30 for natural igm antibodies and inhibitors thereof.
The applicant listed for this patent is The Brigham and Women`s Hospital, Inc., Children's Medical Center Corporation, President and Fellows of Harvard College. Invention is credited to Michael C. Carroll, Herbert B. Hechtman, Francis D. Moore, JR..
Application Number | 20170342109 15/588933 |
Document ID | / |
Family ID | 34922704 |
Filed Date | 2017-11-30 |
United States Patent
Application |
20170342109 |
Kind Code |
A1 |
Carroll; Michael C. ; et
al. |
November 30, 2017 |
Natural IGM Antibodies and Inhibitors Thereof
Abstract
The invention provides natural IgM antibody inhibitors that may
be used to treat various inflammatory diseases or disorders.
Inventors: |
Carroll; Michael C.;
(Wellesley, MA) ; Moore, JR.; Francis D.;
(Medfield, MA) ; Hechtman; Herbert B.; (Chestnut
Hill, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Children's Medical Center Corporation
President and Fellows of Harvard College
The Brigham and Women`s Hospital, Inc. |
Boston
Cambridge
Boston |
MA
MA
MA |
US
US
US |
|
|
Family ID: |
34922704 |
Appl. No.: |
15/588933 |
Filed: |
May 8, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13859054 |
Apr 9, 2013 |
9657060 |
|
|
15588933 |
|
|
|
|
12259767 |
Oct 28, 2008 |
|
|
|
13859054 |
|
|
|
|
11069834 |
Mar 1, 2005 |
7442783 |
|
|
12259767 |
|
|
|
|
60588648 |
Jul 16, 2004 |
|
|
|
60549123 |
Mar 1, 2004 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 39/00 20130101;
A61P 43/00 20180101; A61K 2039/57 20130101; A61K 38/00 20130101;
C07K 7/08 20130101; C07K 16/00 20130101; C07K 16/18 20130101; C07K
2317/52 20130101; A61P 9/10 20180101; A61P 29/00 20180101; C07K
16/28 20130101; C07K 2317/34 20130101; A61K 2039/505 20130101 |
International
Class: |
C07K 7/08 20060101
C07K007/08; C07K 16/28 20060101 C07K016/28; C07K 16/00 20060101
C07K016/00; C07K 16/18 20060101 C07K016/18 |
Goverment Interests
1. GOVERNMENT SUPPORT
[0002] This invention was made with government support under grant
No. GM52585, GM24891, and GM07560 from the National Institutes of
Health. The government has certain rights in the invention.
Claims
1.-47. (canceled)
48. An inhibitor of natural IgM antibodies, wherein the inhibitor
is an isolated antibody or antigen-binding fragment thereof that
inhibits binding of a natural IgM antibody to a self-antigen.
49. The inhibitor of claim 48, wherein the antibody or
antigen-binding fragment thereof inhibits complement
activation.
50. The inhibitor of claim 48, wherein the natural IgM antibody is
a pathogenic antibody.
51. The inhibitor of claim 48, wherein the inhibitor is an isolated
antibody or antigen-binding fragment thereof that competes with
natural IgMs in binding to the self-antigen.
52. The inhibitor of claim 51, wherein the isolated antibody or
antigen-binding fragment thereof blocks binding of a natural IgM
antibody to a self-antigen and inhibits complement activation.
53. The inhibitor of claim 51, wherein the self-antigen comprises
the amino acid sequence of SEQ ID NO:38.
54. The inhibitor of claim 51, wherein the antibody inhibits the
binding of natural IgM antibody IgM.sup.CM-22 to the amino acid
sequence of SEQ ID NO:38.
55. The inhibitor of claim 51, wherein the antibody is a monoclonal
antibody.
56. The inhibitor of claim 55, wherein the antibody is selected
from the group consisting chimeric, CDR-grafted, and humanized
antibodies.
57. The inhibitor of claim 48, wherein the inhibitor is an
antigen-binding fragment.
58. The inhibitor of claim 57, wherein antigen binding fragment is
a Fab fragment, a F(ab').sub.2 fragment, or scFv fragment.
59. The inhibitor of claim 48, wherein the antibody comprises an
antigen-binding fragment of natural IgM antibody IgM.sup.CM-22.
60. A method of for treating an inflammatory condition in a subject
in need thereof comprising administering to said subject an
effective amount of the antibody of claim 48.
61. The method of claim 60, wherein the inflammatory condition is
selected from the group consisting of reperfusion injury, ischemia
injury, stroke, autoimmune hemolytic anemia, idiopathic
thrombocytopenic purpura, rheumatoid arthritis, celiac disease,
hyper-IgM immunodeficiency, arteriosclerosis, coronary artery
disease, sepsis, myocarditis, encephalitis, transplant rejection,
hepatitis, thyroiditis, osteoporosis, polymyositis,
dermatomyositis, Type I diabetes, gout, dermatitis, alopecia
areata, systemic lupus erythematosus, lichen sclerosis, ulcerative
colitis, diabetic retinopathy, pelvic inflammatory disease,
periodontal disease, arthritis, juvenile chronic arthritis,
psoriasis, osteoporosis, nephropathy in diabetes mellitus, asthma,
pelvic inflammatory disease, chronic inflammatory liver disease,
chronic inflammatory lung disease, lung fibrosis, liver fibrosis,
rheumatoid arthritis, chronic inflammatory liver disease, chronic
inflammatory lung disease, lung fibrosis, liver fibrosis, Crohn's
disease, ulcerative colitis, burn injury, and other acute and
chronic inflammatory diseases of the Central Nervous System,
gastrointestinal system, the skin and associated structures, the
immune system, the hepato-biliary system, or any site in the body
where pathology can occur with an inflammatory component.
62. The method of claim 61, wherein the inflammatory condition is
reperfusion injury or ischemia injury.
63. The method of claim 62, wherein the reperfusion or ischemic
injury follows a naturally occurring episode.
64. The method of claim 63, wherein the naturally occurring episode
is stroke or myocardial infarction.
65. The method of claim 63, wherein the reperfusion or ischemic
injury follows a surgical procedure.
66. The use of claim 65, wherein the surgical procedure is selected
from the group consisting of angioplasty, stenting procedure,
atherectomy, and bypass surgery.
67. The method of claim 62, wherein the reperfusion or ischemic
injury occurs in a cardiovascular tissue.
68. The inhibitor of claim 48, wherein the antibody or
antigen-binding fragment is an IgG.
69. A pharmaceutical composition comprising the inhibitor of claim
48, and a pharmaceutically acceptable excipient.
70. A pharmaceutical composition comprising the inhibitor of claim
51, and a pharmaceutically acceptable excipient.
Description
2. CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 13/859,054, filed on Apr. 9, 2013, which is a continuation of
U.S. application Ser. No. 12/259,767, filed on Oct. 28, 2008, which
is a continuation of U.S. application Ser. No. 11/069,834, filed on
Mar. 1, 2005, which claims the benefit of prior U.S. Provisional
Application No. 60/588,648, filed on Jul. 16, 2004 and U.S.
Provisional Application No. 60/549,123, filed on Mar. 1, 2004; the
content of each of these applications is specifically incorporated
by reference herein.
3. BACKGROUND
[0003] Nucleated cells are highly sensitive to hypoxia and even
short periods of ischemia in multi-cellular organisms can have
dramatic effects on cellular morphology, gene transcription, and
enzymatic processes. Mitochondria, as the major site of oxygen
metabolism, are particularly sensitive to changes in oxygen levels
and during hypoxia release reactive oxygen species that chemically
modify intracellular constituents such as lipids and proteins.
Clinically these effects manifest as an inflammatory response in
the patient. Despite intensive investigations of cellular responses
to hypoxia little is known regarding the initiation of acute
inflammation.
[0004] Acute inflammatory responses can result from a wide range of
diseases and naturally occurring events such as stroke and
myocardial infarction. Common medical procedures can also lead to
localized and systemic inflammation. Left untreated inflammation
can result in significant tissue loss and may ultimately lead to
multi-system failure and death. Interfering with the inflammatory
response after injury may be one method to reduce tissue loss.
[0005] Inflammatory diseases and acute inflammatory responses
resulting from tissue injury, however, cannot be explained by
cellular events alone. Accumulating evidence supports a major role
for the serum innate response or complement system in inflammation.
Studies to date have looked at tissue injury resulting from
ischemia and reperfusion as one type of inflammatory disorder that
is complement dependent. For example, in the rat myocardial model
of reperfusion injury, pretreatment of the rats with the soluble
form of the complement type 1 receptor dramatically reduced injury.
Understanding how complement activation contributes to an
inflammatory response is an area of active investigation.
[0006] Inflammatory diseases or disorders are potentially
life-threatening, costly, and affect a large number of people every
year. Thus, effective treatments of inflammatory diseases or
disorders are needed.
4. SUMMARY OF THE INVENTION
[0007] In one aspect, the invention features isolated natural
immunoglobulins (IgMs). In one embodiment, the antibody is produced
by ATCC Accession Number PTA-3507. In another embodiment, the
antibody has a light chain variable region comprising the amino
acid sequence shown as SEQ ID NO: 8. In yet another embodiment, the
antibody has a heavy chain variable region comprising the amino
acid sequence shown as SEQ ID NO: 2.
[0008] In another aspect, the invention features IgM inhibitors and
pharmaceutical preparations thereof. In one embodiment, the IgM
inhibitor is a peptide that specifically binds to a natural IgM and
thereby blocks binding to the antigen and/or complement activation.
In one embodiment, the peptide includes the following consensus
sequence: xNNNxNNxNNNN (SEQ ID NO: 14). Certain inhibitory peptides
are provided as SEQ ID NOs: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,
36, and 38. Inhibitory peptides may be modified, for example to
increase in vivo half-life or bioavailability. Inhibitory peptides
may also be labeled to facilitate detection.
[0009] In another aspect, the invention features nucleic acids
encoding peptides that specifically bind to natural IgM antibodies,
as well as vectors and host cells for expressing the peptides.
Certain nucleic acids are provided as SEQ ID NOs: 13, 15, 17, 19,
21, 23, 25, 27, 29, 31, 33, 35 and 37.
[0010] In a further aspect, the invention features methods of
treating an inflammatory disease in a subject by administering to
the subject a pharmaceutical composition comprising an IgM
inhibitor as disclosed herein.
[0011] In yet other aspects, the invention features method of
detecting, diagnosing or monitoring inflammatory diseases in a
subject using labeled inhibitory antibodies.
[0012] Other features and advantages of the invention will be
apparent based on the following Detailed Description and
Claims.
5. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIGS. 1A-1B show an IgM heavy chain sequence of B-1
hybridoma22A5. (FIG. 1A) shows the IgM.sup.CM-22 (or 22A5 IgM)
heavy chain nucleic acid sequence (SEQ ID NO: 1) and (FIG. 1B)
shows the amino acid sequence corresponding to the heavy chain
sequence of SEQ ID NO: 1 (SEQ ID NO: 2). Framework regions (FVWR)
and complementarity-determining regions (CDR) are indicated above
the nucleotides.
[0014] FIGS. 2A-2B show an IgM light chain sequence of B-1
hybridoma 22A5. (FIG. 2A) shows the IgM.sup.CM-22 (or 22A5 IgM)
light chain nucleic acid sequence (SEQ ID NO: 7) and (FIG. 2B)
shows the amino acid sequence corresponding to the light chain
sequence of SEQ ID NO: 7 (SEQ ID NO: 8). Framework-regions (FVWR)
and complementarity-determining regions (CDR) are indicated above
the nucleotides.
[0015] FIG. 3 is a bar graph depicting changes in intestinal
permeability of inbred mice after intestinal ischemia and
reperfusion or no injury (sham). WT represents parent strain for
Cr2-/- mice Cr2-/- was reconstituted with pooled IgG or IgM or
saline control. Pooled IgM or IgG (0.5 mg) was administered
intravenously approximately 1 hour before treatment. Values are
means+standard error; n equals the number of mice in experimental
groups.
[0016] FIG. 4 demonstrates reconstitution of I/R injury in antibody
deficient mice (RAG-1) by pooled IgM from a single B-1 cell
hybridoma clone. IgM or saline was injected intravenously 30
minutes before initial laparotomy. At the end of reperfusion, blood
is obtained and permeability index is calculated as the ratio of
.sup.125I counts of dried intestine versus that of blood. Values
represent means.+-.standard error; n equals the numbers of mice
used in experimental groups. 1=WT plus normal saline; 2=RAG plus
normal saline; 3=RAG plus IgM hybridoma CM-22; 4=WT sham
control.
[0017] FIG. 5 is a schematic diagram of the proposed role for
complement and complement receptors in positive selection of
peritoneal B-1 lymphocytes.
[0018] FIG. 6A is a graph showing the ELISA screening of M-13
phage-display library for IgM.sup.CM-22-specific peptides. Symbols:
.quadrature.-P1 clone; X-P2 clone, .smallcircle.-P7 clone;
.diamond.-P8 clone. The plate was coated with a solution of
IgM.sup.CM-22 before addition of varying concentrations of
phage-clones. The results are representative of at least three
independent experiments.
[0019] FIG. 6B is a bar graph showing that the synthetic peptide P8
inhibits IgM.sup.CM-22 binding of phage clone P8. ELISA was
performed with varying concentrations of the synthetic peptide P8
added to the IgM.sup.CM-22-coated plate prior to the addition of
5.times.10.sup.11 PFU phage. The results are representative of at
least three independent experiments.
[0020] FIG. 6C is a bar graph showing specific binding of the PS
peptide to IgM.sup.CM-22. The ELISA plates were coated with 50
.mu.g/ml solution of P8 peptide, followed by addition of
IgM.sup.CM-22 or IgM.sup.CM-75 at 1 or 10 .mu.g/ml. IgM binding was
detected with a biotinylated rat anti-mouse IgM followed by
streptavidin-phosphatase and color reaction. The results are
representative of at least three independent experiments.
[0021] FIG. 7A is a series of photomicrographs showing that the P8
peptide blocked IgM.sup.CM-22 mediated injury in vivo. Two upper
panels (i and ii) are representative sections (stained with
Haematoxylin and Eosin) prepared following RI treatment in
RAG-1.sup.-/- mice with IgM.sup.CM-22 alone or mixed with P8
peptide, respectively. Two lower panels (iii and iv) are
representative sections prepared from wild type mice treated for
intestinal reperfusion injury, which received either saline or
peptide P8 5 minutes prior to reperfusion. Arrows indicate
pathologic features of injury. Magnification 200.times..
[0022] FIG. 7B is a scatter plot indicating the mean pathology
score of each group of treated animals. Each symbol represents the
score from one animal. Control group is WT mice pretreated with a
control peptide (ACGMPYVRIPTA; SEQ ID NO: 61) at a similar dose as
the peptide P8. *indicates statistical significance determined by
Student t test of the P8-treated versus untreated groups
(p<0.05).
[0023] FIG. 8A is an immunoblot showing the immune precipitation of
reperfusion injury (RI) specific antigens. Detection of a unique
band (arrow) at approximately 250 kDa on a SDS-PAGE (10%). Size
markers are indicated on the left. Intestinal lysates were prepared
from RAG.sup.-/- mice reconstituted with IgM.sup.CM-22 and either
sham control (no ischemia) or subjected to ischemia followed by
reperfusion for 0 or 15 min.
[0024] FIG. 8B is a series of graphs showing results of in vitro
binding assays of IgM.sup.CM-22 to the isoforms of non-muscle
myosin heavy chain-II ELISA plates were coated with monoclonal
antibodies for 3 different isoforms of NMHC-II (upper left: isoform
A, upper right: isoform B, lower left: isoform C and lower right:
anti-pan myosin antibody). Bound myosin heavy chain from intestinal
lysates was detected by IgM.sup.CM-22 or IgM.sup.CM-31. The results
represent mean.+-.standard error of OD 405 nm units and are
representative of triplicate samples.
[0025] FIG. 8C is a photomicrograph and a scatter plot showing the
restoration of RI injury by anti-pan myosin antibody in RAG.sup.-/-
mice. RAG-1.sup.-/- mice were reconstituted with affinity purified
anti-pan myosin followed by RI surgery. The left panels represents
morphologies of RAG.sup.-/- animals with saline control and with
anti-pan myosin treatment. The right panel is the pathology scores
of intestinal injury. The scatter plot (right panel) represents the
pathology scores where each symbol represents a single animal.
[0026] FIG. 9A is a graph showing the surface plasmon resonance for
the self-peptide N2. Binding isotherms for samples of the
self-peptide N2 with concentration from 10.5 .mu.M to 120 .mu.M
injected over the IgM.sup.CM-22-coupled surface.
[0027] FIG. 9B is a graph showing the surface plasmon resonance for
a control peptide. Binding isotherm for a same-length,
random-sequence control peptide (AGCMPYVRIPTA; SEQ ID NO: 62),
injected at a concentration of 117 .mu.M over the
IgM.sup.CM-22-coupled surface.
[0028] FIG. 9C is a graph showing the nonlinear curve fitting with
a 1:1 Langmuir binding isotherm to the steady-state response levels
for the injection showed in FIG. 9A (X.sup.2=10).
[0029] FIG. 9D is a graph showing the binding isotherm for the
injection of the self-peptide N2 at 120 .mu.M over a surface
coupled with the control IgM.sup.CM-31.
[0030] FIG. 10A is a series of photomicrographs showing that the N2
self-peptide blocking RI in RAG.sup.-/- mice. Two upper panels show
representative sections prepared following RI treatment in
RAG.sup.-/- mice with IgM.sup.CM-22 alone or mixed with N2
self-peptide. Two lower panels are representative sections prepared
from WT mice treated for intestinal RI, which received either
saline or N2 peptide 5 minutes prior to reperfusion.
[0031] FIG. 10B is a scatter plot indicating the mean pathology
score of each group of treated animals. Each symbol represents a
single mouse. * indicates a statistical significance bases on a
Student t test.
6. DETAILED DESCRIPTION
6.1 Definitions
[0032] For convenience, certain terms employed in the
specification, examples, and appended claims are provided. Unless
defined otherwise, all technical and scientific terms used herein
have the same meaning as commonly understood by one of ordinary
skill in the art to which this invention belongs.
[0033] "A" and "an" are used herein to refer to one or to more than
one (i.e., to at least one) of the grammatical object of the
article. By way of example, "an element" means one element or more
than one element.
[0034] "Amino acid" is used herein to refer to either natural or
synthetic amino acids, including glycine and D or L optical
isomers, and amino acid analogs and peptidomimetics.
[0035] "Antibody" is used herein to refer to binding molecules
including immunoglobulin molecules and immunologically active
portions of immunoglobulin molecules, i.e., molecules that contain
an antigen-binding site. Immunoglobulin molecules, useful in the
invention can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA)
or subclass. Native antibodies and immunoglobulins are usually
heterotetrameric glycoproteins of about 150,000 daltons, composed
of two identical light chains and two identical heavy chains. Each
heavy chain has at one end a variable domain followed by a number
of constant domains. Each light chain has a variable domain at one
end and a constant domain at its other end. Antibodies include, but
are not limited to, polyclonal, monoclonal, bispecific, chimeric,
partially or fully humanized antibodies, fully human antibodies
(i.e., generated in a transgenic mouse expressing human
immunoglobulin genes), camel antibodies, and anti-idiotypic
antibodies. An antibody, or generally any molecule, "binds
specifically" to an antigen (or other molecule) if the antibody
binds preferentially to the antigen, and, e.g., has less than about
30%, preferably 20%, 10%, or I % cross-reactivity with another
molecule. The terms "antibody" and "immunoglobulin" are used
interchangeably.
[0036] "Antibody fragment" or "antibody portion" are used herein to
refer to any derivative of an antibody which is less than
full-length. In exemplary embodiments, the antibody fragment
retains at least a significant portion of the full-length
antibody's specific binding ability. Examples of antibody fragments
include, but are not limited to, Fab, Fab', F(ab').sub.2, scFv, Fv,
dsFv diabody, minibody, Fd fragments, and single chain antibodies.
The antibody fragment may be produced by any means. For instance,
the antibody fragment may be enzymatically or chemically produced
by fragmentation of an intact antibody, it may be recombinantly
produced from a gene encoding the partial antibody sequence, or it
may be wholly or partially synthetically produced. The antibody
fragment may optionally be a single chain antibody fragment.
Alternatively, the fragment may comprise multiple chains which are
linked together, for instance, by disulfide linkages. The fragment
may also optionally be a multimolecular complex. A functional
antibody fragment will typically comprise at least about 50 amino
acids and more typically will comprise at least about 200 amino
acids.
[0037] "Antigen-binding site" is used herein to refer to the
variable domain of a heavy chain associated with the variable
domain of a light chain.
[0038] "Bind" or "binding" are used herein to refer to detectable
relationships or associations (e.g. biochemical interactions)
between molecules.
[0039] "Cells," "host cells" or "recombinant host cells" are terms
used interchangeably herein. It is understood that such terms refer
not only to the particular subject cell but to the progeny or
potential progeny of such a cell. Because certain modifications may
occur in succeeding generations due to either mutation or
environmental influences, such progeny may not, in fact, be
identical to the parent cell, but are still included within the
scope of the term as used herein.
[0040] "Comprise" and "comprising" are used in the inclusive, open
sense, meaning that additional elements may be included.
[0041] "Consensus sequence" is used herein to refer to the sequence
formed from the most frequently occurring amino acids (or
nucleotides) in a family of related sequences (See. e.g. Winnaker,
From Genes to Clones, 1987). In a family of proteins, each position
in the consensus sequence is occupied by the amino acid occurring
most frequently at that position in the family. If two amino acids
occur equally frequently, either can be included in the consensus
sequence. A "consensus framework" refers to the framework region in
the consensus immunoglobulin sequence.
[0042] A "conservative amino acid substitution" is one in which the
amino acid residue is replaced with an amino acid residue having a
similar side chain. Families of amino acid residues having similar
side chains have been defined in the art. These families include
amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains
(e.g., threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a
predicted nonessential amino acid residue in a natural
immunoglobulin can be preferably replaced with another amino acid
residue from the same side chain family. Alternatively, in another
embodiment, mutations can be introduced randomly along all or part
of a natural immunoglobulin coding sequence, such as by saturation
mutagenesis, and the resultant mutants can be screened for
biological activity.
[0043] "Detectable label" is used herein to refer to a molecule
capable of detection, including, but not limited to, radioactive
isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme
substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions,
ligands (e.g., biotin or haptens) and the like. "Fluorophore"
refers to a substance or a portion thereof which is capable of
exhibiting fluorescence in the detectable range. Particular
examples of labels which may be used under the invention include
fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol,
NADPH, beta-galactosidase, and horseradish peroxidase.
[0044] "Inhibitor" or "IgM inhibitor" or "antagonist" as used
herein refers to an agent that reduces or blocks (completely or
partially) an interaction between a natural antibody and another
molecule involved in an inflammatory cascade. An inhibitor may
antagonize one or more of the following activities of a natural
IgM: (i) inhibit or reduce an interaction (e.g., binding) between
the IgM and an ischemia-specific antigen; (ii) inhibit or reduce an
interaction (e.g., binding) between the natural IgM and a component
of the complement pathway, e.g., C1q; (iii) neutralize the natural
IgM by, e.g., sequestering the immunoglobulin and/or targeting its
degradation; or (iv) inhibit or reduce production of the natural
IgM e.g., blocks synthesis, assembly, and/or posttranslational
modifications of the IgM. The inhibitor can be a protein or a
peptide, an antibody or fragment thereof (e.g., an anti-idiotypic
antibody), a modified antibody, a carbohydrate, a glycoprotein, or
a small organic molecule.
[0045] "Interaction" refers to a physical association between two
or more molecules, e.g. binding. The interaction may be direct or
indirect.
[0046] "Inflammatory disease" is used herein to refer to a disease
or disorder that is caused or contributed to by a complicated set
of functional and cellular adjustments involving acute or chronic
changes in microcirculation, movement of fluids, and influx and
activation of inflammatory cells (e.g., leukocytes) and complement,
and included autoimmune diseases. Examples of such diseases and
conditions include, but are not limited to: reperfusion injury,
ischemia injury, stroke, autoimmune hemolytic anemia, idiopathic
thrombocytopenic purpura, rheumatoid arthritis, celiac disease,
hyper-IgM immunodeficiency, arteriosclerosis, coronary artery
disease, sepsis, myocarditis, encephalitis, transplant rejection,
hepatitis, thyroiditis (e.g. Hashimoto's thyroiditis, Graves
disease), osteoporosis, polymyositis, dermatomyositis, Type I
diabetes, gout, dermatitis, alopecia areata, systemic lupus
erythematosus, lichen sclerosis, ulcerative colitis, diabetic
retinopathy, pelvic inflammatory disease, periodontal disease,
arthritis, juvenile chronic arthritis (e.g. chronic iridocyclitis),
psoriasis, osteoporosis, nephropathy in diabetes mellitus, asthma,
pelvic inflammatory disease, chronic inflammatory liver disease,
chronic inflammatory lung disease, lung fibrosis, liver fibrosis,
rheumatoid arthritis, chronic inflammatory liver disease, chronic
inflammatory lung disease, lung fibrosis, liver fibrosis, Crohn's
disease, ulcerative colitis, burns, and other acute and chronic
inflammatory diseases of the Central Nervous System (CNS; e.g.
multiple sclerosis), gastrointestinal system, the skin and
associated structures, the immune system, the hepato-biliary
system, or any site in the body where pathology can occur with an
inflammatory component.
[0047] An "isolated" molecule, e.g., an isolated IgM, refers to a
condition of being separate or purified from other molecules
present in the natural environment.
[0048] "Natural IgM" is used herein to refer to an IgM antibody
that is naturally produced in a mammal (e.g., a human). They have a
pentameric ring structure wherein the individual monomers resemble
IgGs thereby having two light (.kappa. or .lamda.) chains and two
heavy (.mu.) chains. Further, the heavy chains contain an
additional C.sub.H4 domain. The monomers form a pentamer by
disulfide bonds between adjacent heavy chains. The pentameric ring
is closed by the disulfide bonding between a J chain and two heavy
chains. Because of its high number of antigen binding sites, a
natural IgM antibody is an effective agglutinator of antigen.
Production of natural IgM antibodies in a subject are important in
the initial activation of B-cells, macrophages, and the complement
system. IgM is the first immunoglobulin synthesized in an antibody
response.
[0049] "Nucleic acid" is used herein to refer to polynucleotides
such as deoxyribonucleic acid (DNA), and, where appropriate,
ribonucleic acid (RNA). The term should also be understood to
include, as equivalents, analogs of either RNA or DNA made from
nucleotide analogs, and, as applicable to the embodiment being
described, single (sense or antisense) and double-stranded
polynucleotides.
[0050] "Operatively linked" is used herein to refer to a
juxtaposition wherein the components so described are in a
relationship permitting them to function in their intended manner.
For example, a coding sequence is "operably linked" to another
coding sequence when RNA polymerase will transcribe the two coding
sequences into a single mRNA, which is then translated into a
single polypeptide having amino acids derived from both coding
sequences. The coding sequences need not be contiguous to one
another so long as the expressed sequences ultimately process to
produce the desired protein. An expression control sequence
operatively linked to a coding sequence is ligated such that
expression of the coding sequence is achieved under conditions
compatible with the expression control sequences. As used herein,
the term "expression control sequences" refers to nucleic acid
sequences that regulate the expression of a nucleic acid sequence
to which it is operatively linked. Expression control sequences are
operatively linked to a nucleic acid sequence when the expression
control sequences control and regulate the transcription and, as
appropriate, translation of the nucleic acid sequence. Thus,
expression control sequences can include appropriate promoters,
enhancers, transcription terminators, a start codon (i.e., ATG) in
front of a protein-encoding gene, splicing signals for introns,
maintenance of the correct reading frame of that gene to permit
proper translation of the mRNA, and stop codons. The term "control
sequences" is intended to include, at a minimum, components whose
presence can influence expression, and can also include additional
components whose presence is advantageous, for example, leader
sequences and fusion partner sequences. Expression control
sequences can include a promoter.
[0051] "Patient", "subject" or "host" are used herein to refer to
either a human or a non-human mammal.
[0052] "Peptide" is used herein to refer to a polymer of amino
acids of relatively short length (e.g. less than 50 amino acids).
The polymer may be linear or branched, it may comprise modified
amino acids, and it may be interrupted by non-amino acids. The term
also encompasses an amino acid polymer that has been modified; for
example, disulfide bond formation, glycosylation, lipidation,
acetylation, phosphorylation, or any other manipulation, such as
conjugation with a labeling component.
[0053] "Promoter" is used herein to refer to a minimal sequence
sufficient to direct transcription. Also included in the invention
are those promoter elements which are sufficient to render
promoter-dependent gene expression controllable for cell-type
specific, tissue-specific, or inducible by external signals or
agents; such elements may be located in the 5' or 3' regions of the
of a polynucleotide sequence. Both constitutive and inducible
promoters, are included in the invention (see e.g., Bitter et al.,
Methods in Enzymology 153:516-544, 1987). For example, when cloning
in bacterial systems, inducible promoters such as pL of
bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the
like may be used. When cloning in mammalian cell systems, promoters
derived from the genome of mammalian cells (e.g., metallothionein
promoter) or from mammalian viruses (e.g., the retrovirus long
terminal repeat; the adenovirus late promoter; the vaccinia virus
7.5K promoter) may be used. Promoters produced by recombinant DNA
or synthetic techniques may also be used to provide for
transcription of the nucleic acid sequences of the invention.
Tissue-specific regulatory elements may be used. Including, for
example, regulatory elements from genes or viruses that are
differentially expressed in different tissues.
[0054] "Specifically binds" is used herein to refer to the
interaction between two molecules to form a complex that is
relatively stable under physiologic conditions. The term is used
herein in reference to various molecules, including, for example,
the interaction of an antibody and an antigen (e.g. a peptide).
Specific binding can be characterized by a dissociation constant of
at least about 1.times.10.sup.-6 M, generally at least about
1.times.10.sup.-7 M, usually at least about 1.times.10.sup.-8 M,
and particularly at least about 1.times.10.sup.-9 M or
1.times.10.sup.-10 M or greater. Methods for determining whether
two molecules specifically bind are well known and include, for
example, equilibrium dialysis, surface plasmon resonance, and the
like.
[0055] "Stringency hybridization" or "hybridizes under low
stringency, medium stringency, high stringency, or very high
stringency conditions" is used herein to describe conditions for
hybridization and washing. Guidance for performing hybridization
reactions can be found in Current Protocols in Molecular Biology,
John Wiley & Sons, N.Y. (1989), 6.3.1-6:3.6, which is
incorporated by reference. Aqueous and non-aqueous methods are
described in that reference and either can be used. Specific
hybridization conditions referred to herein are as follows: 1) low
stringency hybridization conditions in 6.times. sodium
chloride/sodium citrate (SSC) at about 45.degree. C., followed by
two washes in 0.2.times.SSC, 0.1% SDS at least at 50.degree. C.
(the temperature of the washes can be increased to 55.degree. C.
for low stringency conditions); 2) medium stringency hybridization
conditions in 6.times.SSC at about 45.degree. C., followed by one
or more washes in 0.2.times.SSC, 0.1% SDS at 60.degree. C.; 3) high
stringency hybridization conditions in 6.times.SSC at about
45.degree. C., followed by one or more washes in 0.2.times.SSC,
0.1% SDS at 65.degree. C.; and preferably 4) very high stringency
hybridization conditions are 0.5M sodium phosphate, 7% SDS at
65.degree. C., followed by one or more washes at 0.2.times.SSC, 1%
SDS at 65.degree. C. Very high stringency conditions (4) are the
preferred conditions and the ones that should be used unless
otherwise specified. Calculations of homology or sequence identity
between sequences (the terms are used interchangeably herein) are
performed as follows.
[0056] To determine the percent identity of two amino acid
sequences, or of two nucleic acid sequences, the sequences are
aligned for optimal comparison purposes (e.g., gaps can be
introduced in one or both of a first and a second amino acid or
nucleic acid sequence for optimal alignment and non-homologous
sequences can be disregarded for comparison purposes). In a
preferred embodiment, the length of a reference sequence aligned
for comparison purposes is at least 30%, preferably at least 40%,
more preferably at least 50%, 60%, and even more preferably at
least 70%, 80%, 90%, 100% of the length of the reference sequence.
The amino acid residues or nucleotides at corresponding amino acid
positions or nucleotide positions are then compared. When a
position in the first sequence is occupied by the same amino acid
residue or nucleotide as the corresponding position in the second
sequence, then the molecules are identical at that position.
[0057] The percent identity between the two sequences is a function
of the number of identical positions shared by the sequences and
the percent homology between two sequences is a function of the
number of conserved positions shared by the sequences, taking into
account the number of gaps, and the length of each gap, which need
to be introduced for optimal alignment of the two sequences. The
comparison of sequences and determination of percent identity
and/or homology between two sequences can be accomplished using a
mathematical algorithm. In a preferred embodiment, the percent
identity between two amino acid sequences is determined using the
Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm
which has been incorporated into the GAP program in the GCG
software package (available on the world wide web with the
extension gcg.com), using either a Blossum 62 matrix or a PAM250
matrix, and a gap weight o (16, 14, 12, 10, 8, 6, or 4 and a length
weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment,
the percent identity between two nucleotide sequences is determined
using the GAP program in the GCG software package (available on the
world wide web with the extension gcg.com), using a NWSgapdna CMP
matrix and a gap weight of 40, 50, 60, 70; or 80 and a length
weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of
parameters (and the one that should be used unless otherwise
specified) are a Blossum 62 scoring matrix with a gap penalty of
12, a gap extend penalty of 4, and a frame shift gap penalty of
5.
[0058] The percent identity and/or homology between two amino acid
or nucleotide sequences can be determined using the algorithm of E.
Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been
incorporated into the ALIGN program (version 2.0), using a PAM120
weight residue table, a gap length penalty of 12 and a gap penalty
of 4.
[0059] "Treating" is used herein to refer to any treatment of, or
prevention of, or inhibition of a disorder or disease in a subject
and includes by way of example: (a) preventing the disease or
disorder from occurring in a subject that may be predisposed to the
disease or disorder, but has not yet been diagnosed as having it;
(b) inhibiting the disease or disorder, i.e., arresting its
progression; or (c) relieving or ameliorating the disease or
disorder, i.e., causing regression. Thus, treating as used herein
includes, for example, repair and regeneration of damaged or
injured tissue or cells at the site of injury or prophylactic
treatments to prevent damage, e.g., before surgery.
[0060] "Vector" as used herein refers to a nucleic acid molecule,
which is capable of transporting another nucleic acid to which it
has been operatively linked and can include a plasmid, cosmid, or
viral vector. One type of preferred vector is an episome, i.e., a
nucleic acid capable of extra-chromosomal replication. Preferred
vectors are those capable of autonomous replication and/or
expression of nucleic acids to which they are linked. Vectors may
be capable of directing the expression of genes to which they are
operatively linked. A vector may also be capable of integrating
into the host DNA. In the present specification, "plasmid" and
"vector" are used interchangeably as a plasmid (a circular
arrangement of double stranded DNA) is the most commonly used form
of a vector. However, the invention is intended to include such
other forms of vectors which serve equivalent functions and which
become known in the art subsequently hereto. Viral vectors include,
e.g., replication defective retroviruses, adenoviruses and
adeno-associated viruses.
6.2 Natural IgM Antibodies
[0061] The present invention is based, at least in part, on the
identification of natural immunoglobulins (Ig), in particular
natural IgMs. Certain IgMs may be obtained from the hybridoma that
has been deposited with the American Type Culture Collection and
provided Accession Number PTA-3507.
[0062] The nucleotide sequence of the heavy chain variable region
of the IgM produced from hybridoma PTA-3507, IgM.sup.CM-22 (also
referred to as 22A5 IgM) is shown in FIG. 1A (SEQ ID NO: 1), and
the amino acid sequence is shown in FIG. 1B (SEQ ID NO: 2). The
CDRI domain of the heavy chain variable region corresponds to amino
acids 31 to 35 of SEQ ID NO: 2 (SEQ ID NO: 4), which is encoded by
nucleotides 91-105 of SEQ ID NO: 1 (SEQ ID NO: 3), and the CDR2
domain of the heavy chain variable region corresponds to amino
acids 50 to 66 of SEQ ID NO: 2 (SEQ ID NO: 6), which is encoded by
nucleotides 148-198 of SEQ ID NO: 1 (SEQ ID NO: 5).
[0063] The nucleotide sequence of the light chain variable region
of IgM.sup.CM-22 is shown in FIG. 2A (SEQ ID NO: 7), and the amino
acid sequence is shown in FIG. 2B (SEQ ID NO: 8). The CDR1 domain
of the light chain variable region corresponds to amino acids 23 to
37 of SEQ ID NO: 8 (SEQ ID NO: 10), which is encoded by nucleotides
67-111 of SEQ ID NO: 7 (SEQ ID NO: 9), and the CDR2 domain of the
light chain variable region corresponds to amino acids 53 to 59 of
SEQ ID NO: 8 (SEQ ID NO: 12), which is encoded by nucleotides 157
to 177 of SEQ ID NO: 7 (SEQ ID NO: 11). Due to the degeneracy of
the genetic code, other nucleotide sequences can encode the amino
acid sequences listed herein.
[0064] The nucleic acid compositions of the present invention,
while often in a native sequence (except for modified restriction
sites and the like), from either cDNA, genomic or mixtures may be
mutated, in accordance with standard techniques. For coding
sequences, these mutations, may affect the amino acid sequence as
desired. In particular, nucleotide sequences substantially
identical to or derived from native V, D, J, constant, switches and
other such sequences described herein are contemplated.
[0065] For example, an isolated nucleic acid can comprise an
IgM.sup.CM-22 (or 22A5 IgM) heavy chain variable region nucleotide
sequence having a nucleotide sequence as shown in FIG. 1A (SEQ ID
NO: 1), or a sequence, which is at least 80%, 90%, 95%, 96%, 97%,
98%, or 99% identical to SEQ ID NO: 1. A nucleic acid molecule may
comprise the heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3,
or a portion thereof. Further, the nucleic acid molecule may
comprise the heavy chain CDR2 nucleotide sequence of SEQ ID NO: 5,
or a portion thereof. In an exemplary embodiment, the nucleic acid
molecule comprises a heavy chain CDRI nucleotide sequence of SEQ ID
NO: 3, or portion thereof, and a heavy chain CDR2 nucleotide
sequence of SEQ ID NO: 5, or portion thereof. The nucleic acid
molecules of the present invention may comprise heavy chain
sequences, e.g. SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, or
combinations thereof, or encompass nucleotides having at least 80%,
90%, 95%, 96%, 97%, 98%, and 99% sequence identity to SEQ ID NOs:
1, 3 or 5. Further, the nucleic acid molecules of the present
invention may comprise heavy chain sequences, which hybridize under
stringent conditions, e.g. low, medium, high or very high
stringency conditions, to SEQ ID NOs: 1, 3 or 5.
[0066] In another embodiment, the invention features nucleic acid
molecules having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99%
sequence identity with a nucleic acid molecule encoding a heavy
chain polypeptide, e.g., a heavy chain polypeptide of SEQ ID NOs:
2, 4 or 6. The invention also features nucleic acid molecules which
hybridize to nucleic acid sequences encoding a heavy chain variable
region of a natural antibody or portion thereof, e.g., a heavy
chain variable region of SEQ ID NO: 2, 4 or 6.
[0067] In another embodiment, the isolated nucleic acid encodes a
IgM.sup.CM-22 (22A5 IgM) light chain variable region nucleotide
sequence having a nucleotide sequence as shown in FIG. 2A (SEQ ID
NO: 7), or a sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99%
identical to SEQ ID NO: 7. The nucleic acid molecule may comprise
the light chain CDR1 nucleotide sequence of SEQ ID NO: 9, or a
portion thereof. In another preferred embodiment, the nucleic acid
molecule may comprise the light chain CDR2 nucleotide sequence of
SEQ ID NO: 11, or a portion thereof. In an exemplary embodiment,
the nucleic acid molecule comprises a light chain CDR1 nucleotide
sequence of SEQ ID NO: 9, or portion thereof, and a light chain
CDR2 nucleotide sequence of SEQ ID NO: 11, or portion thereof The
nucleic acid molecules of the present invention may comprise light
chain sequences, e.g. SEQ ID NOs: 7, 9 or 11, or combinations
thereof, or encompass nucleotides having at least 80%, 90%, 95%,
96%, 97%, 98%, and 99% sequence identity to SEQ ID NOs: 7, 9 or 11.
Further nucleic acid molecules may comprise light chain sequences,
which hybridize under stringent conditions, e.g. low, medium, high
or very high stringency conditions, to SEQ ID NOs: 7, 9 or 11.
[0068] Nucleic acid molecules can have at least 80%, 90%, 95%, 96%,
97%, 98% or 99% sequence identity with a nucleic acid molecule
encoding a light chain polypeptide, e.g., a light chain polypeptide
of SEQ ID NOs: 8, 10, or 12. The invention also features nucleic
acid molecules which hybridize to a nucleic acid sequence encoding
a light chain variable region of a natural antibody or portion
thereof, e.g., a light chain variable region of SEQ ID NOs: 8, 10
or 12.
[0069] In another embodiment, the invention provides an isolated
nucleic acid encoding a heavy chain CDR1 domain comprising the
amino acid sequence of SEQ ID NO: 4, or a fragment or modified form
thereof. This nucleic acid can encode only the CDR1 region or can
encode an entire antibody heavy chain variable region or a fragment
thereof. For example, the nucleic acid can encode a heavy chain
variable region having a CDR2 domain comprising the amino acid
sequence of SEQ ID NO: 6. In yet another embodiment, the invention
provides an isolated nucleic acid encoding a heavy chain CDR2
domain comprising the amino acid sequence of SEQ ID NO: 6, or a
fragment or modified form thereof. This nucleic acid can encode
only the CDR2 region or can encode an entire antibody heavy chain
variable region or a fragment thereof. For example, the nucleic
acid can encode a light chain variable region having a CDR1 domain
comprising the amino acid sequence of SEQ ID NO: 4.
[0070] In still another embodiment, the invention provides an
isolated nucleic acid encoding a light chain CDR1 domain comprising
the amino acid sequence of SEQ ID NO: 10, or a fragment or modified
form thereof. This nucleic acid can encode only the CDR1 region or
can encode an entire antibody light chain variable region. For
example, the nucleic acid can encode a light chain variable region
having a CDR2 domain comprising the amino acid sequence of SEQ ID
NO: 12. The isolated nucleic acid can also encode a light chain
CDR2 domain comprising the amino acid sequence of SEQ ID NO: 12, or
a fragment or modified form thereof. This nucleic acid can encode
only the CDR2 region or can encode an entire antibody light chain
variable region. For example, the nucleic acid can encode a light
chain variable region having a CDR1 domain comprising the amino
acid sequence of SEQ ID NO: 10.
[0071] The nucleic acid encoding the heavy or light chain variable
region can be of murine or human origin, or can comprise a
combination of murine and human amino acid sequences. For example,
the nucleic acid can encode a heavy chain variable region
comprising the CDR1 of SEQ ID NO: 2 (SEQ ID NO: 4) and/or the CDR2
of SEQ ID NO: 2 (SEQ ID NO: 6), and a human framework sequence. In
addition, the nucleic acid can encode a light chain variable region
comprising the CDR1 of SEQ ID NO: 8 (SEQ ID NO: 10) and/or the CDR2
of SEQ ID NO: 8 (SEQ ID NO: 12), and a human framework sequence.
The invention further encompasses vectors containing the
above-described nucleic acids and host cells containing the
expression vectors.
[0072] The invention also features polypeptides and fragments of
the IgMcM-22 heavy chain variable regions and/or light chain
variable regions. In exemplary embodiments, the isolated
polypeptides comprise, for example, the amino acid sequences of SEQ
ID NOs: 8, 10, or 12, or fragments or combinations thereof; or SEQ
ID NO: 2, 4, or 6, or fragments or combinations thereof. The
polypeptides of the present invention include polypeptides having
at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid
that differs from SEQ ID NOs: 8, 10, 12, 2, 4 or 6. Exemplary
polypeptides are polypeptides that retain biological activity,
e.g., the ability to bind an ischemia-specific antigen, and/or the
ability to bind complement. In another embodiment, the polypeptides
comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%,
and 99% sequence identity with a light chain variable region, or
portion thereof, e.g. a light chain variable region polypeptide of
SEQ ID NOs: 8, 10, or 12. In another embodiment, the polypeptides
comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%,
and 99% sequence identity with a heavy chain variable region, or
portion thereof, e.g. a heavy chain variable region polypeptide of
SEQ ID NOs: 2, 4, or 6. In another embodiment, the invention
features a polypeptide comprising the amino acid sequence of SEQ ID
NO: 8 and SEQ ID NO: 2, further comprising an IRES sequence.
6.3 Inhibitors of Natural IgM Antibodies
6.3.1 Peptide Inhibitors of Natural IgM Antibodies
[0073] The invention further features IgM inhibitors. In one
embodiment, the IgM inhibitor is a peptide that specifically binds
to a natural IgM and thereby blocks binding to the antigen. Such
peptides can include, but are not limited to, the asparagine-rich
peptides described in Table 1 below.
TABLE-US-00001 TABLE 1 Amino acid sequences of natural IgM
antibody-binding peptides SEQ ID NO. SEQUENCE Name 14 xNNNxNNxNNNN
Asparagine-rich Consensus 16 YNNNNGNYTYRN P1 18 ANTRNGATNNNM P2 20
CDSSCDSVGNCN P3 22 WNNNGRNACNAN P4 24 HNSTSNGCNDNV P5 26
NSNSRYNSNSNN P6 28 KRNNHNNHNRSN P7 30 NGNNVNGNRNNN P8 32
NVANHNNSNHGN P9 34 SYNNNNHVSNRN P10
[0074] The peptides can also include certain "self-peptides" as
described in Table 2 below.
TABLE-US-00002 TABLE 2 Amino acid sequences of self-peptides SEQ ID
NO. SEQUENCE Name 36 LMKNMDPLNDNI Self-1 38 LMKNMDPLNDNV Self-2
("N-2")
[0075] As described in more detail in the Exemplification,
self-peptides bind to the natural IgM antibody IgM.sup.CM-22.
[0076] In addition to the peptides described above, the present
invention encompasses modified peptides whose activity may be
identified and/or assayed using a variety of methods well known to
the skilled artisan. For example, binding of the peptide to the IgM
may be detected using biological assays, Western blotting,
immunoprecipitation, or immonocytochemical techniques, such as
those described below. In particular, the biological activity
(e.g., the ability to a bind natural IgM antibody) of a modified
peptide can be characterized relative to that of PS (SEQ ID NO: 30)
or N2 (SEQ ID NO: 38).
[0077] Such modified peptides, when designed to retain at least one
activity of the naturally-occurring form of the protein, are
considered "functional equivalents" of the peptides described in
more detail herein. Such modified peptides may be produced, for
instance, by amino acid substitution, deletion, or addition, which
substitutions may consist in whole or part by conservative amino
acid substitutions.
[0078] For instance, it is reasonable to expect that an isolated
conservative amino acid substitution, such as replacement of a
leucine with an isoleucine or valine, an aspartate with a
glutamate, or a threonine with a serine, will not have a major
effect on the biological activity of the resulting molecule.
Whether a change in the amino acid sequence of a peptide results in
a functional homolog may be readily determined by assessing the
ability of the variant peptide to produce a response similar to
that of the wild-type peptide (e.g. ability to bind natural IgM
antibodies). Peptides in which more than one replacement has taken
place may readily be tested in the same manner.
[0079] Mutagenesis of the peptide may give rise to homologs, which
have improved in vivo half-lives relative to the corresponding
wild-type peptide. For example, the altered peptide may be rendered
more stable to proteolytic degradation or other cellular processes
which result in destruction or inactivation of the protein.
[0080] The amino acid sequences for a population of peptide homo
logs can be aligned, preferably to promote the highest homology
possible. Such a population of variants may include, for example,
homologs from one or more species, or homologs from the same
species but which differ due to mutation. Amino acids which appear
at each position of the aligned sequences are selected to create a
degenerate set of combinatorial sequences. In certain embodiments,
the combinatorial library is produced by way of a degenerate
library of genes encoding a library of polypeptides which each
include at least a portion of potential peptide sequences. For
instance, a mixture of synthetic oligonucleotides may be
enzymatically ligated into gene sequences such that the degenerate
set of potential nucleotide sequences are expressible as individual
polypeptides, or alternatively, as a set of larger fusion proteins
(e.g., for phage display).
[0081] There are many ways by which the library of potential
homologs may be generated from a degenerate oligonucleotide
sequence. Chemical synthesis of a degenerate gene sequence may be
carried out in an automatic DNA synthesizer, and the synthetic
genes may then be ligated into an appropriate vector for
expression. One purpose of a degenerate set of genes is to provide,
in one mixture, all of the sequences encoding the desired set of
potential peptide sequences. The synthesis of degenerate
oligonucleotides is well known in the art (see for example, Narang,
S A (1983) Tetrahedron 39:3; Itakura et al., (1981) Recombinant
DNA, Proc. 3rd Cleveland Sympos. Macromolecules, ed. AG Walton,
Amsterdam: Elsevier pp. 273-289; Itakura et al., (1984) Annu. Rev.
Biochem. 53:323; Itakura et al., (1984) Science 198:1056; Ike et
al., (1983) Nucleic Acid Res. 11:477). Such techniques have been
employed in the directed evolution of other proteins (see, for
example, Scott et al., (1990) Science 249:386-390; Roberts et al.,
(1992) PNAS USA 89:2429-2433; Devlin et al., (1990) Science 249:
404-406; Cwirla et al., (1990) PNAS USA 87: 6378-6382; as well as
U.S. Pat. Nos. 5,223,409, 5,198,346, and 5,096,815).
[0082] Alternatively, other forms of mutagenesis may be utilized to
generate a combinatorial library. For example, peptide homologs may
be generated and isolated from a library by screening using, for
example, alanine scanning mutagenesis and the like (Ruf et al.,
(1994) Biochemistry 33:1565-1572; Wang et al., (1994) J. Biol.
Chem. 269:3095-3099; Balint et al., (1993) Gene 137:109-118;
Grodberg et al., (1993) Eur. J. Biochem. 218:597-601; Nagashima et
al., (1993) J. Biol. Chem. 268:2888-2892; Lowman et al., (1991)
Biochemistry 30:10832-10838; and Cunningham et al., (1989) Science
244:1081-1085), by linker scanning mutagenesis (Gustin et al.,
(1993) Virology 193:653-660; Brown et al., (1992) Mol. Cell Biol.
12:2644-2652; McKnight et al., (1982) Science 232:316); by
saturation mutagenesis (Meyers et al., (1986) Science 232:613); by
PCR mutagenesis (Leung et al., (1989) Method Cell Mol. Biol.
1:11-19); or by random mutagenesis (Miller et al., (1992) A Short
Course in Bacterial Genetics, CSHL Press, Cold Spring Harbor, N.Y.;
and Greener et al., (1994) Strategies in Mol. Biol. 7:32-34).
[0083] A wide range of techniques are known in the art for
screening gene products of combinatorial libraries made by point
mutations and truncations, and for screening cDNA libraries for
gene products having a certain property (e.g., the ability to bind
a natural IgM antibody). Such techniques will be generally
adaptable for rapid screening of the gene libraries generated by
the combinatorial mutagenesis of peptide homo logs. The most widely
used techniques for screening large gene libraries typically
comprises cloning the gene library into replicable expression
vectors, transforming appropriate cells with the resulting library
of vectors, and expressing the combinatorial genes under conditions
in which detection of a desired activity facilitates relatively
easy isolation of the vector encoding the gene whose product was
detected. Each of the illustrative assays described below are
amenable to high through-put analysis as necessary to screen large
numbers of degenerate sequences created by combinatorial
mutagenesis techniques.
[0084] In an illustrative embodiment of a screening assay,
candidate combinatorial gene products are passed over a column
containing beads having attached to it the binding protein, such as
an IgM or portion thereof. Those candidate combinatorial gene
products that are retained on the column may be further
characterized for binding to IgMs in a manner that could be useful
in blocking natural IgM antibody binding and treating inflammatory
diseases.
[0085] In another example, the gene library may be expressed as a
fusion protein on the surface of a viral particle. For instance, in
the filamentous phage system, foreign peptide sequences may be
expressed on the surface of infectious phage, thereby conferring
two benefits. First, because these phage may be applied to affinity
matrices at very high concentrations, a large number of phage may
be screened at one time. Second, because each infectious phage
displays the combinatorial gene product on its surface, if a
particular phage is recovered from an affinity matrix in low yield,
the phage may be amplified by another round of infection. The group
of almost identical E. coli filamentous phages Ml3, fd, and fl are
most often used in phage display libraries, as either of the phage
gIII or gVIII coat proteins may be used to generate fusion proteins
without disrupting the ultimate packaging of the viral particle
(Ladner et al., PCT publication WO 90/02909; Garrard et al., PCT
publication WO 92/09690; Marks et al., (1992) J. Biol. Chem.
267:16007-16010; Griffiths et al., (1993) EMBO J. 12:725-734;
Clackson et al., (1991) Nature 352:624-628; and Barbas et al.,
(1992) PNAS USA 89:4457-4461). Other phage coat proteins may be
used as appropriate.
[0086] The invention also provides for mimetics (e.g., non-peptide
agents) which are able to mimic binding of the authentic peptide to
a natural IgM antibody. For example, the critical residues of a
peptide which are involved in molecular recognition of a natural
IgM antibody may be determined and used to generate peptidomimetics
that bind to a natural IgM antibody. The peptidomimetic may then be
used as an inhibitor of the wild-type protein by binding to the
natural IgM antibodies and covering up the critical residues needed
for interaction with the wildtype protein, thereby preventing
interaction of the protein and the natural IgM antibody.
Peptidomimetic compounds may be generated which mimic those
residues in binding to the natural IgM antibody. For instance,
non-hydrolyzable peptide analogs of such residues may be generated
using benzodiazepine (e.g., see Freidinger et al., in Peptides:
Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden,
Netherlands, 1988), azepine (e.g., see Huffman et al., in Peptides:
Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden,
Netherlands, 1988), substituted gamma lactam rings (Garvey et al.,
in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM
Publisher: Leiden, Netherlands, 1988), keto-methylene
pseudopeptides (Ewenson et al., (1986) J. Med. Chem. 29:295; and
Ewenson et al., in Peptides: Structure and Function (Proceedings of
the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, I
L, 1985), .beta.-turn dipeptide cores (Nagai et al., (1985)
Tetrahedron Lett 26:647; and Sato et al., (1986) J Chem Soc Perkin
Trans 1:1231), and .beta.-aminoalcohols (Gordon et al., (1985)
Biochem Biophys Res Commun 126:419; and Dann et al., (1986) Biochem
Biophys Res Commun 134:71).
6.3.2 Nucleic Acids Encoding Peptide Inhibitors
[0087] The invention also features nucleic acids, which encode the
peptides discussed above. Exemplary nucleic acids are provided in
Table 3.
TABLE-US-00003 TABLE 3 Nucleic acids encoding natural IgM
antibody-binding peptides SEQ ID NO: SEQUENCE Name 13 NNN AAY AAY
AAY NNN AAY Aparagine- AAY NNN AAY AAY AAY AAY rich Consensus 15
TAY AAY AAY AAY AAY GGN P1 AAY TAY ACN TAY MGN AAY 17 GCN AAY ACN
MGN AAY GGN P2 GCN ACN AAY AAY AAY ATG 19 TGY GAY WSN WSN TGY GAY
P3 WSN GTN GGN AAY TGY AAY 21 TGG AAY AAY AAY GGN MGN P4 AAY GCN
TGY AAY GCN AAY 23 CAY AAY WSN ACN WSN AAY P5 GCN TGY AAY GAY AAY
GTN 25 AAY WSN AAY WSN MGN TAN P6 AAN WSN AAY WSN AAY AAY 27 AAR
MGN AAY AAY CAY AAY P7 AAY CAY AAY MGN WSN AAY 29 AAY GGN AAY AAY
GTN AAY P8 GGN AAY MGN AAY AAY AAY 31 AAY GTN GCN AAY CAY AAY P9
AAY WSN AAY CAY GGN AAY 33 WSN TAY AAY AAY AAY AAY P10 CAY GTN WSN
AAY MGN AAY 35 YTN ATG AAR AAY ATG GAY Self-1 CCN YTN AAY GAY AAY
ATH 37 YTN ATG AAR AAY ATG GAY Se1f-2 CCN YTN AAY GAY AAY GTN
[0088] The isolated nucleic acids in Table 3 reflect degeneracy in
the genetic code. In particular, an "R" corresponds to a base that
may be a A or G; a "S" corresponds to a base that may be a G or C;
a "V" corresponds to a base that may be an A, C or G; a "Y"
corresponds to a base that may be a C or T; a "W" corresponds to a
base that may be an A or T; a "D" corresponds to a base that may be
an A, G or T; a "N" corresponds to a base that may be an A or C; a
"H" corresponds to a base that may be an A, C or T; a "N"
corresponds to a base that may be an A, C, G or T; a "K"
corresponds to a base that may be a G or T and a "B" corresponds to
a base that maybe a C, G or T.
[0089] It is expected that DNA sequence polymorphisms that lead to
changes in the amino acid sequences of the subject proteins will
exist among mammalian cells. One skilled in the art will appreciate
that these variations in one or more nucleotides (from less than 1%
up to about 3 or 5% or possibly more of the nucleotides) of the
nucleic acids encoding a particular peptide of the invention may
exist among individuals of a given species due to natural allelic
variation. Any and all such nucleotide variations and resulting
amino acid polymorphisms are within the scope of this invention.
Preferred nucleic acids encode a peptide, which is at least about
60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% homologous or more with an
amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22, 24, 26, 28,
30, 32, 34, 36, 38 or another peptide of the invention. Nucleic
acids which encode peptides having an activity of a peptide of the
invention and having at least about 60%, 70%, 80%, 85%, 90%, 95%,
98%, 99% homology or more with SEQ ID NO: 14, 16, 18, 20, 22, 24,
26, 28, 30, 32, 34, 36, 38, or another peptide of the invention are
also within the scope of the invention.
[0090] Bias in codon choice within genes in a single species
appears related to the level of expression of the protein encoded
by that gene. Accordingly, the invention encompasses nucleic acid
sequences which have been optimized for improved expression in a
host cell by altering the frequency of codon usage in the nucleic
acid sequence to approach the frequency of preferred codon usage of
the host cell. Due to codon degeneracy, it is possible to optimize
the nucleotide sequence without effecting the amino acid sequence
of an encoded polypeptide. Accordingly, the instant invention
relates to any nucleotide sequence that encodes the peptides set
forth in SEQ ID NO: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38 or other peptides of the invention.
[0091] Nucleic acids within the scope of the invention may also
contain linker sequences, modified restriction endonuclease sites
and other sequences useful for molecular cloning, expression or
purification of such recombinant polypeptides.
[0092] A nucleic acid encoding a peptide of the invention may be
obtained from mRNA or genomic DNA from any organism in accordance
with protocols described herein, as well as those generally known
to those skilled in the art. A cDNA encoding a peptide of the
invention, for example, may be obtained by isolating total mRNA
from an organism, e.g. a bacteria, virus, mammal, etc. Double
stranded cDNAs may then be prepared from the total mRNA, and
subsequently inserted into a suitable plasmid or bacteriophage
vector using any one of a number of known techniques. A gene
encoding a peptide of the invention may also be cloned using
established polymerase chain reaction techniques in accordance with
the nucleotide sequence information provided by the invention.
[0093] In another aspect of the invention, the subject nucleic acid
is provided in an expression vector comprising a nucleotide
sequence encoding a peptide of the invention and operably linked to
at least one regulatory sequence. It should be understood that the
design of the expression vector may depend on such factors as the
choice of the host cell to be transformed and/or the type of
protein desired to be expressed. Moreover, the vector's copy
number, the ability to control that copy number and the expression
of any other protein encoded by the vector, such as antibiotic
markers, should also be considered.
[0094] As will be apparent, the subject gene constructs may be used
to cause expression of a peptide of the invention in cells
propagated in culture, e.g., to produce proteins or polypeptides,
including fusion proteins or polypeptides, for purification.
[0095] This invention also pertains to a host cell transfected with
a recombinant gene in order to express a peptide of the invention.
The host cell may be any prokaryotic or eukaryotic cell. For
example, a polypeptide of the present invention may be expressed in
bacterial cells, such as E. coli, insect cells (baculovirus),
yeast, or mammalian cells. Other suitable host cells are known to
those skilled in the art. Additionally, the host cell may be
supplemented with tRNA molecules not typically found in the host so
as to optimize expression of the peptide. Other methods suitable
for maximizing expression of the peptide will be known to those in
the art.
6.3.3 Methods of Producing Peptide Inhibitors
[0096] Peptide inhibitors may be synthesized, for example,
chemically, ribosomally in a cell free system, or ribosomally
within a cell. Chemical synthesis of peptides of the invention may
be carried out using a variety of art recognized methods, including
stepwise solid phase synthesis, semi-synthesis through the
conformationally-assisted re-ligation of peptide fragments,
enzymatic ligation of cloned or synthetic peptide segments, and
chemical ligation. Merrifield et al. in J. Am. Chem. Soc., Volume
85, page 2149 (1964), by Houghten et al. in Proc. Natl. Acad. Sci.
USA, Volume 82, page 5132 (1985), and by Stewart and Young in Solid
Phase Peptide Synthesis, Pierce Chem. Co, Rockford, Ill. (1984).
Native chemical ligation employs a chemoselective reaction of two
unprotected peptide segments to produce a transient
thioester-linked intermediate. The transient thioester-linked
intermediate then spontaneously undergoes a rearrangement to
provide the full length ligation product having a native peptide
bond at the ligation site. Full length ligation products are
chemically identical to proteins produced by cell free synthesis.
Full length ligation products may be refolded and/or oxidized, as
allowed, to form native disulfide-containing protein molecules.
(see e.g., U.S. Pat. Nos. 6,184,344 and 6,174,530; and T. W. Muir
et al., Curr. Opin. Biotech. (1993): vol. 4, p 420; M. Miller, et
al., Science (1989): vol. 246, p 1149; A. Wlodawer, et al., Science
(1989): vol. 245, p 616; L. H. Huang, et al., Biochemistry (1991):
vol. 30, p 7402; M. Schnolzer, et al., Int. J. Pept. Prot. Res.
(1992): vol. 40, p 180-193; K. Rajarathnam, et al., Science (1994):
vol. 264, p 90; R. E. Offord, "Chemical Approaches to Protein
Engineering", in Protein Design and the Development of New
therapeutics and Vaccines, J. B. Hook, G. Poste, Eds., (Plenum
Press, New York, 1990) pp. 253-282; C. J. A. Wallace, et al., J.
Biol. Chem. (1992): vol. 267, p 3852; L. Abrahmsen, et al.,
Biochemistry (1991): vol. 30, p 4151; T. K. Chang, et al., Proc.
Natl. Acad. Sci. USA (1994) 91: 12544-12548; M. Schnlzer, et al.,
Science (1992): vol., 3256, p 221; and K. Akaji, et al., Chem.
Pharm. Bull. (Tokyo) (1985) 33: 184).
[0097] In another variation, peptide production may be achieved
using in vitro translation systems. An in vitro translation systems
is, generally, a translation system which is a cell-free extract
containing at least the minimum elements necessary for translation
of an RNA molecule into a protein. An in vitro translation system
typically comprises at least ribosomes, tRNAs, initiator
methionyl-tRNAMet, proteins or complexes involved in translation,
e.g., eIF2, eIF3, the cap-binding (CB) complex, comprising the
cap-binding protein (CBP) and eukaryotic initiation factor 4F
(eIF4F). A variety of in vitro translation systems are well known
in the art and include commercially available kits. Examples of in
vitro translation systems include eukaryotic lysates, such as
rabbit reticulocyte lysates, rabbit oocyte lysates, human cell
lysates, insect cell lysates and wheat germ extracts. Lysates are
commercially available from manufacturers such as Promega Corp.,
Madison, Wis.; Stratagene, La Jolla, Calif.; Amersham, Arlington
Heights, Ill.; and GIBCO/BRL, Grand Island, N.Y. In vitro
translation systems typically comprise macromolecules, such as
enzymes, translation, initiation and elongation factors, chemical
reagents, and ribosomes. In addition, an in vitro transcription
system may be used. Such systems typically comprise at least an RNA
polymerase holoenzyme, ribonucleotides and any necessary
transcription initiation, elongation d termination factors. In
vitro transcription and translation may be carried out within in
the same reaction to produce peptides from one or more isolated
DNAs.
[0098] Nucleic acids encoding peptide inhibitors may be expressed
in vitro by DNA transfer into a suitable host cell. Expression of
peptides may be facilitated by inserting the nucleic acids encoding
the peptides into a vector, such as a plasmid, virus or other
vehicle known in the art that has been manipulated by insertion or
incorporation of the natural antibody-binding peptide genetic
sequences. Such vectors contain a promoter sequence which
facilitates the efficient transcription of the inserted genetic
sequence of the host. The vector typically contains an origin of
replication, a promoter, as well as specific genes which allow
phenotypic selection of the transformed cells. Vectors suitable for
use in the present invention include, but are not limited to the
T7-based expression vector for expression in bacteria (Rosenberg,
et al., Gene, 56: 125, 1987), the pMSXND expression vector for
expression in mammalian cells (Lee and Nathans, J. Biol. Chem.,
263:3521, 1988) and baculovirus-derived vectors for expression in
insect cells. The DNA segment can be present in the vector operably
linked to regulatory elements, for example, a promoter (e.g., T7,
metallothionein I, or polyhedrin promoters).
[0099] Nucleic acids encoding peptide inhibitors may be expressed
in either prokaryotes or eukaryotes. Hosts can include microbial,
yeast, insect, and mammalian organisms. Methods of expressing DNA
sequences having eukaryotic or viral sequences in prokaryotes are
well known in the art. Biologically functional viral and plasmid
DNA vectors capable of expression and replication in a host are
known in the art. Such vectors can incorporate DNA sequences of the
invention. Methods which are well known to those skilled in the art
can be used to construct vectors containing the natural
antibody-binding peptide coding sequence and appropriate
transcriptional/translational control signals. These methods
include in vitro recombinant DNA techniques, synthetic techniques,
and in vivo recombination/genetic techniques. (See, for example,
the techniques described in Maniatis et al., 1989 Molecular Cloning
A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.)
[0100] A variety of host-expression vector systems may be utilized.
These include but are not limited to microorganisms such as
bacteria transformed with recombinant bacteriophage DNA, plasmid
DNA, or cosmid DNA expression vectors; yeast transformed with
recombinant yeast expression vectors; plant cell systems infected
with recombinant virus expression vectors (e.g., cauliflower mosaic
virus, CaMV; tobacco mosaic virus, TMV) or transformed with
recombinant plasmid expression vectors (e.g., Ti plasmid); insect
cell systems infected with recombinant virus expression vectors
(e.g., baculovirus); or animal cell systems infected with
recombinant virus expression vectors (e.g., retroviruses,
adenovirus, vaccinia virus), or transformed animal cell systems
engineered for stable expression.
[0101] Depending on the host/vector system utilized, any of a
number of suitable transcription and translation elements,
including constitutive and inducible promoters, transcription
enhancer elements, transcription terminators, etc. may be used in
the expression vector (see e.g., Bitter et al., 1987, Methods in
Enzymology 153:516-544). For example, when cloning in bacterial
systems, inducible promoters such as pL of bacteriophage .gamma.,
plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be
used. When cloning in mammalian cell systems, promoters derived
from the genome of mammalian cells (e.g., metallothionein promoter)
or from mammalian viruses (e.g., the retrovirus long terminal
repeat; the adenovirus late promoter; the vaccinia virus 7.5K
promoter) may be used. Promoters produced by recombinant DNA or
synthetic techniques may also be used.
[0102] In yeast, a number of vectors containing constitutive or
inducible promoters may be used. For a review see, Current
Protocols in Molecular Biology, Vol. 2, 1988, Ed. Ausubel et al.,
Greene Publish. Assoc. & Wiley Interscience, Ch. 13; Grant et
al., 1987, Expression and Secretion Vectors for Yeast, in Methods
in Enzymology, Eds. Wu & Grossman, 31987, Acad. Press, N.Y.,
Vol. 153, pp. 516-544; Glover, 1986, DNA Cloning, Vol. II, IRL
Press, Wash., D.C., Ch. 3; and Bitter, 1987, Heterologous Gene
Expression in Yeast, Methods in Enzymology, Eds. Berger &
Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and The Molecular
Biology of the Yeast Saccharomyces, 1982, Eds. Strathem et al.,
Cold Spring Harbor Press, Vols. I and II. A constitutive yeast
promoter such as ADH or LEU2 or an inducible promoter such as GAL
may be used (Cloning in Yeast, Ch. 3, R. Rothstein In: DNA Cloning
Vol. 11, A Practical Approach, Ed. D M Glover, 1986, IRL Press,
Wash., D.C.). Alternatively, vectors may be used which promote
integration of foreign DNA sequences into the yeast chromosome.
[0103] Eukaryotic systems, and preferably mammalian expression
systems, allow for proper post-translational modifications of
expressed mammalian proteins to occur. Eukaryotic cells which
possess the cellular machinery for proper processing of the primary
transcript, glycosylation, phosphorylation, and advantageously,
plasma membrane insertion of the gene product may be used as host
cells.
[0104] Mammalian cell systems which utilize recombinant viruses or
viral elements to direct expression may be engineered. For example,
when using adenovirus expression vectors, a natural
antibody-binding peptide coding sequence may be ligated to an
adenovirus transcription/-translation control complex, e.g., the
late promoter and tripartite leader sequence. Alternatively, the
vaccinia virus 7.5K promoter may be used. (e.g., see, Mackett et
al., 1982, Proc. Natl. Acad. Sci. USA 79: 7415-7419; Mackett et
al., 1984, J. Virol. 49: 857-864; Panicali et al., 1982, Proc.
Natl. Acad. Sci. USA 79: 4927-4931). Of particular interest are
vectors based on bovine papilloma virus which have the ability to
replicate as extrachromosomal elements (Sarver, et al., 1981, Mol.
Cell. Biol. 1: 486). Shortly after entry of this DNA into mouse
cells, the plasmid replicates to about 100 to 200 copies per cell.
Transcription of the inserted cDNA does not require integration of
the plasmid into the host's chromosome, thereby yielding a high
level of expression. These vectors can be used for stable
expression by including a selectable marker in the plasmid, such
as, for example, the neo gene. Alternatively, the retroviral genome
can be modified for use as a vector capable of introducing and
directing the expression of a natural antibody-binding peptide gene
in host cells (Cone & Mulligan, 1984, Proc. Natl. Acad. Sci.
USA 81:6349-6353). High level expression may also be achieved using
inducible promoters, including, but not limited to, the
metallothionine IIA promoter and heat shock promoters.
[0105] For long-term, high-yield production of recombinant
proteins, stable expression is preferred. Rather than using
expression vectors which contain viral origins of replication, host
cells can be transformed with a cDNA controlled by appropriate
expression control elements (e.g., promoter, enhancer, sequences,
transcription terminators, polyadenylation sites, etc.) and a
selectable marker. The selectable marker in the recombinant plasmid
confers resistance to the selection and allows cells to stably
integrate the plasmid into their chromosomes and grow to form foci
which in turn can be cloned and expanded into cell lines. For
example, following the introduction of foreign DNA, engineered
cells may be allowed to grow for 1-2 days in an enriched media, and
then are switched to a selective media. A number of selection
systems may be used, including but not limited to the herpes
simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:
223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska
& Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48: 2026), and
adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:
817) genes can be employed in tk.sup.-, hgprf.sup.- or aprt.sup.-
cells respectively. Also, antimetabolite resistance can be used as
the basis of selection for dhfr, which confers resistance to
methotrexate (Wigler, et al, 1980, Natl. Acad. Sci. USA 77: 3567;
O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt,
which confers resistance to mycophenolic acid (Mulligan & Berg,
1981, Proc. Natl Acad Sci. USA 78: 2072; neo, which confers
resistance to the aminoglycoside G-418 (Colberre-Garapin, et al.,
1981, J. Mol. Biol. 150: 1); and hygro, which confers resistance to
hygromycin (Santerre, et al., 1984, Gene 30: 147) genes. Additional
selectable genes include trpB, which allows cells to utilize indole
in place of tryptophan; hisD, which allows cells to utilize
histinol in place of histidine (Hartman & Mulligan, 1988, Proc.
Natl. Acad. Sci. USA 85: 8047); and ODC (ornithine decarboxylase)
which confers resistance to the ornithine decarboxylase inhibitor,
2-(difluoromethyl)-DL-omithine, DFMO (McConlogue L., 1987,
In:Current Communications in Molecular Biology, Cold Spring Harbor
Laboratory ed.).
[0106] For stable recombinant cell lines, suitable cell types
include but are not limited to cells of the following types: NIH
3T3 (Murine), C2Cl 2, L6, and P19. C2C12 and L6 myoblasts will
differentiate spontaneously in culture and form myotubes depending
on the particular growth conditions (Yaffe and Saxel, 1977; Yaffe,
1968) P19 is an embryonic carcinoma cell line. Such cells are
described, for example, in the Cell Line Catalog of the American
Type Culture Collection (ATCC). These cells can be stably
transformed by a method known to the skilled artisan. See, for
example, Ausubel et al., Introduction of DNA Into Mammalian Cells,
in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, sections 9.5.1-9.5.6
(John Wiley & Sons, Inc. 1995). "Stable" transformation in the
context of the invention means that the cells are immortal to the
extent of having gone through at least 50 divisions.
[0107] When the host is a eukaryote, such methods of transfection
of DNA as calcium phosphate co-precipitates, conventional
mechanical procedures such as microinjection, electroporation,
insertion of a plasmid encased in liposomes, or virus vectors may
be used. Eukaryotic cells can also be co-transformed with DNA
sequences encoding natural antibody-binding peptides, and a second
foreign DNA molecule encoding a selectable phenotype, such as the
herpes simplex thymidine kinase gene. Another method is to use a
eukaryotic viral vector, such as simian virus 40 (SV40) or bovine
papilloma virus, to transiently infect or transform eukaryotic
cells and express the protein. (see for example, Eukaryotic Viral
Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).
[0108] To interact with natural antibodies or for isolation and
purification, natural antibody-binding proteins may need to be
secreted from the host cell. Accordingly a signal sequence may be
used to direct the peptide out of the host cell where it is
synthesized. Typically, the signal sequence is positioned in the
coding region of nucleic acid sequence, or directly at the 5' end
of the coding region. Many signal sequences have been identified,
and any that are functional in the selected host cell may be used.
Accordingly, the signal sequence may be homologous or heterologous
to the polypeptide. Additionally, the signal sequence may be
chemically synthesized using recombinant DNA techniques well known
in the art.
[0109] The amount of peptide produced in the host cell can be
evaluated using standard methods known in the art. Such methods
include, without limitation, Western blot analysis,
SDS-polyacrylamide gel electrophoresis, non-denaturing gel
electrophoresis, HPLC separation, immunoprecipitation, and/or
activity assays such as DNA binding gel shift assays.
[0110] When natural antibody-binding peptides are secreted from the
host cells, the majority of the peptide will likely be found in the
cell culture medium. If, however, the peptide is not secreted, it
will be present in the cytoplasm (for eukaryotic, Gram-positive
bacteria, and insect host cells) or in the periplasm (for
Gram-negative bacteria host cells).
[0111] If the natural antibody-binding peptide remains in the
intracellular space, the host cells are typically first disrupted
mechanically or osmotically to release the cytoplasmic contents
into a buffered solution. The peptide is then isolated from this
solution. Purification of the peptide from solution can thereafter
be accomplished using a variety of techniques. If the peptide has
been synthesized such that it contains a tag such as hexahistidine
or other small peptides at either its carboxyl or amino terminus,
it may be purified in a one-step process by passing the solution
through an affinity column where the column matrix has a high
affinity for the tag or for the peptide directly (i.e., a
monoclonal antibody). For example, polyhistidine binds with great
affinity and specificity to nickel, thus an affinity column of
nickel (such as the Qiagen nickel columns) can be used for
purification. (See, for example, Ausubel et al., eds., Current
Protocols in Molecular Biology, John Wiley & Sons, New York,
1994.)
[0112] Where, on the other hand, the peptide has no tag and it is
not practical to use an antibody to purify the peptide, other
well-known procedures for purification can be used. Such procedures
include, without limitation, ion exchange chromatography, molecular
sieve chromatography, HPLC, native gel electrophoresis in
combination with gel elution, and preparative isoelectric focusing
("Isoprime" machine/technique, Hoefer Scientific). In some cases,
two or more of these techniques may be combined to achieve
increased purity.
[0113] If it is anticipated that the peptide will be found
primarily in the periplasmic space of the bacteria or the cytoplasm
of eukaryotic cells, the contents of the periplasm or cytoplasm,
including inclusion bodies (e.g., Gram-negative bacteria) if the
processed peptide has formed such complexes, can be extracted from
the host cell using any standard technique known to the skilled
artisan. For example, the host cells can be lysed to release the
contents of the periplasm by the use of a French press,
homogenization, and/or sonication. The homogenate can then be
centrifuged.
6.3.4 Antibody Inhibitors of Natural IgM Antibodies
[0114] IgM inhibitors may also be antibodies that compete with
natural IgMs in binding to antigen. Methods of producing antibodies
are well known in the art. For example, a monoclonal antibody
against a target (e.g., a pathogenic immunoglobulin or an ischemia
specific antigen on a cell) can be produced by a variety of
techniques, including conventional monoclonal antibody methodology
e.g., the standard somatic cell hybridization technique of Kohler
and Milstein, Nature 256: 495 (1975). Although somatic cell
hybridization procedures are preferred, in principle, other
techniques for producing monoclonal antibody can be employed e.g.,
viral or oncogenic transformation of B lymphocytes. The preferred
animal system for preparing hybridomas is the murine system.
Hybridoma production in the mouse is a very well-established
procedure. Immunization protocols and techniques for isolation of
immunized splenocytes for fusion are known in the art. Fusion
partners (e.g., murine myeloma cells) and fusion procedures are
also known.
[0115] Human monoclonal antibodies can be generated using
transgenic mice carrying the human immunoglobulin genes rather than
mouse immunoglobulin genes. Splenocytes from these transgenic mice
immunized with the antigen of interest are used to produce
hybridomas that secrete human mAbs with specific affinities for
epitopes from a human protein (see, e.g., Wood et al. International
Application WO 91/00906, Kucherlapati et al. PCT publication WO
91/10741; Lonberg et al. International Application WO 92/03918; Kay
et al. International Application 92/03917; Lonberg, N. et al. 1994
Nature 368:856-859; Green, L. L. et al. 1994 Nature Genet. 7:13-21;
Morrison, S. L. et al. 1994 Proc. Natl. Acad. Sci. USA
81:6851-6855; Bruggeman et al. 1993 Year Immuno. 17:33-40; Tuaillon
et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur. J.
Immunol 21:1323-1326). In one embodiment, hybridomas can be
generated from human CD5+, B-1 cells. Alternatively, "humanized"
murine hybridomas can be used that recognize cross-reactive
"ischemic antigen".
[0116] Monoclonal antibodies can also be generated by other methods
known to those skilled in the art of recombinant DNA technology. An
alternative method, referred to as the "combinatorial antibody
display" method, has been developed to identify and isolate
antibody fragments having a particular antigen specificity, and can
be utilized to produce monoclonal antibodies (for descriptions of
combinatorial antibody display see e.g., Sastry et al. 1989 PNAS
86:5,728; Huse et al. 1989 Science 246:1275; and Orlandi et al.
1989 PNAS 86:3833). After immunizing an animal with an immunogen as
described above, the antibody repertoire of the resulting B-cell
pool is cloned. Methods are generally known for obtaining the DNA
sequence of the variable regions of a diverse population of
immunoglobulin molecules by using a mixture of oligomer primers and
PCR. For instance, mixed oligonucleotide primers corresponding to
the 5' leader (signal peptide) sequences and/or framework 1 (FR1)
sequences, as well as primer to a conserved 3' constant region
primer can be used for PCR amplification of the heavy and light
chain variable regions from a number of murine antibodies (Larrick
et al., 1991, Biotechniques 11:152-156). A similar strategy can
also been used to amplify human heavy and light chain variable
regions from human antibodies (Larrick et al., 1991, Methods:
Companion to Methods in Enzymology 2: 106-110).
[0117] In an illustrative embodiment, RNA is isolated from B
lymphocytes, for example, peripheral blood cells, bone marrow, or
spleen preparations, using standard protocols (e.g., U.S. Pat. No.
4,683,202; Orlandi, et al. PNAS (1989) 86:3833-3837; Sastry et al.,
PNAS (1989) 86:5728-5732; and Huse et al. (1989) Science
246:1275-1281.) First-strand cDNA is synthesized using primers
specific for the constant region of the heavy chain(s) and each of
the .kappa. and .lamda. light chains, as well as primers for the
signal sequence. Using variable region PCR primers, the variable
regions of both heavy and light chains are amplified, each alone or
in combination, and ligated into appropriate vectors for further
manipulation in generating the display packages. Oligonucleotide
primers useful in amplification protocols may be unique or
degenerate or incorporate inosine at degenerate positions.
Restriction endonuclease recognition sequences may also be
incorporated into the primers to allow for the cloning of the
amplified fragment into a vector in a predetermined reading frame
for expression.
[0118] The V-gene library cloned from the immunization-derived
antibody repertoire can be expressed by a population of display
packages, preferably derived from filamentous phage; to form an
antibody display library. Ideally, the display package comprises a
system that allows the sampling of very large variegated antibody
display libraries, rapid sorting after each affinity separation
round, and easy isolation of the antibody gene from purified
display packages. In addition to commercially available kits for
generating phage display libraries (e.g., the Pharmacia Recombinant
Phage Antibody System, catalog no. 27-9400-01; and the Stratagene
SurfZAP.TM. phage display kit, catalog no. 240612), examples of
methods and reagents particularly amenable for use in generating a
variegated antibody display library can be found in, for example,
Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. International
Publication No. WO 92/18619; Dower et al. International Publication
No. WO 91/17271; Winter et al. International Publication WO
92/20791; Markland et al. International Publication No. WO
92/15679; Breitling et al. International Publication WO 93/01288;
McCafferty et al. International Publication No. WO 92/01047;
Garrard et al. International Publication No. WO 92/09690; Ladner et
al. International Publication No. WO 90/02809; Fuchs et al. (1991)
Bio/Technology 9:1370-1372; Hay et al. (1992) Human Antibody
Hybridomas 3:81-85; Huse et al. (1989) Science 246: 1275-1281;
Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J.
Mol. Biol. 226:889-896; Clackson et al. (1991) Nature 352:624-628;
Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991)
Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc. Acid Res.
19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982.
[0119] In certain embodiments, the V region domains of heavy and
light chains can be expressed on the same polypeptide, joined by a
flexible linker to form a single-chain Fv fragment, and the scFV
gene subsequently cloned into the desired expression vector or
phage genome. As generally described in McCafferty et al., Nature
(1990) 348:552-554, complete VH and VL domains of an antibody,
joined by a flexible (Gly.sub.4-Ser).sub.3 linker can be used to
produce a single chain antibody which can render the display
package separable based on antigen affinity. Isolated scFV
antibodies immunoreactive with the antigen can subsequently be
formulated into a pharmaceutical preparation for use in the subject
method.
[0120] Once displayed on the surface of a display package (e.g.,
filamentous phage), the antibody library is screened with the
target antigen, or peptide fragment thereof, to identify and
isolate packages that express an antibody having specificity for
the target antigen. Nucleic acid encoding the selected antibody can
be recovered from the display package (e.g., from the phage genome)
and subcloned into other expression vectors by standard recombinant
DNA techniques.
[0121] Specific antibody molecules with high affinities for a
surface protein can be made according to methods known to those in
the art, e.g., methods involving screening of libraries (Ladner, R.
C., et al., U.S. Pat. No. 5,233,409; Ladner, R. C., et al., U.S.
Pat. No. 5,403,484). Further, these libraries can be used in
screens to obtain binding determinants that are mimetics of the
structural determinants of antibodies.
[0122] In particular, the Fv binding surface of a particular
antibody molecule interacts with its target ligand according to
principles of protein-protein interactions, hence sequence data for
VH and VL (the latter of which may be of the .kappa. or .lamda.
chain type) can be used in protein engineering techniques known to
those with skill in the art. Details of the protein surface that
comprises the binding determinants can be obtained from antibody
sequence information, by a modeling procedure using previously
determined three-dimensional structures from other antibodies
obtained from NMR studies or crystallographic data. See for example
Bajorath, J. and S. Sheriff, 1996, Proteins: Struct. Funct. and
Genet. 24 (2), 152-157; Webster, D. M. and A. R. Rees, 1995,
"Molecular modeling of antibody-combining sites," in S. Paul, Ed.,
Methods in Molecular Biol. 51, Antibody Engineering Protocols,
Humana Press, Totowa, N.J., pp 17-49; and Johnson, G., Wu, T. T.
and E. A. Kabat, 1995, "Seqhunt: A program to screen aligned
nucleotide and amino acid sequences," in Methods in Molecular Biol.
51, op. cit., pp 1-15.
[0123] In one embodiment, a variegated peptide library is expressed
by a population of display packages to form a peptide display
library. Ideally, the display package comprises a system that
allows the sampling of very large variegated peptide display
libraries, rapid sorting after each affinity separation round, and
easy isolation of the peptide-encoding gene from purified display
packages. Peptide display libraries can be in, e.g., prokaryotic
organisms and viruses, which can be amplified quickly, are
relatively easy to manipulate, and which allow the creation of
large number of clones. Preferred display packages include, for
example, vegetative bacterial cells, bacterial spores, and most
preferably, bacterial viruses (especially DNA viruses). However,
the present invention also contemplates the use of eukaryotic
cells, including yeast and their spores, as potential display
packages. Phage display libraries are described above.
[0124] Other techniques include affinity chromatography with an
appropriate "receptor", e.g., a target antigen, followed by
identification of the isolated binding agents or ligands by
conventional techniques (e.g., mass spectrometry and NMR).
Preferably, the soluble receptor is conjugated to a label (e.g.,
fluorophores, colorimetric enzymes, radioisotopes, or luminescent
compounds) that can be detected to indicate ligand binding.
Alternatively, immobilized compounds can be selectively released
and allowed to diffuse through a membrane to interact with a
receptor.
[0125] Combinatorial libraries of compounds can also be synthesized
with "tags" to encode the identity of each member of the library
(see, e.g., W. C. Still et al., International Application WO
94/08051). In general, this method features the use of inert but
readily detectable tags that are attached to the solid support or
to the compounds. When an active compound is detected, identity of
the compound is determined by identification of the unique
accompanying tag. This tagging method permits the synthesis of
large libraries of compounds which can be identified at very low
levels among the total set of all compounds in the library.
[0126] An antibody of the present invention can be one in which the
variable region, or a portion thereof, e.g., the complementarity
determining regions (CDR or CDRs), are generated in a non-human
organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and
humanized antibodies are within the invention. Antibodies generated
in a non-human organism, e.g., a rat or mouse, and then modified,
e.g., in the variable framework or constant region, to decrease
antigenicity in a human are within the invention. Any modification
is within the scope of the invention so long as the antibody has at
least one antigen binding portion.
[0127] Chimeric antibodies (e.g. mouse-human monoclonal antibodies)
can be produced by recombinant DNA techniques known in the art. For
example, a gene encoding the Fc constant region of a murine (or
other species) monoclonal antibody molecule is digested with
restriction enzymes to remove the region encoding the murine Fc,
and the equivalent portion of a gene encoding a human Fc constant
region is substituted. (see Robinson et al., International Patent
Publication PCT/US86/02269; Akira, et al., European Patent
Application 184,187; Taniguchi, M., European Patent Application
171,496; Morrison et al., European Patent.Application 173,494;
Neuberger et al., International Application WO 86/01533; Cabilly et
al. U.S. Pat. No. 4,816,567; Cabilly et al., European Patent
Application 125,023; Better et al. (1988 Science 240:1041-1043);
Liu et al. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol.
139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al.,
1987, Canc. Res. 47:999-1005; Wood et al. (1985) Nature
314:446-449; and Shaw et al., 1988, J. Natl. Cancer Inst.
80:1553-1559).
[0128] A chimeric antibody can be further humanized by replacing
sequences of the Fv variable region which are not directly involved
in antigen binding with equivalent sequences from human Fv variable
regions. General methods for generating humanized antibodies are
provided by Morrison, S. L., 1985, Science 229:1202-1207 by Oi et
al., 1986, BioTechniques 4:214, and by Queen et at. U.S. Pat. No.
5,585,089, U.S. Pat. No. 5,693,761 and U.S. Pat. No. 5,693,762, the
contents of all of which are hereby incorporated by reference.
Those methods include isolating, manipulating, and expressing the
nucleic acid sequences that encode all or part of immunoglobulin Fv
variable regions from at least one of a heavy or light chain.
Sources of such nucleic acid are well known to those skilled in the
art and, for example, may be obtained from 7E3, an
anti-GPII.sub.bIII.sub.a antibody producing hybridoma. The
recombinant DNA encoding the chimeric antibody, or fragment
thereof, can then be cloned into an appropriate expression vector.
Suitable humanized antibodies can alternatively be produced by CDR
substitution. U.S. Pat. No. 5,225,539; Jones et al. 1986 Nature
321:552-525; Verhoeyan et al. 1988 Science 239: 1534; and Beidler
et al. 1988 J Immunol. 141:4053-4060.
[0129] Humanized or CDR-grafted antibodies can be produced by
CDR-grafting or CDR substitution, wherein one, two, or all CDRs of
an immunoglobulin chain can be replaced. See e.g., U.S. Pat. No.
5,225,539; Jones et al. 1986 Nature 321:552-525; Verhoeyan et al.
1988 Science 239: 1534; Beidler et al. 1988 J. Immunol.
141:4053-4060; Winter U.S. Pat. No. 5,225,539, the contents of all
of which are hereby expressly incorporated by reference. Winter
describes a CDR-grafting method which may be used to prepare the
humanized antibodies of the present invention (UK Patent
Application GB 2188638A, filed on Mar. 26, 1987; Winter U.S. Pat.
No. 5,225,539), the contents of which is expressly incorporated by
reference.
[0130] A humanized or CDR-grafted antibody will have at least one
or two but generally all recipient CDRs (of heavy and/or light
immunoglobulin chains) replaced with a donor CDR. Preferably, the
donor will be a rodent antibody, e.g., a rat or mouse antibody, and
the recipient will be a human framework or a human consensus
framework. Typically, the immunoglobulin providing the CDRs is
called the "donor" and the immunoglobulin providing the framework
is called the "acceptor." In one embodiment, the donor
immunoglobulin is a non-human (e.g., rodent). The acceptor
framework can be a naturally-occurring (e.g., a human) framework or
a consensus framework, or a sequence about 85% or higher,
preferably 90%, 95%, 99% or higher identical thereto.
[0131] All of the CDRs of a particular antibody may be replaced
with at least a portion of a non-human CDR or only some of the CDRs
may be replaced with non-human CDRs. It is only necessary to
replace the number of CDRs required for binding of the humanized
antibody to the Fc receptor.
[0132] Also within the scope of the invention are chimeric and
humanized antibodies in which specific amino acids have been
substituted, deleted or added. In particular, preferred humanized
antibodies have amino acid substitutions in the framework region,
such as to improve binding to the antigen. For example, a humanized
antibody will have framework residues identical to the donor
framework residue or to another amino acid other than the recipient
framework residue.
[0133] As another example, in a humanized antibody having mouse
CDRs, amino acids located in the human framework region can be
replaced with the amino acids located at the corresponding
positions in the mouse antibody. Such substitutions are known to
improve binding of humanized antibodies to the antigen in some
instances.
[0134] Antibody fragments of the invention are obtained using
conventional procedures known to those with skill in the art. For
example, digestion of an antibody with pepsin yields F(ab')2
fragments and multiple small fragments. Mercaptoethanol reduction
of an antibody yields individual heavy and light chains. Digestion
of an antibody with papain yields individual Fab fragments and the
Fc fragment.
[0135] In another aspect, the invention also features a modified
natural immunoglobulin, e.g., which functions as an agonist
(mimetic) or as an antagonist. Preferably the modified natural
immunoglobulin, e.g., modified pathogenic immunoglobulin, functions
as an antagonist of complement activation. Variants of the
pathogenic immunoglobulin can be generated by mutagenesis, e.g.,
discrete point mutation, the insertion or deletion of sequences or
the truncation of a pathogenic immunoglobulin. An agonist of the
natural immunoglobulin can retain substantially the same, or a
subset, of the biological activities of the naturally occurring
form of the protein. An antagonist of a natural immunoglobulin can
inhibit one or more of the activities of the naturally occurring
form of the pathogenic immunoglobulin by, for example, being
capable of binding to an ischemic specific antigen, but incapable
of activating a complement pathway. Thus, specific biological
effects can be elicited by treatment with a variant of limited
function.
[0136] In one embodiment, the site within the natural
immunoglobulin (e.g., a pathogenic IgM) that binds C1q can be
mutated such that it is no longer capable of binding C1q. For
example, the CH2 domain of an IgG and the CH4 domain of an IgM,
which are known to contain binding sites for C1q, can be mutated
(see WO 94/29351). For example, the carboxyl terminal half of the
CH2 domain of an IgG (residues 231 to 239, preferably within 234 to
239), which appear to mediate C1q binding and subsequent complement
activation, can be mutated. As another example, Wright et al. have
demonstrated that a single nucleotide change in the IgM constant
region domain renders the antibody defective in initiating
complement-dependent cytolysis. The single nucleotide change
results in the encoding of a serine residue, rather than the normal
proline residue, at amino acid position 436 in the third constant
domain (Wright et al. 1988, J. Biol. Chem. 263: 11221). The amino
acid substitutions that can be made to antibodies in order to alter
complement binding or activity are well known in the art (see for
example, Wright et al. 1988, J. Biol. Chem. 263: 11221; Shulman et
al. (1986), Proc. Natl. Acad. Sci. USA 83: 7678-7682; Arya et al.,
(1994) J. Immunol. 253: 1206-1212; Poon et al., (1995) J. Biol.
Chem. 270: 8571-8577, the contents of all of which are hereby
incorporated by reference). Accordingly, in one embodiment, the
antibodies of the present invention have a mutation that alters
complement binding or activity. Antibodies in which amino acids
have been added, deleted, or substituted are referred to herein as
modified antibodies or altered antibodies. As will be appreciated
by the skilled artisan, the methods used for causing such changes
in nucleotide or amino acid sequence will vary depending upon the
desired results.
[0137] Variants of a natural immunoglobulin can be identified by
screening combinatorial libraries of mutants, e.g., truncation
mutants, of a natural immunoglobulin for agonist or antagonist
activity.
[0138] Libraries of fragments e.g., N terminal, C terminal, or
internal fragments, of a natural immunoglobulin coding sequence can
be used to generate a variegated population of fragments for
screening and subsequent selection of variants of this protein.
Variants in which a cysteine residue is added or deleted or in
which a residue that is glycosylated is added or deleted are
particularly preferred.
[0139] Methods for screening gene products of combinatorial
libraries made by point mutations or truncation, and for screening
cDNA libraries for gene products having a selected property.
Recursive ensemble mutagenesis (REM), a technique which enhances
the frequency of functional mutants in the libraries, can be used
in combination with the screening assays to identify variants
(Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815;
Delgrave et al. (1993) Protein Engineering 6(3):327-331).
[0140] Cell based assays can be exploited to analyze a variegated
library. For example, a library of expression vectors can be
transfected into a cell line, e.g., a cell line, which ordinarily
responds to the protein in a substrate-dependent manner. Plasmid
DNA can then be recovered from the cells which score for
inhibition, or alternatively, potentiation of signaling by the
pathogenic immunoglobulin-substrate, and the individual clones
further characterized.
[0141] The invention also features a method of making a natural
immunoglobulin, e.g., a pathogenic immunoglobulin having a non-wild
type activity, e.g., an antagonist, agonist, or super agonist of a
naturally occurring pathogenic immunoglobulin. The method includes:
altering the sequence of a natural immunoglobulin, e.g., by
substitution or deletion of one or more residues of a non-conserved
region, a domain or residue disclosed herein, and testing the
altered polypeptide for the desired activity.
[0142] Further, the invention features a method of making a
fragment or analog of a natural immunoglobulin, e.g., a pathogenic
immunoglobulin having an altered biological activity of a naturally
occurring pathogenic immunoglobulin. The method includes: altering
the sequence, e.g., by substitution or deletion of one or more
residues, of a pathogenic immunoglobulin, e.g., altering the
sequence of a non-conserved region, or a domain or residue
described herein, and testing the altered polypeptide for the
desired activity. In an exemplary embodiment, the modified natural
immunoglobulin may have a reduced ability to activate complement.
For example, one or more of the amino acid residues involved in
complement binding and/or activation are mutated.
[0143] In certain embodiment, the modified natural antibody may
comprise at least the CDR1 region of SEQ ID NO: 8 (SEQ ID NO: 10),
or antigen binding portions thereof, and/or at least the CDR2
region of SEQ ID NO: 8 (SEQ ID NO: 12), or antigen binding portions
thereof. In another embodiment, the modified antibody may comprise
at least the CDR1 region of SEQ ID NO: 2 (SEQ ID NO: 4), or antigen
binding portions thereof, and/or at least the CDR2 region of SEQ ID
NO: 2 (SEQ ID NO: 6), or antigen binding portions thereof. In an
exemplary embodiment, the modified antibody comprises the CDR1
region of SEQ ID NO: 8 (SEQ ID NO: 10) and the CDR2 region of SEQ
ID NO: 8 (SEQ ID NO: 12) or antigen binding portion thereof. In
another exemplary embodiment, the modified antibody comprises the
CDRI region of SEQ ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of
SEQ ID NO: 2 (SEQ ID NO: 6) or antigen binding portions thereof.
The modified antibody may also comprise the CDRI region of SEQ ID
NO: 8 (SEQ ID NO: IO) and the CDR2 region of SEQ ID NO: 8 (SEQ ID
NO: 12) and the modified antibody comprises the CDR1 region of SEQ
ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of SEQ ID NO: 2 (SEQ ID
NO: 6) or antigen binding portions thereof.
[0144] The modified natural antibody can be a human antibody having
a binding affinity to the ischemic-specific antigen, similar, e.g.,
greater than, less than, or equal to, the binding affinity of the
antibody produced by the hybridoma deposited with the ATCC, having
the accession number PTA-3507. In another embodiment, the natural
antibody can be a non-human antibody, e.g., a cow, goat, mouse,
rat, sheep, pig, or rabbit. In an exemplary embodiment, the
non-human antibody is a murine antibody. The natural antibody may
also be a recombinant antibody. In an exemplary embodiment, the
natural antibody is a humanized antibody. The modified natural
antibody may be an IgG or IgM antibody. In another embodiment, the
isolated natural immunoglobulin possess the same antigenic
specificity as the immunoglobulin produced by the hybridoma
deposited with the ATCC, having accession number PTA-3507.
6.4 Screening Assay to Identify Additional Inhibitors
[0145] Other inhibitors of an interaction between a natural IgM
antibody and an antigen or a component of the complement pathway
may be identified from one or more (e.g., a plurality of) test
compounds, comprising (i) providing a reaction mixture which
includes the natural IgM antibody and the antigen or the component
of the complement pathway under conditions that allow binding of
the natural IgM antibody and the antigen or the component of the
complement pathway to occur; (ii) contacting the natural IgM
antibody and the antigen or the component of the complement pathway
with one or more test compounds (e.g., members of a combinatorial
library); and (iii) detecting any changes in binding of the natural
IgM antibody and the antigen or the component of the complement in
the presence of a given test compound relative to that detected in
the absence of the test compound. A change (e.g., decrease) in the
level of binding between the natural IgM antibody and the antigen
or the component of the complement pathway in the presence of the
test compound relative to that detected in the absence of the test
compound indicates that the test compound is an inhibitor of the
interaction between the natural IgM antibody and the antigen or the
component of the complement pathway.
[0146] The method can further include pre-treating the natural IgM
antibodies with one or more test compounds. The pre-treated natural
IgM antibodies can then be injected into mice deficient in natural
immunoglobulins.
[0147] In certain embodiments, the methods is performed in vitro.
In an exemplary embodiment, the contacting step is effected in
vivo. In an exemplary embodiment, the antigen is myosin. In other
embodiments, the antigen is an endothelial tissue or lysate
obtained from a subject e.g., a human patient with reperfusion or
ischemic injury. In another exemplary embodiment, the component of
the complement pathway is a component of the classical pathway of
complement. In a further exemplary embodiment, the component of the
complement pathway is a C1 molecule or a subunit thereof (e.g.,
C1q).
[0148] In exemplary embodiments, either the natural IgM antibody or
the antigen (or both) is labeled with a detectable signal, e.g.,
fluorophores, colorimetric enzymes, radioisotopes, luminescent
compounds, and the like. The method can further include repeating
at least one step, e.g., the contacting step with a second or
subsequent member or members of the library.
[0149] In an exemplary embodiment, a plurality of test compounds,
e.g., library members, is tested. The plurality of test compounds,
e.g., library members, can include at least 10, 10.sup.2, 10.sup.3,
10.sup.4, 10.sup.5, 10.sup.6, 10.sup.7, or 10.sup.8 compounds. In a
preferred embodiment, the plurality of test compounds, e.g.,
library members, share a structural or functional characteristic.
The test compound can be a peptide or a small organic molecule.
[0150] In one embodiment, the inhibitor is a small organic molecule
that may be identified in a combinatorial library. In one
embodiment, the invention provides libraries of inhibitors. The
synthesis of combinatorial libraries is well known in the art and
has been reviewed (see, e.g. E. M. Gordon et al., J. Med. Chem.
(1994) 37:1385-1401; DeWitt, S. H.; Czarnik, A. W. Acc. Chem. Res.
(1996) 29:114; Armstrong, R. W.; Combs, A. P.; Tempest, P. A.;
Brown, S. D.; Keating, T. A. Acc. Chem. Res. (1996) 29:123; Ellman,
J. A. Acc. Chem. Res. (1996) 29:132; Gordon, E. M.; Gallop, M. A.;
Patel, D. V. Acc. Chem. Res. (1996) 29:144; Lowe, G. Chem. Soc.
Rev. (1995) 309, Blondelle et al., Trends Anal. Chem. (1995) 14:83;
Chen et al. J Am. Chem. Soc. (1994) 116:2661; U.S. Pat. Nos.
5,359,115, 5,362,899, and 5,288,514; PCT Publication Nos.
WO92/10092, WO93/09668, WO91/07087, WO93/20242, WO94/08051).
[0151] Libraries of compounds of the invention can be prepared
according to a variety of methods, some of which are known in the
art. For example, a "split-pool" strategy can be implemented in the
following way: beads of a functionalized polymeric support are
placed in a plurality of reaction vessels; a variety of polymeric
supports suitable for solid-phase peptide synthesis are known, and
some are commercially available (for examples, see, e.g., M.
Bodansky "Principles of Peptide Synthesis", 2nd edition,
Springer-Verlag, Berlin (1993)). To each aliquot of beads is added
a solution of a different activated amino acid, and the reactions
are allowed to proceed to yield a plurality of immobilized amino
acids, one in each reaction vessel. The aliquots of derivatized
beads are then washed, "pooled" (i.e., recombined), and the pool of
beads is again divided, with each aliquot being placed in a
separate reaction vessel. Another activated amino acid is then
added to each aliquot of beads. The cycle of synthesis is repeated
until a desired peptide length is obtained. The amino acid residues
added at each synthesis cycle can be randomly selected;
alternatively, amino acids can be selected to provide a "biased"
library, e.g., a library in which certain portions of the inhibitor
are selected non-randomly, e.g., to provide an inhibitor having
known structural similarity or homology to a known peptide capable
of interacting with an antibody, e.g., the an anti-idiotypic
antibody antigen binding site. It will be appreciated that a wide
variety of peptidic, peptidomimetic, or non-peptidic compounds can
be readily generated in this way.
[0152] The "split-pool" strategy results in a library of peptides,
e.g., inhibitors, which can be used to prepare a library of test
compounds of the invention. In another illustrative synthesis, a
"diversomer library" is created by the method of Hobbs DeWitt et
al. (Proc. Natl. Acad. Sci. USA 90:6909 (1993)). Other synthesis
methods, including the "tea-bag" technique of Houghten (see, e.g.,
Houghten et al., Nature 354:84-86 (1991)) can also be used to
synthesize libraries of compounds according to the subject
invention. Libraries of compounds can be screened to determine
whether any members of the library have a desired activity, and, if
so, to identify the active species. Methods of screening
combinatorial libraries have been described (see, e.g., Gordon et
al., J Med. Chem., supra). Soluble compound libraries can be
screened by affinity chromatography with an appropriate receptor to
isolate ligands for the receptor, followed by identification of the
isolated ligands by conventional techniques (e.g., mass
spectrometry, NMR, and the like). Immobilized compounds can be
screened by contacting the compounds with a soluble receptor;
preferably, the soluble receptor is conjugated to a label (e.g.,
fluorophores, colorimetric enzymes, radioisotopes, luminescent
compounds, and the like) that can be detected to indicate ligand
binding. Alternatively, immobilized compounds can be selectively
released and allowed to diffuse through a membrane to interact with
a receptor. Exemplary assays useful for screening the libraries of
the invention are described below.
[0153] In one embodiment, compounds of the invention can be
screened for the ability to interact with a natural immunoglobulin
by assaying the activity of each compound to bind directly to the
immunoglobulin or to inhibit an interaction between the
immunoglobulin and an ischemic antigen, e.g., by incubating the
test compound with an immunoglobulin and a lysate, e.g., an
endothelial cell lysate, e.g., in one well of a multiwell plate,
such as a standard 96-well microtiter plate. In this embodiment,
the activity of each individual compound can be determined. A well
or wells having no test compound can be used as a control. After
incubation, the activity of each test compound can be determined by
assaying each well. Thus, the activities of a plurality of test
compounds can be determined in parallel.
6.5 Modified Inhibitors and Pharmaceutical and Diagnostic
Preparations
[0154] IgM inhibitors may be modified, for example to increase
solubility and/or facilitate purification, identification,
detection, and/or structural characterization. Exemplary
modifications, include, for example, addition of: glutathione
S-transferase (GST), protein A, protein G, calmodulin-binding
peptide, thioredoxin, maltose binding protein, HA, myc,
poly-arginine, poly-His, poly-His-Asp or FLAG fusion proteins and
tags. In various embodiments, an IgM inhibitors may comprise one or
more heterologous fusions. For example, peptides may contain
multiple copies of the same fusion domain or may contain fusions to
two or more different domains. The fusions may occur at the
N-terminus of the peptide, at the C-terminus of the peptide, or at
both the N- and C-terminus of the peptide. It is also within the
scope of the invention to include linker sequences between a
peptide of the invention and the fusion domain in order to
facilitate construction of the fusion protein or to optimize
protein expression or structural constraints of the fusion protein.
In another embodiment, the peptide may be constructed so as to
contain protease cleavage sites between the fusion peptide and
peptide of the invention in order to remove the tag after protein
expression or thereafter. Examples of suitable endoproteases,
include, for example, Factor Xa and TEV proteases.
[0155] Techniques for making fusion genes are well known.
Essentially, the joining of various DNA fragments coding for
different polypeptide sequences is performed in accordance with
conventional techniques, employing blunt-ended or stagger-ended
termini for ligation, restriction enzyme digestion to provide for
appropriate termini, filling-in of cohesive ends as appropriate,
alkaline phosphatase treatment to avoid undesirable joining, and
enzymatic ligation. In another embodiment, the fusion gene may be
synthesized by conventional techniques including automated DNA
synthesizers. Alternatively, PCR amplification of gene fragments
may be carried out using anchor primers which give rise to
complementary overhangs between two consecutive gene fragments,
which may subsequently be annealed to generate a chimeric gene
sequence (see, for example, Current Protocols in Molecular Biology,
eds. Ausubel et al., John Wiley & Sons: 1992).
[0156] IgM inhibitors may be chemically modified based on linkage
to a polymer. The polymer is typically water soluble so that the
inhibitor to which it is attached does not precipitate in an
aqueous environment, such as a physiological environment. The
polymer may have a single reactive group, such as an active ester
for acylation or an aldehyde for alkylation, so that the degree of
polymerization may be controlled. A preferred reactive aldehyde is
polyethylene glycol propionaldehyde, which is water stable, or mono
C1-C10 alkoxy or aryloxy derivatives thereof (see U.S. Pat. No.
5,252,714). The polymer may be branched or unbranched. Preferably,
for therapeutic use of the end-product preparation, the polymer
will be pharmaceutically acceptable. The water soluble polymer, or
mixture thereof if desired, may be selected from the group
consisting of, for example, polyethylene glycol (PEG),
monomethoxy-polyethylene glycol, dextran, cellulose, or other
carbohydrate based polymers, poly-(N-vinyl pyrrolidone)
polyethylene glycol, propylene glycol homopolymers, a polypropylene
oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g.,
glycerol) and polyvinyl alcohol.
[0157] IgM inhibitors may be labeled, for example with an isotopic
label to facilitate its detection using nuclear magnetic resonance
or another applicable technique. Exemplary isotopic labels include
radioisotopic labels such as, for example, potassium-40 (.sup.40K),
carbon-14 (.sup.14c) tritium (.sup.3H), sulphur-35 (.sup.35S),
phosphorus-32 (.sup.32P), technetium-99m (.sup.99mTc), thallium-201
(.sup.201Tl), gallium-67 (.sup.67Ga), indium-111 (.sup.111In),
iodine-123 (.sup.1231), iodine-131 (.sup.131I), yttrium-90
(.sup.90Y), samarium-153 (.sup.153Sm), rhenium-186 (.sup.186Re),
rhenium-188 (.sup.188Re), dysprosium-165 (.sup.165Dy) and
holmium-166 (.sup.166Ho). The isotopic label may also be an atom
with non-zero nuclear spin, including, for example, hydrogen-I
(.sup.1H), hydrogen-2 (.sup.2H), hydrogen-3 (3H), phosphorous-31
(.sup.31P), sodium-23 (.sup.23Na), nitrogen-14 (.sup.14N),
nitrogen-15 (.sup.15N), carbon-13 (.sup.13C) and fluorine-19
(.sup.19F). In certain embodiments, the inhibitor is uniformly
labeled with an isotopic label, for example, wherein at least 50%,
70%, 80%, 90%, 95%, or 98% of the inhibitor is labeled. In other
embodiments, the isotopic label is located in one or more specific
locations within the inhibitor, for example, the label may be
specifically incorporated into one or more of the leucine residues
of a peptide. A single inhibitor may comprise two or more different
isotopic labels, for example, a peptide may comprise both .sup.15N
and .sup.13C labeling.
[0158] Inhibitors may be labeled with a fluorescent label. In an
exemplary embodiment, an inhibitor is fused to a heterologous
polypeptide sequence which produces a detectable fluorescent
signal, including, for example, green fluorescent protein (GFP),
enhanced green fluorescent protein (EGFP), Renilla reniformis green
fluorescent protein, GFPmut2, GFPuv4, enhanced yellow fluorescent
protein (EYFP), enhanced cyan fluorescent protein (ECFP), enhanced
blue fluorescent protein (EBFP), citrine and red fluorescent
protein from discosoma (dsRED).
[0159] Toxicity and therapeutic efficacy of natural antibody
inhibitors including natural IgM antibody-binding peptides or
modified natural IgM antibodies can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD.sub.50 (the dose lethal to 50% of the
population) and the ED.sub.50 (the dose therapeutically effective
in 50% of the population). The dose ratio between toxic and
therapeutic effects is the therapeutic index and it can be
expressed as the ratio LD.sub.50/ED.sub.50. Natural antibody
inhibitors which exhibit large therapeutic effects are preferred.
While natural antibody inhibitors or natural antibody binding
peptides that exhibit toxic side effects may be used, care should
be taken to design a delivery system that targets such peptides or
modified antibodies to the site of affected tissue in order to
minimize potential damage to uninfected cells and, thereby, reduce
side effects.
[0160] The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use in
humans. The dosage of a natural antibody inhibitor or a natural
antibody-binding peptides lies preferably within a range of
circulating concentrations that include the ED.sub.50 with little
or no toxicity. The dosage may vary within this range depending
upon the dosage form employed and the route of administration
utilized. For any inhibitor or peptide used in the method of the
invention, the therapeutically effective dose can be estimated
initially from cell culture assays. A dose may be formulated in
animal models to achieve circulating plasma concentration range
that includes the IC.sub.50 (i.e., the concentration of the test
compound which achieves a half-maximal inhibition of symptoms) as
determined in cell culture. Such information can be used to more
accurately determine useful doses in humans. Levels in plasma may
be measured, for example, by high performance liquid
chromatography.
[0161] In another embodiment, a single bolus of a natural antibody
inhibitor including a natural IgM antibody-binding peptide and
modified natural IgM antibodies is administered prior to,
contemporaneously with, or subsequent to a tissue injury. Typically
a single dose injection will be a few hours, a few days or a few
weeks after tissue injury. The present invention is based in part
upon the discovery that a natural IgM antibody inhibitor prevents
reperfusion injury. A single unit dosage delivery can be
immediately adjacent to the site of injury or can be, for example,
to a vessel that drains or flows to the site of injury.
[0162] A natural IgM antibody inhibitor such as natural IgM
antibody-binding peptide or modified natural IgM antibody is
administered initially at a point in time prior to the time of
damage of the target organ or tissue. This may be a useful approach
in subjects who are determined to be at risk for reperfusion
injury, such as those with a history of reperfusion injury or those
about to undergo surgery.
[0163] In yet another embodiment, a single bolus of a natural IgM
antibody inhibitor can be followed by subsequence administrations
of a natural IgM antibody inhibitor as continuous infusions or
additional single bolus deliveries. The inhibitor may be administer
in sequential exposures over a period of hours, days, weeks, months
or years. In addition, it is contemplated that additional
therapeutic agents can be combined with, administered prior to or
subsequent to administration of a natural antibody-binding peptide
or another natural antibody inhibitor. Other therapeutic agents
that may be administered with a natural IgM antibody inhibitor
include, but are not limited to, anti-coagulation agents and
complement inhibitors.
[0164] The subject inhibitors may be provided in pharmaceutically
acceptable carriers or formulated for a variety of modes of
administration, including systemic and topical or localized
administration. Techniques and formulations generally may be found
in Remington's Pharmaceutical Sciences, Meade Publishing Co.,
Easton, Pa. In certain embodiments, the inhibitor is provided for
transmucosal or transdermal delivery. For such administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation with the polypeptide. Such penetrants are generally
known in the art, and include, for example, for transmucosal
administration bile salts and fusidic acid derivatives. In
addition, detergents may be used to facilitate permeation.
Transmucosal administration may be through nasal sprays or using
suppositories. For topical administration, the inhibitors of the
invention are formulated into ointments, salves, gels, or creams as
generally known in the art.
[0165] The pharmaceutical compositions according to the invention
are prepared by bringing a natural IgM antibody inhibitors into a
form suitable for administration to a subject using carriers,
excipients and additives or auxiliaries. Frequently used carriers
or auxiliaries include magnesium carbonate, titanium dioxide,
lactose, mannitol and other sugars, talc, milk protein, gelatin,
starch, vitamins, cellulose and its derivatives, animal and
vegetable oils, polyethylene glycols and solvents, such as sterile
water, alcohols, glycerol and polyhydric alcohols. Intravenous
vehicles include fluid and nutrient replenishers. Preservatives
include antimicrobial, anti-oxidants, chelating agents and inert
gases. Other pharmaceutically acceptable carriers include aqueous
solutions, non-toxic excipients, including salts, preservatives,
buffers and the like, as described, for instance, in Remington's
Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co.,
1405-1412, 1461-1487 (1975) and The National Formulary XIV, 14th
ed. Washington: American Pharmaceutical Association (1975), the
contents of which are hereby incorporated by reference. The pH and
exact concentration of the various components of the pharmaceutical
composition are adjusted according to routine skills in the art.
See Goodman and Oilman's The Pharmacological Basis for Therapeutics
(7th ed.).
[0166] The pharmaceutical compositions are preferably prepared and
administered in dose units. Solid dose units are tablets, capsules
and suppositories and including, for example, alginate based pH
dependent release gel caps. For treatment of a subject, depending
on activity of the compound, manner of administration, nature and
severity of the disorder, age and body weight of the subject,
different daily doses are necessary. Under certain circumstances,
however, higher or lower daily doses may be appropriate. The
administration of the daily dose can be carried out both by single
administration in the form of an individual dose unit or by several
smaller dose units and also by multiple administration of
subdivided doses at specific intervals.
[0167] The pharmaceutical compositions according to the invention
may be administered locally or systemically in a therapeutically
effective dose. Amounts effective for this use will, of course,
depend on the severity of the disease and the weight and general
state of the subject. As discussed above, dosages used in vitro may
provide useful guidance in the amounts useful for in situ
administration of the pharmaceutical composition, and animal models
may be used to determine effective dosages for treatment of
particular disorders. Various considerations are described, e.g.,
in Langer, Science, 249: 1527, (1990); Gilman et al. (eds.) (1990),
each of which is herein incorporated by reference.
[0168] In one embodiment, the invention provides a pharmaceutical
composition useful for administering a natural antibody-binding
peptide to a subject in need of such treatment. "Administering" the
pharmaceutical composition of the invention may be accomplished by
any means known to the skilled artisan. Preferably a "subject"
refers to a mammal, most preferably a human.
[0169] The natural IgM antibody inhibitor can be administered
parenterally, enterically, by injection, rapid infusion,
nasopharyngeal absorption, dermal absorption, rectally and orally.
Pharmaceutically acceptable carrier preparations for parenteral
administration include sterile or aqueous or non-aqueous solutions,
suspensions, and emulsions. Examples of non-aqueous solvents are
propylene glycol, polyethylene glycol, vegetable oils such as olive
oil, and injectable organic esters such as ethyl oleate. Carriers
for occlusive dressings can be used to increase skin permeability
and enhance antigen absorption. Liquid dosage forms for oral
administration may generally comprise a liposome solution
containing the liquid dosage form. Suitable solid or liquid
pharmaceutical preparation forms are, for example, granules,
powders, tablets, coated tablets, (micro)capsules, suppositories,
syrups, emulsions, suspensions, creams, aerosols, drops or
injectable solution in ampule form and also preparations with
protracted release of active compounds, in whose preparation
excipients and additives and/or auxiliaries such as disintegrants,
binders, coating agents, swelling agents, lubricants, flavorings,
sweeteners and elixirs containing inert diluents commonly used in
the art, such as purified water. Where the disease or disorder is a
gastrointestinal disorder oral formulations or suppository
formulations are preferred.
[0170] Sterile injectable solutions can be prepared by
incorporating a natural antibody-binding peptide in the required
amount (e.g., about 10 .mu.g to about 10 mg/kg) in an appropriate
solvent and then sterilizing, such as by sterile filtration.
Further, powders can be prepared by standard techniques such as
freeze drying or vacuum drying.
[0171] In another embodiment, a natural IgM antibody inhibitor is
prepared with a biodegradable carrier for sustained release
characteristics for either sustained release in the GI tract or for
target organ implantation with long term active agent release
characteristics to the intended site of activity. Biodegradable
polymers include, for example, ethylene vinyl acetate,
polyanhydrides, polyglycolic acids, polylactic acids, collagen,
polyorthoesters, and poly acetic acid. Liposomal formulation can
also be used.
[0172] Another means of delivering natural IgM antibody inhibitor
(e.g., a natural IgM antibody-binding peptide) is by delivering
host cells that express natural antibody-binding peptides to a site
or tissue in need of repair. Alternatively, the cells may be
delivered in conjunction with various delivery vehicles, including
biocompatible biodegradable or non-biodegradable sponges (e.g.,
collagen, or other extracellular matrix materials), cotton,
polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran,
polyamide, a polyester, a polystyrene, a polypropylene, a
polyacrylate, a polyvinyl, a polycarbonate, a
polytetrafluorethylene, or a nitrocellulose compound formed into a
three-dimensional structure (see, for example, U.S. Pat. No.
5,858,721 to Naughton et al., the disclosure of which is
incorporated herein by reference).
[0173] Any route of administration compatible with the active
principle can be used. The preferred is parenteral administration,
such as subcutaneous, intramuscular or intravenous injection. The
dose of the active ingredient to be administered depends on the
basis of the medical prescriptions according to age, weight and the
individual response of the patient.
[0174] The daily non-weighted dosage for the patient can be between
about 2.5-5.0 mg/Kg, e.g., about 2.5-3.0 mg/Kg, about 3.0-3.5
mg/Kg, about 3.5-4.0 mg/Kg, about 4.0-4.5 mg/Kg, and about 4.5-5.0
mg/Kg.
[0175] The pharmaceutical composition for parenteral administration
can be prepared in an injectable form comprising the active
principle and a suitable vehicle. Vehicles for the parenteral
administration are well known in the art and comprise, for example,
water, saline solution, Ringer solution and/or dextrose.
[0176] The vehicle can contain small amounts of excipients in order
to maintain the stability and isotonicity of the pharmaceutical
preparation.
[0177] The preparation of the cited solutions can be carried out
according to the ordinary modalities.
[0178] The present invention has been described with reference to
the specific embodiments, but the content of the description
comprises all modifications and substitutions which can be brought
by a person skilled in the art without extending beyond the meaning
and purpose of the claims. The compositions may, if desired, be
presented in a pack or dispenser device which may contain one or
more unit dosage forms containing the active ingredient. The pack
may for example comprise metal or plastic foil, such as a blister
pack. The pack or dispenser device may be accompanied by
instructions for administration.
6.6 Diseases and Conditions that can be Treated with Natural IgM
Antibody Inhibitors
[0179] IgM inhibitors, such as natural IgM antibody-binding
peptides or modified natural IgM antibodies, may be used for
treating a number of inflammatory diseases and conditions that are
triggered by binding of natural IgM antibodies. For instance, the
inhibitors may be used to treat inflammatory diseases or conditions
such as reperfusion injury, ischemia injury, stroke, autoimmune
hemolytic anemia, idiopathic thrombocytopenic purpura, rheumatoid
arthritis, celiac disease, hyper-IgM immunodeficiency,
arteriosclerosis, coronary artery disease, sepsis, myocarditis,
encephalitis, transplant rejection, hepatitis, thyroiditis (e.g.,
Hashimoto's thyroiditis, Graves disease), osteoporosis,
polymyositis, dermatomyositis, Type I diabetes, gout, dermatitis,
alopecia areata, systemic lupus erythematosus, lichen sclerosis,
ulcerative colitis, diabetic retinopathy, pelvic inflammatory
disease, periodontal disease, arthritis, juvenile chronic arthritis
(e.g., chronic iridocyclitis), psoriasis, osteoporosis, nephropathy
in diabetes mellitus, asthma, pelvic inflammatory disease, chronic
inflammatory liver disease, chronic inflammatory lung disease, lung
fibrosis, liver fibrosis, rheumatoid arthritis, chronic
inflammatory liver disease, chronic inflammatory lung disease, lung
fibrosis, liver fibrosis, Crohn's disease, ulcerative colitis, burn
injury (or thermal injury), and other acute and chronic
inflammatory diseases of the Central Nervous System (CNS; e.g.,
multiple sclerosis), gastrointestinal system, the skin and
associated structures, the immune system, the hepato-biliary
system, or any site in the body where pathology can occur with an
inflammatory component.
[0180] An inflammatory condition such as reperfusion or ischemic
injury may result following a naturally occurring episode, e.g., as
a stroke or myocardial infarction. Reperfusion or ischemic injury
may also occur during and/or following a surgical procedure.
Exemplary surgical procedures that cause can cause injury include a
vessel-corrective technique selected from the group consisting of
angioplasty, stenting procedure, atherectomy, and bypass surgery.
In an exemplary embodiment, reperfusion or ischemic injury occurs
in a cardiovascular tissue, such as the heart.
[0181] In addition, diseases or conditions that are triggered by
binding of natural IgM antibodies may be treated or prevented in a
subject by removing from the subject or inactivating a natural or
pathogenic IgM and/or B cells producing the pathogenic
immunoglobulin (e.g., B-1 cells as described herein), thereby
reducing the amount of the pathogenic immunoglobulin and/or B cells
present in the subject.
[0182] The methods described herein may comprise removing from the
subject or inactivating a pathogenic immunoglobulin, e.g., a
pathogenic IgM as described herein, and/or B-cells producing the
pathogenic IgM (e.g., B-1 cells as described herein), thereby
reducing the amount of the pathogenic immunoglobulin and/or B cells
present in the subject.
[0183] In one embodiment, the removing or inactivating step is
performed ex vivo. The pathogenic immunoglobulins or B cells can be
removed by hemoperfusion. Alternatively, the B cells can be removed
using a B cell-specific antibody (e.g., an anti-B-1 antibody or an
anti-CD5 antibody or anti-CD 11 G/CD 18). The pathogenic
immunoglobulin, e.g., an IgM, can be removed by contacting blood
from a subject with an immobilized antigen (e.g., an
ischemia-specific antigen) or an immobilized anti-idiotypic
antibody. The removing or inactivating step of the pathogenic
immunoglobulin may be performed by administering an anti-idiotypic
antibody to the subject. In another embodiment, the removing or
inactivating step of the B cell is performed by administering to
the subject a B cell targeting moiety (e.g., an antibody or an
antigen binding fragment thereof, or an antigen) coupled to a
toxin, e.g., ricin or diphteria toxin. The subject is a mammal,
e.g., a rodent (e.g., a mouse) or a primate (e.g., a human). In an
exemplary embodiment, the subject has sustained a reperfusion or
ischemic injury following a naturally occurring episode, e.g., as a
stroke, and the removing step is carried out within minutes, one to
five hours, five to ten hours, ten to twenty hours, one to five
days, following the naturally occurring episode. In another
exemplary embodiment, the reperfusion or ischemic injury occurs in
a cardiovascular tissue, e.g., the heart, and the reperfusion or
ischemic injury is prevented and/or decreased by, removing from the
subject, the pathogenic immunoglobulin, and/or the B cells, prior
to, during, and/or following the surgical procedure. For example,
the removing step can be carried out at least one to five hours,
five to ten hours, ten to twenty hours, or one, two or three days
prior to the surgical procedure. The removing step can also be
continued for appropriate time intervals during and after the
surgical procedure.
6.7 Diagnostic Assays
[0184] The invention further provides a method for detecting the
presence of a natural IgM antibody in a biological sample.
Detection of a natural IgM antibody in a subject, particularly
mammal, and especially a human, will provide a diagnostic method
for diagnosis of an inflammatory disease or condition in the
subject. In general, the method involves contacting the biological
sample with a compound or an agent capable of detecting natural IgM
antibody of the invention or a nucleic acid of the invention in the
sample. The term "biological sample" when used in reference to a
diagnostic assay is intended to include tissues, cells and
biological fluids isolated from a subject, as well as tissues,
cells and fluids present within a subject.
[0185] The detection method of the invention may be used to detect
the presence of a natural IgM antibody or a nucleic acid of the
invention in a biological sample in vitro as well as in vivo. For
example, in vitro techniques for detection of a nucleic acid of the
invention include Northern hybridizations and in situ
hybridizations. In vitro techniques for detection of polypeptides
of the invention include enzyme linked immunosorbent assays
(ELISAs), Western blots, immunoprecipitations, immunofluorescence,
radioimmunoassays and competitive binding assays.
[0186] Nucleic acids for diagnosis may be obtained from an infected
individual's cells and tissues, such as bone, blood, muscle,
cartilage, and skin. Nucleic acids, e.g., DNA and RNA, may be used
directly for detection or may be amplified, e.g., enzymatically by
using PCR or other amplification technique, prior to analysis.
Using amplification, characterization of the species and strain of
prokaryote present in an individual, may be made by an analysis of
the genotype of the prokaryote gene. Deletions and insertions can
be detected by a change in size of the amplified product in
comparison to the genotype of a reference sequence. Point mutations
can be identified by hybridizing a nucleic acid, e.g., amplified
DNA, to a nucleic acid of the invention, which nucleic acid may be
labeled. Perfectly matched sequences can be distinguished from
mismatched duplexes by RNase digestion or by differences in melting
temperatures. DNA sequence differences may also be detected by
alterations in the electrophoretic mobility of the DNA fragments in
gels, with or without denaturing agents, or by direct DNA
sequencing. See, e.g. Myers et al., Science, 230: 1242 (1985).
Sequence changes at specific locations also may be revealed by
nuclease protection assays, such as RNase and S1 protection or a
chemical cleavage method. See, e.g., Cotton et al., Proc. Natl.
Acad. Sci., USA, 85: 4397-4401 (1985).
[0187] Agents for detecting a nucleic acid of the invention, e.g.,
comprising the sequence set forth in a subject nucleic acid
sequence, include labeled nucleic acid probes capable of
hybridizing to a nucleic acid of the invention. The nucleic acid
probe can comprise, for example, the full length sequence of a
nucleic acid of the invention, or an equivalent thereof, or a
portion thereof, such as an oligonucleotide of at least 15, 30, 50,
100, 250 or 500 nucleotides in length and sufficient to
specifically hybridize under stringent conditions to a subject
nucleic acid sequence, or the complement thereof. Agents for
detecting a polypeptide of the invention, e.g., comprising an amino
acid sequence of a subject amino acid sequence, include labeled
anti-antibodies capable of binding to a natural IgM antibody of the
invention. Anti-idiotypic antibodies may be polyclonal, or
alternatively, monoclonal. An intact anti-idiotypic antibody, or a
fragment thereof can be used. Labeling the probe or antibody also
encompasses direct labeling of the probe or antibody by coupling
(e.g., physically linking) a detectable substance to the probe or
antibody, as well as indirect labeling of the probe or antibody by
reactivity with another reagent that is directly labeled. Examples
of indirect labeling include detection of a primary antibody using
a fluorescently labeled secondary antibody and end-labeling of a
DNA probe with biotin such that it can be detected with
fluorescently labeled streptavidin.
[0188] In certain embodiments, detection of a nucleic acid of the
invention in a biological sample involves the use of a probe/primer
in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos.
4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or,
alternatively, in a ligation chain reaction (LCR) (see, e.g.,
Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al.
(1994) PNAS 91:360-364), the latter of which can be particularly
useful for distinguishing between orthologs of polynucleotides of
the invention (see Abravaya et al. (1995) Nucleic Acids Res.
23:675-682). This method can include the steps of collecting a
sample of cells from a patient, isolating nucleic acid (e.g.,
genomic, mRNA or both) from the cells of the sample, contacting the
nucleic acid sample with one or more primers which specifically
hybridize to a nucleic acid of the invention under conditions such
that hybridization and amplification of the polynucleotide (if
present) occurs, and detecting the presence or absence of an
amplification product, or detecting the size of the amplification
product and comparing the length to a control sample.
[0189] In one aspect, the present invention contemplates a method
for detecting the presence of a natural IgM antibody in a sample,
the method comprising: (a) providing a sample to be tested for the
presence of a natural IgM antibody; (b) contacting the sample with
an anti-idiotypic antibody reactive against about eight consecutive
amino acid residues of a subject amino acid sequence from such
species under conditions which permit association between the
anti-idiotypic antibody and its ligand; and (c) detecting
interaction of the anti-idiotypic antibody with its ligand, thereby
detecting the presence of a natural IgM antibody in the sample.
[0190] In another aspect, the present invention contemplates a
method for detecting the presence of a natural IgM antibody in a
sample, the method comprising: (a) providing a sample to be tested
for the presence of a natural IgM antibody; (b) contacting the
sample with an anti-idiotypic antibody that binds specifically to a
polypeptide of the invention from such species under conditions
which permit association between the anti-idiotypic antibody and
its ligand; and (c) detecting interaction of the anti-idiotypic
antibody with its ligand, thereby detecting the presence of such
species in the sample.
[0191] In yet another example, the present invention contemplates a
method for diagnosing a patient suffering from an inflammatory
disease or condition related to the presence of a natural IgM
antibody, comprising: (a) obtaining a biological sample from a
patient; (b) detecting the presence or absence of a polypeptide of
the invention, e.g., a natural IgM antibody, or a nucleic acid
encoding a polypeptide of the invention, in the sample; and (c)
diagnosing a patient suffering from such an inflammatory disease or
condition based on the presence of a polypeptide of the invention,
or a nucleic acid encoding a polypeptide of the invention, in the
patient sample.
[0192] The diagnostic assays of the invention may also be used to
monitor the effectiveness of a treatment in an individual suffering
from an inflammatory disease or condition related to a natural IgM
antibody. For example, the presence and/or amount of a nucleic acid
of the invention or a polypeptide of the invention can be detected
in an individual suffering from an inflammatory disease or
condition related to a natural IgM antibody before and after
treatment with a natural IgM antibody therapeutic agent. Any change
in the level of a polynucleotide or polypeptide of the invention
after treatment of the individual with the therapeutic agent can
provide information about the effectiveness of the treatment
course. In particular, no change, or a decrease, in the level of a
polynucleotide or polypeptide of the invention present in the
biological sample will indicate that the therapeutic is
successfully combating such disease or disorder.
[0193] Alternatively, polypeptides of the invention, e.g., natural
IgM antibodies, can be detected in vivo in a subject by introducing
into the subject a labeled antibody specific for a polypeptide of
the invention, e.g., an anti-idiotypic antibody to detect natural
IgM antibodies. For example, the anti-idiotypic antibody can be
labeled with a radionuclide marker whose presence and location in a
subject can be detected by standard imaging techniques.
[0194] A "radionuclide" refers to molecule that is capable of
generating a detectable image that can be detected either by the
naked eye or using an appropriate instrument, e.g. positron
emission tomography (PET), and single photon emission tomography
(SPECT). Radionuclides useful within the present disclosure include
penetrating photon emitters including gamma emitters and X-ray
emitters. These rays accompany nuclear transformation such as
electron capture, beta emission and isomeric transition.
Radionuclides useful include those with photons between 80 and 400
keV and positron producers, 511 keV annihilation photons and
acceptable radiation doses due to absorbed photons, particles and
half-life. Radionuclides include radioactive isotopes of an
element. Examples of radionuclides include .sup.123I, .sup.125I,
.sup.99mTc, .sup.18F, .sup.68Ga, .sup.62Cu, .sup.111IN, .sup.131I,
.sup.188RE, .sup.90Y, .sup.212Bi, .sup.211AT, .sup.89Sr,
.sup.166Ho, .sup.153Sm, .sup.67Cu, .sup.64Cu, .sup.100Pd,
.sup.109Pd, .sup.67Ga, .sup.94Tc, .sup.105Rh, .sup.95Ru,
.sup.177Lu, .sup.170Lu, .sup.11C, and .sup.76Br.
[0195] In one embodiment, an anti-idiotypic antibody that
recognizes a natural IgM antibody of the present invention may be
labeled with .sup.99MTC. .sup.9mTc, a commonly used radionuclide in
Nuclear Medicine, combines desirable physical properties with a 6
hr half-life and a 140-KeV gamma energy (85% as gamma photons) and
widespread availability, since it can readily be eluted from
molybdenum generators.
[0196] The imaging agents of the disclosure may be used in the
following manner. An effective amount of the imaging agent (from 1
to 50 mCi) may be combined with a pharmaceutically acceptable
carrier for use in imaging studies. In accordance with the
disclosure, "an effective amount" of the imaging agent of the
disclosure is defined as an amount sufficient to yield an
acceptable image using equipment which is available for clinical
use. An effective amount of the imaging agent of the disclosure may
be administered in more than one injection. Effective amounts of
the imaging agent of the disclosure will vary according to factors
such as the degree of susceptibility of the individual, the age,
sex, and weight of the individual, idiosyncratic responses of the
individual and dosimetry. Effective amounts of the imaging agent of
the disclosure will also vary according to instrument and
film-related factors. Optimization of such factors is well within
the level of skill of a person skilled in the art.
[0197] The amount of imaging agent used for diagnostic purposes and
the duration of the imaging study will depend upon the nature and
severity of the condition being treated, on the nature of
therapeutic treatments which the patient has undergone, and on the
idiosyncratic responses of the patient. Ultimately, the attending
physician will decide the amount of imaging agent to administer to
each individual patient and the duration of the imaging study.
[0198] The pharmaceutically acceptable carrier for an imaging agent
of the disclosure may include any and all solvents, dispersion
media, coatings, antibacterial and antifungal agents,
pharmaceutically active substances is well known in the art. The
imaging agent of the disclosure isotonic agents, absorption
delaying agents, and the like. The use of such media and agents for
may further be administered to an individual in an appropriate
diluent or adjuvant, co-administered with enzyme inhibitors or in
an appropriate carrier such as human serum albumin or liposomes.
Supplementary active compounds can also be incorporated into the
imaging agent of the disclosure. Pharmaceutically acceptable
diluents; include saline and aqueous buffer solutions. Adjuvants
contemplated herein include resorcinols, non-ionic surfactants such
as polyoxyethylene oleyl ether and nhexadecyl polyethylene ether.
Enzyme inhibitors include pancreatic trypsin inhibitor,
diethylpyrocarbonate, and trasylol. Liposomes include
water-in-oil-in-water CGF emulsions as well as conventional
liposomes (Strejan et al. (1984).1 Neuroimmunol. 7, 27).
[0199] In one embodiment, the imaging agent of the disclosure is
administered parenterally as injections (intravenous, intramuscular
or subcutaneous). The imaging agent may be formulated as a sterile,
pyrogen-free, parenterally acceptable aqueous solution. The
preparation of such parenterally acceptable solutions, having due
regard to pH, isotonicity, stability, and the like, is within the
skill in the art. Certain pharmaceutical compositions of this
disclosure suitable for parenteral administration comprise one or
more imaging agents in combination with one or more
pharmaceutically acceptable sterile powders which may be
reconstituted into sterile injectable solutions or dispersions just
prior to use, which may contain antioxidants, buffers,
bacteriostats, solutes which render the formulation isotonic with
the blood of the intended recipient or suspending or thickening
agents. A formulation for injection should contain, in addition to
the cardiovascular imaging agent, an isotonic vehicle such as
sodium chloride solution, Ringer's solution, dextrose solution,
dextrose and sodium chloride solution, lactated Ringer's solution,
dextran solution, sorbitol solution, a solution containing
polyvinyl alcohol, or an osmotically balanced solution comprising a
surfactant and a viscosity-enhancing agent, or other vehicle as
known in the art. The formulation used in the present disclosure
may also contain stabilizers, preservatives, buffers, antioxidants,
or other additives known to those of skill in the art.
[0200] The invention also encompasses kits for detecting the
presence of a natural IgM antibody in a biological sample. For
example, the kit can comprise a labeled compound or agent capable
of detecting a polynucleotide or polypeptide of the invention in a
biological sample; means for determining the amount of a natural
IgM antibody in the sample; and means for comparing the amount of a
natural IgM antibody in the sample with a standard. An unlabeled
compound may also be provided with instructions for labeling the
compound. The compound or agent can be packaged in a suitable
container. The kit can further comprise instructions for using the
kit to detect a polynucleotide or polypeptide of the invention.
EXEMPLIFICATION
[0201] The invention, having been generally described, may be more
readily understood by reference to the following examples, which
are included merely for purposes of illustration of certain aspects
and embodiments of the present invention, and are not intended to
limit the invention in any way.
Example 1: Mechanism of Ischemia-Reperfusion Injury
[0202] This Example shows that mice deficient in the complement
system were resistant to ischemia-reperfusion injury.
[0203] To examine the mechanism of ischemia-reperfusion injury,
mice deficient in complement C3 were treated in the hindlimb model.
The C3-/- mice were partially protected from injury based on an
approximate 50% reduction in permeability index (see Weiser et al.
(1996) J. Exp. Med. 1857-1864). Thus, complement C3 is essential
for induction of full injury in this murine model.
[0204] The experiments in Weiser et al. did not identify how
complement was activated. The serum complement system can be
activated by at least three distinct pathways, classical, lectin or
alternative. Knowing which pathway is involved, is important as it
suggests a mechanism for injury. For example, the classical
pathways is activated very efficiently by IgM and IgG isotypes of
immunoglobulin or by the serum recognition protein C-reactive
protein. Whereas, the lectin pathway is activated following
recognition of specific carbohydrates such as mannan by mannan
binding lectin (MBL) (Epstein et al., (1996) Immunol 8, 29-35). In
both pathways, complement C4 is required in forming an enzyme
complex with C2 that catalyzes cleavage of the central component
C3. By contrast, the alternative pathway activates spontaneously
leading to conversion of C3 to its active form (C3b) and attachment
to foreign- or self-tissues. The pathway is tightly regulated as
all host cells express inhibitors of amplification of the
complement pathway by inactivating, or displacing the C3 convertase
(Muller-Eberhard, H. J., (1988) Ann. Rev. Biochem. 57, 321-347).
One approach for determining the pathway involved is use of mice
deficient in C4, i.e., cannot form C3 convertase via classical or
lectin pathways. Comparison of mice deficient in either C3 or C4
with wild type (WT) controls in the hindlimb model, revealed that
C4 was also required for induction of full injury (Weiser et al.
supra). This finding was important as it suggested that antibody or
MBL might be involved.
Example 2: Natural IgM Mediates Ischemia Reperfusion (I/R)
Injury
[0205] This Example shows that mice deficient in immunoglobulin
were resistant to ischemia reperfusion injury.
[0206] To determine if antibody was involved in mediating I/R
injury, mice totally deficient in immunoglobulin, RAG2-/-
(recombinase activating gene-2 deficient) were characterized along
with the complement deficient animals in the intestinal model.
Significantly, the RAG-2-/- mice were protected to a similar level
as observed in the complement deficient animals (Weiser et al.
supra). Since the RAG2-/- animals are also missing mature
lymphocytes, it was important to determine that the pathogenic
effect was antibody dependent (Shinkai et al. (1992) Cell 68,
855-867). To confirm that injury was mediated by serum antibody,
the deficient animals were reconstituted with either normal mouse
sera (Weiser et al. supra) or purified IgM (Williams et al. (1999)
J. Appl. Physiol 86; 938-42). In both cases, the reconstituted
RAG-2-/- mice were no longer protected and injury was restored. In
the latter experiments, a model of intestinal injury was used as in
this model, injury is thought to be mediated primarily by
complement.
[0207] The interpretation of these results is that during the
period of ischemia, neoantigens are either expressed or exposed on
the endothelial cell surface. Circulating IgMs appear to recognize
the new determinant, bind and activate classical pathway of
complement. While the nature of the antigen is not known, IgM
rather than IgG seems to be primarily responsible for activation of
complement as reconstitution of deficient mice with pooled IgG did
not significantly restore injury in the mice. An alternative
hypothesis is that there is another initial event such as the MBL
pathway that recognizes the altered endothelial surface, induces
low level complement activation which in turn exposes new antigenic
sites and the pathway is amplified by binding of IgM.
Example 3: Pathogenic IgM is a Product of B-1 Cells
[0208] Since a major fraction of circulating IgM is thought to
represent natural antibody, i.e. product of rearranged germline
genes, it is possible that mice bearing deficiencies in the B-1
fraction of lymphocytes might also be protected. B-1 cells have a
distinct phenotype from more conventional B-2 cells in that they
express low levels of IgD and CD23 and a major fraction express the
cell surface protein CDS (Hardy et al., (1994) Immunol. Rev.: 137,
91; Kantor et al. (1993) Annu. Rev. Immunol. 11, S01-538, 1993. B-1
cells are also distinguished by reduced circulation in mice,
limited frequency in the peripheral lymph nodes and spleen and are
primarily localized within the peritoneal cavity. To examine a role
for B-1 cells as a source of pathogenic IgM, antibody-deficient
mice (RAG-2-/-) were reconstituted with 5.times.105 peritoneal B-1
cells and rested approximately 30 days before treatment.
Circulating IgM levels reach a near normal range within a month
following adoptive transfer. Characterization of the B-1 cell
reconstituted mice in the intestinal ischemia model confirmed that
B-1 cells were a major source of pathogenic IgM (see Williams et
al. (1999) supra). This was an important observation because the
repertoire of B-1 cell natural antibody is considerably more
limited than would be expected for conventional B-2 cells.
Therefore, it is possible that the pathogenic antibody represents a
product of the germline.
Example 4: Cr2-/- Mice are Protected from Ischemia Reperfusion
Injury
[0209] The initial characterization of Cr2-/- knockout mice
revealed an approximate SO % reduction in the frequency of B-1a or
CDS+B-1 cells (Ahearn et al. (1996) Immunity 4: 2S 1-262). Although
characterization of another strain of Cr2-deficient mice did not
identify a similar reduction (Molina et al. (1996) Proc. Natl.
Acad. Sci. USA 93, 33 S7-3361). Whether the difference in frequency
of CDS+cells was due to variation in strain background or
environmental differences is not known. Despite the reduced
frequency of B-1 a cells in the Cr2-/- mice, circulating levels of
IgM were within the normal range. These findings suggested that the
repertoire of IgM might be different in the Cr2-deficient animals.
To test this hypothesis, mice in the intestinal J/R model were
characterized. Surprisingly, the Cr2-/- mice were equally protected
as the complete-antibody deficient mice (FIG. 3). Comparison of
survival over a five-day period following treatment in the
intestinal model demonstrated a significant increase in mortality
of the WT compared to Cr2-deficient animals. Consistent with an
increased mortality, a dramatic reduction in injury was observed in
tissue sections harvested from treated WT or Cr2-/- deficient
mice.
[0210] Extensive injury to the mucosal layer of the intestine was
observed in WT mice or Cr2-/- mice reconstituted with pooled IgM or
B-1 cells. By contrast, tissue sections isolated from treated
Cr2-/- mice were similar to that of sham controls. Thus, despite
normal circulating levels of IgM, the Cr2-deficient mice were
protected from injury. These results not only confirm the
importance of B-1 cells as a source of pathogenic antibody but
suggest that the complement system is somehow involved in formation
or maintenance of the repertoire of natural antibody. For example,
complement may be involved in positive selection of B-1 cells.
Example 5: Identification of Pathogenic IgMs
[0211] This Example describes the generation of a specific
hybridoma clone from normal B-1 cells and the identification of one
clone that produces a pathogenic IgM. The pathogenic IgM was shown
to restore injury in vivo to antibody deficient mice.
[0212] Studies in mice bearing a deficiency in complement receptors
CD21/CD35, revealed that the mice were missing the pathogenic
antibody. This finding was unexpected because they have a normal
level of IgM in their blood. These findings led to the hypothesis
that a special population of B cells termed B-1 cells are
responsible for secreting the pathogenic IgM. For example,
engraftment of the receptor deficient mice (Cr2-/-) with B-1 cells
from normal mice restored injury, confirming the importance of B-1
cells. To identify thy specific antibody or antibodies responsible
for injury, a panel of hybridoma clones were constructed from an
enriched pool of peritoneal B-1 cells harvested from normal mice.
The general approach for preparing hybridomas from enriched
fraction of peritoneal cells includes harvesting peritoneal cells
from mice treated 7 days earlier with IL-10 and subsequently
enriched for CD23 negative B cells by negative selection with
magnetic beads. Enriched B cells are analyzed by FACS following
staining with IgM, Mac-I and CD23 specific Mab. The enriched
population is further activated by culturing with LPS for 24 hours.
Activated cells are hybridized with fusion partner myeloma cells in
the presence of PEG and grown in HAT-selective medium. Hybridomas
are screened for IgM secreting clones by ELISA, and positive wells
are expanded for purification of IgM.
[0213] Twenty-two IgM-secreting hybridoma clones were analyzed by
pooling an equal amount I IgM restored injury similar to that seen
with pooled IgM from serum. This finding confirmed of IgM product
from each of the clones. Treatment of antibody-deficient mice with
the pooled that the pathogenic IgM was among the twenty-two
hybridomas produced. By dividing the pools into two fractions,
i.e., 1-11 and 12-22, and treatment mice with the two fractions,
the pathogenic antibody was found to fractionate with the pool that
included clone #22. Finally, mice were reconstituted with either
clone 17 or 22. Clone 22 restored injury whereas the other clones
did not (see FIG. 4).
Example 6: Complement Involvement in B-1 Cell Selection
[0214] Two different models have been proposed to explain the
development of B-1 cells. The lineage hypothesis proposes that B-1
cells develop in early fetal life as a distinct population (Kantor
et al. (1993) supra). Alternatively, B-1 cells develop from the
same progenitors as conventional B cells but depending on their
environment, i.e., encounter with antigen, they develop into B-1 or
retain the B-2 cell phenotype (Wortis, H. H. (1992) Int. Rev.
Immunol. 8, 235; Clarke, J. (1998) Exp. Med. 187, 1325-1334).
Irrespective of their origin, it is known that B-1 cells are not
replenished from adult bone marrow at the same frequency as B-2
cells and that their phenotype is more similar to that of early
fetal liver B cells or neonatal bone marrow (BM) cells. Consistent
with an early origin, their repertoire tends to be biased towards
expression of more proximal VH genes and N-nucleotide addition is
limited (Gu et al. (1990) EMBO J 9, 2133; Feeney, J. (1990) Exp.
Med. 172, 1377). It seems reasonable that given the reduced
replenishment by adult BM stem cells, B-1 cells are self-renewed
and that antigen stimulation might be important in their renewal,
expansion or even initial selection (Hayakawa et al., (1986) Eur.
J. Immunol. 16, 1313). Indeed inherent to the conventional model,
B-1 cells must be antigen selected.
[0215] Evidence in support of a B-cell receptor (BCR) signaling
requirement for positive selection of B-1 cells comes from mice
bearing mutations that alter BCR signaling. For example, impairment
of BCR signaling through CD 19, vav, or Btk dramatically affects
development of B-1 cells. By contrast, loss of negative selection
such as in CD22- or SHIP-I deficient mice can lead to an increase
in B-1 cell frequency (O'Keefe et al. (1996) Science 274, 798-80 I;
Shultz et al. (1993) Cell 73, 1445.). Recent, elegant studies with
mice bearing two distinct 1 g transgenes, V.sub.H12 (B-1 cell
phenotype) or V.sub.HB1-8 (B-2 cell phenotype) support the view
that B-1 cells are positively selected by self-antigens. For
example, B cells expressing V.sub.H12 either alone or together with
B1-8 developed a B-1 cell phenotype. Whereas, few if any B cells
were identified that expressed the B1-8 transgene only. Thus, these
results suggested that encounter of transgenic B cells with
self-PtC resulted in expansion of those expressing V.sub.H12.
Selection of B-1 cells was recently reported by Hardy et al. (1994)
Immunol. Rev. 137, 91). In their model, B cells expressing an
immunoglobulin transgene specific for Thy 1.1 were selected and
expanded in mice expressing the cognate antigen. By contrast,
transgene+B-1 cells were not found in mice that expressed the
alternative allotype Thy 1.2.
[0216] Where does complement fit into B-1 cell development? The
overall reduction in B-1a cell frequency and the more specific loss
of B-1 cells expressing IgM involved in IIR injury suggests a role
for CD21/CD35 in either positive selection or maintenance of B-1a
cells. One possible role for complement is that it enhances BCR
signaling on encounter with cognate antigen. Biochemical studies
and analysis of CD21/CD35 deficient mice demonstrate the importance
of co-receptor signaling in activation and survival of conventional
B cells (Carroll, M. C., (1998) Ann. Rev. Immunol. 16, 545-568;
Fearon et al. (1995) Annu. Rev. Immunol. 13, 127-149). It is very
likely that B-1 cells likewise utilize co-receptor signaling to
enhance the BCR signal. For example, bacteria express typical B-1
cell antigens such as phosphoryl choline and it is not unreasonable
that coating of bacteria with complement ligand C3d would enhance
crosslinking of the co-receptor with the BCR and enhance overall
signaling. Thus, antigens expressed at lower concentrations might
require complement enhancement in order for the cognate B-cell to
recognize it and expand or be positively selected. Another role for
complement receptors is in localizing antigen on follicular
dendritic cells (FDC) within the lymphoid compartment. However,
since the major population of B-1 cells occupy the peritoneal
tissues it is not clear if they would encounter FDC within lymphoid
structures. The actual site or sites in which B-1 cells undergo
positive selection are not known. It is possible that they must
encounter cognate antigen in early fetal development or in neonatal
BM. If this is the case, it might be expected that complement
receptors on stromal cells within these compartments bind antigen
for presentation to B cells. It is possible that complement
receptors could participate in both stages of development. First,
they might enhance antigens signaling in initial positive
selection. Secondly, as selected B-1 cells are replenished at
peripheral sites, complement receptors might again be involved in
enhancement of BCR signaling.
[0217] FIG. 5 is a schematic diagram of the proposed role for
complement and complement receptors in positive selection of
peritoneal B-1 lymphocytes. The interaction of complement-ligand
coated antigens (self- and non-self) results in co-ligation of the
CD21/CD19 co-receptor and BCR on the cell surface leading to
enhanced signaling and positive selection.
Example 7: Materials and Methods for Examples 8-11
[0218] Phase Display Peptide Library and Peptide Synthesis
[0219] A 12-mer M-13 phage display library (New England Biolab,
Mass.) was screened by 4 rounds with MBL-beads coated with
IgM.sup.CM-22 and 2 rounds with IgM.sup.CM-75 according to the
manufacturer's recommendation. Phage clones were selected from the
enriched pool and the nucleotide sequence of the relevant phage
gene determined for at least ten clones. Selected peptides were
synthesized with purity>95% in Harvard Proteomic Core or New
England Peptide, Inc. (Gardner, Mass.).
[0220] Binding Assays
[0221] ELISA was performed as described earlier (Zhang et al.
(2004) PNAS USA 101:3886-91). Briefly, IgM binding to phage or
phage-specific peptides was determined by coating a 96-well plate
with saturating amounts of antigen. Subsequent to blocking, IgM was
added (1 or 10 .mu.g/ml) for 2 hr at 37.degree. C. Plates were
washed and then developed with alkaline phosphatase-labeled goat
anti-mouse IgM (Sigma, Mo.). Binding of IgM to NMHC-II was
determined by culturing 96-well plates previously coated with
specific rabbit antibody (NMHC-II A & B; Covance Research
Products; NMHC-II C a gift from Dr. Adelstein, NHLBI, NIH,
Bethesda, Md.) or pan-myosin He (Sigma, Mo.) with intestinal
lysates prepared from IM.sup.cm-22 reconstituted RAG-1.sup.-/- mice
either sham treated or treated for ischemia as described (Zhang et
al. (2004) PNAS USA 101:3886-91). Lysates were prepared as
described for immune precipitation (see below).
Alkaline-phosphatase labeled goat anti-mouse IgM (Sigma, Mo.) was
then used to detect bound IgM.
[0222] Intestinal RI Model
[0223] Surgical protocol for RI was performed as previously
described (Zhang et al. (2004) PNAS USA 101:3886-91). Briefly, a
laparotomy is performed, and a microclip (125 g pressure, Roboz,
Md.) was applied to the superior mesenteric artery and bilateral
circulation limited with silk sutures flanking a 20 cm segment of
the jejunum. After 40 minutes of ischemia, the microclip was
removed, and reperfusion of the mesenteric vasculature was
confirmed by the return of pulsation to the vascular arcade and a
change to pink color. The incision was closed, and an animals kept
warm for 3 hours. Reconstituted RAG-1.sup.-/- animals received
either IgM mixed with peptide or saline in 0.2 ml volume
intravenously 30 min before the initial laparotomy. WT animals were
treated with saline or peptide i.v. 5 minutes prior to reperfusion.
At the end of reperfusion, the ischemi segment of the jejunum was
harvested and the central 4 cm was cut for pathological
analysis.
[0224] Histopathology and Immuno-Histochemistry Analysis
[0225] Cryostat sections of intestinal tissues were stained by
hematoxylin and eosin (H&E) and examined by light microscopy
for mucosal damage. Pathology score was assessed based on procedure
by Chiu (Chiu et al, Arch Surg 101: 484-488, 1970; Chiu, et al,
Arch Surg 101: 478-483, 1970) that included direct inspection of
all microvilli over a 4 cm stretch of jejuneum as described. Zhang
et al. (2004) PNAS USA 101:3886-91. For immuno-fluorescence,
cryosections fixed with 4% (w/v) paraformaldehyde were incubated
for varying periods with either biotin-labeled anti-mouse IgM
(Becton Dickinson, Calif.) followed by 1 hour with
streptavidin-Alexa-568 (1:500 dilution, Molecular Probes, OR). C4
deposition was detected by staining with FITC-labeled rabbit
anti-huC4c (DAKO, Colo.), followed by anti-rabbit-Alexa 488
(Molecular Probes, OR). The specificity of anti-C4c staining was
confirmed by staining serial sections with biotin-labeled
anti-mouse C4 for 1 hour followed by streptavidin-FITC (Becton
Dickinson, Calif.). C3 deposition was detected by treating with
FITC-labeled anti-C3 (DAKO, Colo.). Sections were mounted in
Anti-fade Mounting Medium with DAPI (Molecular Probes, OR).
[0226] SPR Analysis of Peptide Binding to Antibody
[0227] An IgM (IgM.sup.CM-22 or IgM.sup.CM-31) antibody was
immobilized by amine coupling in a BiaCore SPR CMS.TM. chip
flowcell at a density of 33,400 response units (RU) .about.33
ng/mm.sup.2 as described. Vorup-Jensen et al, PNAS USA 100:
1873-1878, 2003. Briefly, a reference flow cell was prepared by
coupling of ethanolamine-HCl. Peptides, diluted in PBS running
buffer, were flowed separately over the IgM-coupled surface and the
reference at a rate of 10 .mu.l/min. at 25.degree. C. and with the
data collection rate at 10 Hz. The injection phase had a duration
of 240 s (end of injection phases are marked by arrow heads in
FIGS. 9A, B and D). Binding isotherms were derived by subtracting
the response in the reference cell from the response of the
IgM-coupled surface. Following each run, the surface was
regenerated by injecting 40 .mu.l 0.05% (v/v)
polyoxyethylenesorbitan monolaurate/PBS.
[0228] Immune Precipitation
[0229] Frozen tissues were homogenized in a lysis buffer containing
detergent and a cocktail of enzyme inhibitors. A sample of lysate
is analyzed for total protein content (Bio-Rad kit) to insure
similar levels of protein for analysis. Lysates are mixed with
sepharose beads coated with rat anti-mouse IgM for 1 hr at
4.degree. C. Subsequently, beads were pelleted gently, washed in
lysis buffer and then boiled in SDS-sample buffer under reducing
conditions to elute bound complexes. Samples were fractionated on
6% (w/v) polyacrylamide SDS gels and subsequently fixed and then
stained with either coomassie blue or silver stain to identify
protein bands.
[0230] Protein Identification by Tandem Mass Spectrometry
[0231] Individual Coomassie Blue-stained bands were excised from
SDS-gels, destained, and subjected to enzyme digestion as described
previously. Borodovsky et al, Chem Biol 9: 1149-1159, 2002. The
peptides were separated using a nanoflow liquid coupled
chromatography system (Waters Cap LC) and amino acid sequences
determined by tandem mass spectrometer (Q-TOF micro, Waters,
Mass.). MS/MS data were processed and subjected to database
searches using Mascot (Matrixscience) against Swissprot, TREMBL/New
or the NCBY non-redundant database.
Example 8: Identification of Asparagine-Rich Peptides that Bind
Natural IgM Antibody
[0232] We previously identified a hybridoma clone of a natural IgM
antibody (IM.sup.CM-22) that binds ischemic tissue in the
intestinal RI model, which support our hypothesis that ischemic
tissue was altered relative to normal tissue and that neo-epitopes
expressed during ischemia were targets for an innate response to
self. To characterize the ligand bound by pathogenic IgM.sup.CM-22,
a M-13 phage-display library of random 12-mer amino acid sequences
was screened using beads coated with the specific IgM.
[0233] After four rounds of specific screening and two rounds with
a control IgM (clone IgM.sup.CM-75), ten phage clones were isolated
and the nucleotide sequence of the relevant M-13 gene sequenced.
Notably, all ten clones contain sequences rich in asparagine. Five
of the clones were selected for a relative binding assay with
IgM.sup.CM-22 and one of these clones, P8, which bound with the
highest efficiency was selected for further study (Table 4 and FIG.
6A).
TABLE-US-00004 TABLE 4 Phage displayed peptides bind to
IgM.sup.CM-22 Phage Clone Sequence SEQ ID NO. P1 YNNNNGNYTYRN 16 P2
ANTRNGATNNNM 18 P3 CDSSCDSVGNCN 20 P4 WNNNGRNACNAN 22 P5
HNSTSNGCNDNV 24 P6 NSNSRYNSNSNN 26 P7 KRNNHNNHNRSN 28 P8
NGNNVNGNRNNN 30 P9 NVANHNNSNHGN 32 P10 SYNNNNHVSNRN 34
Asparagine-rich xNNNxNNxNNNN 14 Consensus
[0234] A 12-amino acid peptide (P8) was synthesized based on the
phage sequence and assayed for inhibition of phage P8 binding to
IgM.sup.CM-22 (FIG. 6B). Titration of increasing amounts of PB
peptide yielded 50% inhibition at an estimated concentration of 10
.mu.mole. This assay indicates a reasonable overall avidity of
binding based on multiple binding sites expressed on the phage
surface. This result suggested that IgM.sup.CM-22 binding to phage
P8 was specific for the peptide region and that the synthetic
peptide could be used as a mimotope for the actual antigen. To
further characterize binding of P8 peptide to IgM.sup.CM-22, ELISA
plates were coated with the peptide and tested with IgM.sup.CM-22
or control IgM.sup.CM-75 for binding (FIG. 6C). At the lower
concentration of 1 .mu.g/ml, neither IgM bound above background.
However, at 10 .mu.g/ml, significantly more IgM.sup.CM-22 bound
than IgM.sup.CM-75. Together, the three results suggest that
peptide P8 binds specifically to IgM.sup.CM-22 and can be used for
identification of the actual antigen.
Example 9: Asparagine-Rich Peptide PS Blocks Intestinal RI
[0235] Previous studies had demonstrated that intestinal RI in
RAG-1.sup.-/- mice was IgM-dependent and that IgM.sup.CM-22 alone
was sufficient to restore injury. As expected, reconstitution of
RAG-1.sup.-/- mice with IgM.sup.CM-22 but not saline prior to
reperfusion resulted in RI (FIG. 7A(i) and FIG. 7B). By contrast,
mixing of IgM.sup.CM-22 with P8 prior to injection in ischemic mice
significantly blocked apparent injury (mean pathology score 6.+-.3
versus 31.+-.13; p<0.001) (FIG. 7Aii and FIG. 7B). Previous
titration of peptide with IgMCM-22 suggested an optimal
concentration of 10 .mu.M of PS was sufficient to block 50-100
.mu.g of IgM.sup.CM-22 (0.1-0.2 .mu.M).
[0236] Immunohistological analyses of serial sections of reperfused
intestinal tissue Gejuneum) following RI identified co-localization
of IgM and complement C4 and C3 within the microvilli in
RAG-1.sup.-/- mice reconstituted with IgM.sup.CM-22 By contrast,
sections prepared from mice receiving P8 showed no evidence of IgM
or complement binding. No binding of IgM or complement was observed
in IgM.sup.CM-22 reconstituted sham controls, nor RAG-1.sup.-/-
mice reconstituted with control IgM.sup.CM-31 or RAG-1.sup.-/- mice
reconstituted with saline only (Zhang et al. (2004) PNAS USA
101:3886-91). Thus, P8 blocks the binding of IgM.sup.CM-22 and the
induction of injury in vivo.
[0237] The identification of a single natural IgM antibody that
could initiate RI in RAG-1.sup.-/- mice led to the general question
of the number of possible neo-epitopes expressed on ischemic
tissues and the corresponding number of pathogenic clones of IgM in
the repertoire of wild type (WT) mice. It might be predicted that
the number of antibodies is limited based on the current
understanding that the repertoire of natural IgMs is relatively
small. Herzenberg et al, Immunol Today I 4: 79-S3, discussion
88-90, 1993; Arnold et al, J Exp Med 179: I 5S5-I 595, I 994.
Moreover, ligands of natural IgM antibodies are considered highly
conserved structures and also are probably limited in number. To
test if PS represented a mimotope for a major self-antigen, WT mice
were pretreated with PS (approximately 10 .mu.M) five minutes prior
to reperfusion in the intestinal model. Analysis of jejuneum
tissues of mice treated with saline or a control peptide prior to
reperfusion identified significant injury to the microvilli as
expected (FIG. 7Aiii). By contrast, pretreatment of WT mice with P8
five minutes prior to reperfusion blocked apparent injury (mean
pathology score 5.+-.3 versus 24.+-.16 and 23.+-.19; p<0.005 and
0.027, respectively) (FIG. 7A(iv) and FIG. 7B). As expected, IgM,
C4 and C3 co-localized within microvilli of RI treated WT mice. By
contrast, no apparent deposits of IgM or complement were observed
in reperfused tissues of mice administered P8. These results
suggest that the number of key epitopes required to initiate RI is
limited as a single peptide blocks injury and deposition of IgM and
complement.
Example 10: Immunoprecipitation of Self-Peptides with
IgM.sup.CM-22
[0238] Using the amino acid sequence of PS, a homology search of
the genomic database revealed no exact matches. Therefore, an
immune-precipitation approach was used to identify the ischemia
antigen/antigens in RAG-14 mice reconstituted with
IgM.sup.CM-22.
[0239] RAG-1.sup.-/- mice were reconstituted with an optimal amount
of IgM.sup.CM-22, treated for intestinal ischemia and reperfused
for varying lengths of time, i.e., 0 minutes or 15 minutes before
harvesting of tissues. Immune complexes of IgM-antigen were
isolated from lysates of jejuneum at the varying time points and
fractionated by SDS-PAGE under reducing conditions. Analysis of the
stained gels indicated common bands at lower molecular weight for
all time points (FIG. 8A). However, at 15 minutes, a band at high
molecular weight (>200 kD) was identified (FIG. 8A).
[0240] Protein bands were excised from stained gels, enzymatically
digested and peptides analyzed by Tandem Mass Spec as described.
Kocks et al, Mol Cell Proteomics 2: 1188-1197, 2003. Analysis of
eluted peptides indicated that the common bands at approximately
25, 50 and 75 kDa represented immunoglobulin light chain (Le), and
IgG heavy chain (He) and IgM He, respectively. Analysis of the high
molecular weight band yielded peptide sequences homologous to
non-muscle myosin heavy chain (NMHC) type II isoforms A and C
(Table 5).
TABLE-US-00005 TABLE 5 Mass Spectrometry Results Mass Spectroscopy
Matched proteins sequenced peptides Mouse non muscle myosin VVFQEFR
heavy chain II-A (MS-1; SEQ ID NO: 39) (gi/20137006; GenBank.TM.
CNGVLEGIR Accession NO: NP_071855) (MS-2; SEQ ID NO: 40) total
score = 130; KFDQLLAEEK peptides matched = 6 (MS-3; SEQ ID NO: 41)
KFDQLLAEEK EQADFAIEALAK (MS-4; SEQ ID NO: 42) QLLQANPILEAFGNAK
(MS-5; SEQ ID NO: 43) Mouse non muscle CNGVLEGIR myosin heavy chain
VKPLLQVTR II-C (gi/33638127; (MS-6; SEQ ID NO: 44) GenBank.TM.
Accession KFDQLLAEEK NO: AAQ24173) KFDQLLAEEK total score = 133;
EQADFALEALAK peptides matched = 7 LAQAEEQLEQESR (MS-7; SEQ ID NO:
45) QLLQANPILEAFGNAK (MS-8; SEQ ID NO: 46) *Score is -10XLog (P),
where P is the probability that the observed match is a random
event. Individual ion scores >53 indicate identity or extensive
homology (p < 0.05).
[0241] In similar experiments using lysates prepared from WT mice
treated for 3 hours in intestinal RI, a similar size band at 200 kD
was also observed and sequence analysis identified NMHC-A and C
peptides.
[0242] Three forms of type II NMHC have been identified (A, B and
C) in the mouse and human genome. Golomb et al, J Biol Chem 279:
2800-2808, 2004; Kelley et al, J Cell Biol 134: 675-687, 1996. All
eukaryotic cells express type II NMHC but the distribution of the
three isoforms varies. NMHC-II A and B are approximately 85%
homologous; whereas NMHC-II C is approximately 65% similar. Golomb
et al, J Biol Chem 279: 2800-2808, 2004. The three isotypes are
highly conserved among mice and humans.
[0243] To confirm the binding of IgM.sup.CM-22 to type IINMHC, an
ELISA approach was used. Plates were coated with antibody specific
for each of the three forms of NMHC or with a panmyosin antibody to
capture the relevant antigen from lysates prepared from jejuneum of
RAG-mice. Subsequently, IgM.sup.CM-22 or IgM.sup.CM-31 were added
and then developed with a labeled anti-mouse IgM antibody. Above
background binding of IgM.sup.CM-22 but not IgM.sup.CM-31 to all
three of the isoforms of NMHC-II was observed (Figure SB). The
combined sequence analysis and ELISA results show that
IgM.sup.CM-22 recognizes a conserved region of the type II
NMHC.
[0244] To determine whether myosin is exposed to circulating
antibody following ischemia, RAG-1.sup.-/- mice were reconstitute
with a purified IgG fraction of rabbit anti-pan myosin heavy chain.
Analysis of tissues of sham treated RAG-1.sup.-/- following
reconstitution with the rabbit IgG mice showed no evidence of
injury or deposition of IgG. By contrast, ischemic RAG-1.sup.-/-
mice reconstituted with the pan-myosin IgG prior to reperfusion
developed significant RI compared to saline controls (33.+-.11
versus 11.+-.8, p<0.025) (Figure SC). Accordingly, myosin is
exposed to antibody in circulation following ischemia.
[0245] Comparison of the sequences of the three NMHC-II isoforms
with the PS peptide sequence identified one region of apparent
homology (Table 6). All three isoforms include a motif of NxxxxNxNx
that has similarity with the PS sequence. A 12-amino acid
self-peptide (N2) sequence (NMHC-IIC isoform) was prepared for
further study.
TABLE-US-00006 TABLE 6 Conserved homologous sequence in NMHC-II A-C
Sequence Phage Clone P8 NGNNVNGNRNNN (SEQ ID NO: 30) Consensus
xNNNx(N/D)NxN(N/D)N(NN) (SEQ ID NO: 14) NMHC-II Sequence Mouse-IIA
(542-556) LMKNMDPLNDI (SEQ ID NO: 36) Human-IIA (585-596)
LMKNMDPLNDI Mouse-IIB (592-603) LMKNMDPLNDNV (N2; SEQ ID NO: 38)
Human-IIB (592-603) LMKNMDPLNDNV Mouse-IIC (607-619) LMKNMDPLNDNV
(N2; SEQ ID NO: 38) Human-IIC (611-622) LMKNMDPLNDNV
[0246] To test that this region bound IgM.sup.CM-22 surface,
plasmon resonance analysis was used (FIG. 9). N2 peptide was
injected over a surface coupled with IgM.sup.CM-22 (FIG. 9A) and
generated a robust response, which corresponded to a K.sub.D of
123.+-.61 .mu.M (mean.+-.SD, n=2) as calculated from the
steady-state response levels (FIG. 9C). In contrast, no binding was
observed when a control peptide was injected over the specific
IgM-coupled surface (FIG. 9B) or when the N2 peptide was injected
over a surface coupled with the IgM.sup.CM-31 control (FIG.
9D).
Example 11: Self-Peptide N2 Blocks Intestinal RI
[0247] To test the functional binding of N2 with pathogenic IgM,
approximately 100 nmoles of the peptide (or saline control) was
mixed with IgM.sup.CM-22 prior to reconstitution of RAG-1.sup.-/-
mice and treatment in the RI model. Analysis of histology of tissue
sections prepared from the reperfused jejuneum of IgM.sup.CM-22 and
saline-treated mice identified injury and deposition of IgM and
complement as expected (FIG. 5Ai and 5B). By contrast, mixing the
N2 peptide with IgM.sup.CM-22 prior to reperfusion was protective
from injury (mean pathology score 13.+-.8 versus 31.+-.10;
p<0.049) (FIG. 10Aii and 10B). In addition, no deposition of IgM
and complement was observed in reperfused jejuneum when
IgM.sup.CM-22 was mixed with the N2 peptide prior to injection in
RAG-1.sup.-/- mice. Thus, as observed with the synthetic peptide
P8, the self-peptide N2 blocked functional binding of IgM.sup.CM-22
in vivo.
[0248] To test if self-peptide N2 represents the major self-epitope
in intestinal RI, WT mice were treated with approximately 40 .mu.M
of the synthetic peptide P8 prior to reperfusion in the intestinal
model. Histological analysis of tissue sections of saline treated
WT mice identified injury and deposition of IgM and complement as
expected (FIG. 10Aiii). By contrast, treatment of WT mice with
self-peptide N2 blocked both injury (mean pathology score 8.+-.5
versus 22.+-.17) and deposition of IgM and complement (FIG. 10Aiv;
FIG. 10B). These results suggest that a conserved region within
type II NMHC proteins represents the major epitope for binding of
natural IgM following ischemia in the intestinal model.
INCORPORATION BY REFERENCE
[0249] All publications, patents, and patent applications mentioned
herein are hereby incorporated by reference in their entirety as if
each individual publication or patent was specifically and
individually indicated to be incorporated by reference. In case of
conflict, the present application, including any definitions
herein, will control.
[0250] Also incorporated by reference in their entirety are any
polynucleotide and polypeptide sequence which reference an
accession number correlating to an entry in a public database, such
as those maintained by The Institute for Genomic Research (TIGR) on
the world wide web with the extension tigr.org and or the National
Center for Biotechnology Information (NCBI) on the world wide web
with the extension ncbi.nlm.nih.gov.
EQUIVALENTS
[0251] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
Sequence CWU 1
1
651402DNAMus musculus 1caggttcagc tgcagcagtc tggggctgag ctggtgaagc
ctggggcctc agtgaagatt 60tcctgcaaag cttctggcta cgcattcagt agctactgga
tgaactgggt gaagcagagg 120cctggaaagg gtcttgagtg gattggacag
atttatcctg gagatggtga tactaactac 180aacggaaagt tcaagggcaa
ggccacactg actgcagaca aatcctccag cacagcctac 240atgcagctca
gcagcctgac ctctgaggac tctgcggtct atttctgtgc aagagaagat
300tactacggta gtgactggta cttcgatgtc tggggcacag ggaccacggt
caccgtctcc 360tcaggtaagc tggctttttt ctttctgcac attccattct ga
4022133PRTMus musculus 2Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu
Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser
Gly Tyr Ala Phe Ser Ser Tyr 20 25 30 Trp Met Asn Trp Val Lys Gln
Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Gln Ile Tyr Pro
Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys
Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met
Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90
95 Ala Arg Glu Asp Tyr Tyr Gly Ser Asp Trp Tyr Phe Asp Val Trp Gly
100 105 110 Thr Gly Thr Thr Val Thr Val Ser Ser Gly Lys Leu Ala Phe
Phe Phe 115 120 125 Leu His Ile Pro Phe 130 315DNAMus musculus
3agctactgga tgaac 1545PRTMus musculus 4Ser Tyr Trp Met Asn 1 5
557DNAMus musculus 5cagatttatc ctggagatgg tgatactaac tacaacggaa
agttcaaggg caaggcc 57616PRTMus musculus 6Gln Ile Tyr Pro Gly Asp
Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys 1 5 10 15 7324DNAMus
musculus 7attgtgatga cccagtctgc tgcttcctta gctgtatctc tggggcagag
ggccaccatc 60tcatacaggg ccagcaaaag tgtcagtaca tctggctata gttatatgca
ctggaaccaa 120cagaaaccag gacagccacc cagactcctc atctatcttg
tatccaacct agaatctggg 180gtccctgcca ggttcagtgg cagtgggtct
gggacagact tcaccctcaa catccatcct 240gtggaggagg aggatgctgc
aacctattac tgtcagcaca ttagggagct tacacgttcg 300gaggggggac
caagctggaa ataa 3248107PRTMus musculus 8Ile Val Met Thr Gln Ser Ala
Ala Ser Leu Ala Val Ser Leu Gly Gln 1 5 10 15 Arg Ala Thr Ile Ser
Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser Gly 20 25 30 Tyr Ser Tyr
Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro Arg 35 40 45 Leu
Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala Arg 50 55
60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro
65 70 75 80 Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile
Arg Glu 85 90 95 Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys 100
105 945DNAMus musculus 9agggccagca aaagtgtcag tacatctggc tatagttata
tgcac 451015PRTMus musculus 10Arg Ala Ser Lys Ser Val Ser Thr Ser
Gly Tyr Ser Tyr Met His 1 5 10 15 1121DNAMus musculus 11cttgtatcca
acctagaatc t 21127PRTMus musculus 12Leu Val Ser Asn Leu Glu Ser 1 5
1336DNAArtificial SequenceSynthetic DNA
sequencemodified_base(1)..(3)a, c, g or tmisc_feature(1)..(3)n is
a, c, g, or tmodified_base(13)..(15)a, c, g or
tmisc_feature(13)..(15)n is a, c, g, or tmodified_base(22)..(24)a,
c, g or tmisc_feature(22)..(24)n is a, c, g, or t 13nnnaayaaya
aynnnaayaa ynnnaayaay aayaay 361412PRTArtificial SequenceSynthetic
peptideMOD_RES(1)..(1)Variable amino acidMOD_RES(5)..(5)Variable
amino acidMOD_RES(8)..(8)Variable amino acid 14Xaa Asn Asn Asn Xaa
Asn Asn Xaa Asn Asn Asn Asn 1 5 10 1536DNAArtificial
SequenceSynthetic DNA sequencemodified_base(18)..(18)a, c, g or
tmisc_feature(18)..(18)n is a, c, g, or tmodified_base(27)..(27)a,
c, g or tmisc_feature(27)..(27)n is a, c, g, or
tmodified_base(33)..(33)a, c, g or tmisc_feature(33)..(33)n is a,
c, g, or t 15tayaayaaya ayaayggnaa ytayacntay mgnaay
361612PRTArtificial SequenceSynthetic peptide 16Tyr Asn Asn Asn Asn
Gly Asn Tyr Thr Tyr Arg Asn 1 5 10 1736DNAArtificial
SequenceSynthetic DNA sequencemodified_base(3)..(3)a, c, g or
tmisc_feature(3)..(3)n is a, c, g, or tmodified_base(9)..(9)a, c, g
or tmisc_feature(9)..(9)n is a, c, g, or tmodified_base(12)..(12)a,
c, g or tmisc_feature(12)..(12)n is a, c, g, or
tmodified_base(18)..(18)a, c, g or tmisc_feature(18)..(18)n is a,
c, g, or tmodified_base(21)..(21)a, c, g or
tmisc_feature(21)..(21)n is a, c, g, or tmodified_base(24)..(24)a,
c, g or tmisc_feature(24)..(24)n is a, c, g, or t 17gcnaayacnm
gnaayggngc nacnaayaay aayatg 361812PRTArtificial SequenceSynthetic
peptide 18Ala Asn Thr Arg Asn Gly Ala Thr Asn Asn Asn Met 1 5 10
1936DNAArtificial SequenceSynthetic DNA
sequencemodified_base(9)..(9)a, c, g or tmisc_feature(9)..(9)n is
a, c, g, or tmodified_base(12)..(12)a, c, g or
tmisc_feature(12)..(12)n is a, c, g, or tmodified_base(21)..(21)a,
c, g or tmisc_feature(21)..(21)n is a, c, g, or
tmodified_base(24)..(24)a, c, g or tmisc_feature(24)..(24)n is a,
c, g, or tmodified_base(27)..(27)a, c, g or
tmisc_feature(27)..(27)n is a, c, g, or t 19tgygaywsnw sntgygayws
ngtnggnaay tgyaay 362012PRTArtificial SequenceSynthetic peptide
20Cys Asp Ser Ser Cys Asp Ser Val Gly Asn Cys Asn 1 5 10
2136DNAArtificial SequenceSynthetic DNA
sequencemodified_base(15)..(15)a, c, g or tmisc_feature(15)..(15)n
is a, c, g, or tmodified_base(18)..(18)a, c, g or
tmisc_feature(18)..(18)n is a, c, g, or tmodified_base(24)..(24)a,
c, g or tmisc_feature(24)..(24)n is a, c, g, or
tmodified_base(33)..(33)a, c, g or tmisc_feature(33)..(33)n is a,
c, g, or t 21tggaayaaya ayggnmgnaa ygcntgyaay gcnaay
362212PRTArtificial SequenceSynthetic peptide 22Trp Asn Asn Asn Gly
Arg Asn Ala Cys Asn Ala Asn 1 5 10 2336DNAArtificial
SequenceSynthetic DNA sequencemodified_base(9)..(9)a, c, g or
tmisc_feature(9)..(9)n is a, c, g, or tmodified_base(12)..(12)a, c,
g or tmisc_feature(12)..(12)n is a, c, g, or
tmodified_base(15)..(15)a, c, g or tmisc_feature(15)..(15)n is a,
c, g, or tmodified_base(21)..(21)a, c, g or
tmisc_feature(21)..(21)n is a, c, g, or tmodified_base(36)..(36)a,
c, g or tmisc_feature(36)..(36)n is a, c, g, or t 23cayaaywsna
cnwsnaaygg ntgyaaygay aaygtn 362412PRTArtificial SequenceSynthetic
peptide 24His Asn Ser Thr Ser Asn Gly Cys Asn Asp Asn Val 1 5 10
2536DNAArtificial SequenceSynthetic DNA
sequencemodified_base(6)..(6)a, c, g, or tmisc_feature(6)..(6)n is
a, c, g, or tmodified_base(12)..(12)a, c, g, or
tmisc_feature(12)..(12)n is a, c, g, or tmodified_base(15)..(15)a,
c, g, or tmisc_feature(15)..(15)n is a, c, g, or
tmodified_base(18)..(18)a, c, g, or tmisc_feature(18)..(18)n is a,
c, g, or tmodified_base(21)..(21)a, c, g, or
tmisc_feature(21)..(21)n is a, c, g, or tmodified_base(24)..(24)a,
c, g, or tmisc_feature(24)..(24)n is a, c, g, or
tmodified_base(30)..(30)a, c, g, or tmisc_feature(30)..(30)n is a,
c, g, or t 25aaywsnaayw snmgntanaa nwsnaaywsn aayaay
362612PRTArtificial SequenceSynthetic peptide 26Asn Ser Asn Ser Arg
Tyr Asn Ser Asn Ser Asn Asn 1 5 10 2736DNAArtificial
SequenceSynthetic DNA sequencemodified_base(6)..(6)a, c, g or
tmisc_feature(6)..(6)n is a, c, g, or tmodified_base(30)..(30)a, c,
g or tmisc_feature(30)..(30)n is a, c, g, or
tmodified_base(33)..(33)a, c, g or tmisc_feature(33)..(33)n is a,
c, g, or t 27aarmgnaaya aycayaayaa ycayaaymgn wsnaay
362812PRTArtificial SequenceSynthetic peptide 28Lys Arg Asn Asn His
Asn Asn His Asn Arg Ser Asn 1 5 10 2936DNAArtificial
SequenceSynthetic DNA sequencemodified_base(6)..(6)a, c, g or
tmisc_feature(6)..(6)n is a, c, g, or tmodified_base(15)..(15)a, c,
g or tmisc_feature(15)..(15)n is a, c, g, or
tmodified_base(21)..(21)a, c, g or tmisc_feature(21)..(21)n is a,
c, g, or tmodified_base(27)..(27)a, c, g or
tmisc_feature(27)..(27)n is a, c, g, or t 29aayggnaaya aygtnaaygg
naaymgnaay aayaay 363012PRTArtificial SequenceSynthetic peptide
30Asn Gly Asn Asn Val Asn Gly Asn Arg Asn Asn Asn 1 5 10
3136DNAArtificial SequenceSynthetic DNA
sequencemodified_base(6)..(6)a, c, g or tmisc_feature(6)..(6)n is
a, c, g, or tmodified_base(9)..(9)a, c, g or tmisc_feature(9)..(9)n
is a, c, g, or tmodified_base(24)..(24)a, c, g or
tmisc_feature(24)..(24)n is a, c, g, or tmodified_base(33)..(33)a,
c, g or tmisc_feature(33)..(33)n is a, c, g, or t 31aaygtngcna
aycayaayaa ywsnaaycay ggnaay 363212PRTArtificial SequenceSynthetic
peptide 32Asn Val Ala Asn His Asn Asn Ser Asn His Gly Asn 1 5 10
3336DNAArtificial SequenceSynthetic DNA
sequencemodified_base(3)..(3)a, c, g or tmisc_feature(3)..(3)n is
a, c, g, or tmodified_base(24)..(24)a, c, g or
tmisc_feature(24)..(24)n is a, c, g, or tmodified_base(27)..(27)a,
c, g or tmisc_feature(27)..(27)n is a, c, g, or
tmodified_base(33)..(33)a, c, g or tmisc_feature(33)..(33)n is a,
c, g, or t 33wsntayaaya ayaayaayca ygtnwsnaay mgnaay
363412PRTArtificial SequenceSynthetic peptide 34Ser Tyr Asn Asn Asn
Asn His Val Ser Asn Arg Asn 1 5 10 3536DNAArtificial
SequenceSynthetic DNA sequencemodified_base(3)..(3)a, c, g or
tmisc_feature(3)..(3)n is a, c, g, or tmodified_base(21)..(21)a, c,
g or tmisc_feature(21)..(21)n is a, c, g, or
tmodified_base(24)..(24)a, c, g or tmisc_feature(24)..(24)n is a,
c, g, or t 35ytnatgaara ayatggaycc nytnaaygay aayath
363612PRTArtificial SequenceSynthetic peptide 36Leu Met Lys Asn Met
Asp Pro Leu Asn Asp Asn Ile 1 5 10 3736DNAArtificial
SequenceSynthetic DNA sequencemodified_base(3)..(3)a, c, g or
tmisc_feature(3)..(3)n is a, c, g, or tmodified_base(21)..(21)a, c,
g or tmisc_feature(21)..(21)n is a, c, g, or
tmodified_base(24)..(24)a, c, g or tmisc_feature(24)..(24)n is a,
c, g, or tmodified_base(36)..(36)a, c, g or
tmisc_feature(36)..(36)n is a, c, g, or t 37ytnatgaara ayatggaycc
nytnaaygay aaygtn 363812PRTArtificial SequenceSynthetic peptide
38Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val 1 5 10 397PRTMus
musculus 39Val Val Phe Gln Glu Phe Arg 1 5 409PRTMus musculus 40Cys
Asn Gly Val Leu Glu Gly Ile Arg 1 5 4110PRTMus musculus 41Lys Phe
Asp Gln Leu Leu Ala Glu Glu Lys 1 5 10 4212PRTMus musculus 42Glu
Gln Ala Asp Phe Ala Ile Glu Ala Leu Ala Lys 1 5 10 4316PRTMus
musculus 43Gln Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn
Ala Lys 1 5 10 15 449PRTMus musculus 44Val Lys Pro Leu Leu Gln Val
Thr Arg 1 5 4513PRTMus musculus 45Leu Ala Gln Ala Glu Glu Gln Leu
Glu Gln Glu Ser Arg 1 5 10 4616PRTMus musculus 46Gln Leu Leu Gln
Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys 1 5 10 15
477355DNAMus musculus 47tgggcagggc acggaaggct caagaacctg acctgctgca
gcttccagtc tcgcgttcgc 60cccaccccgc cgcgccgccc gagcgctcga gaaagtccac
tcggaagaac cagcgcctgt 120tccccgggca gacccaggtt caggtcctgg
ccgcaagtca ccatggctca gcaggctgca 180gacaagtacc tctatgtgga
taaaaacttc atcaataacc cgctggccca agctgactgg 240gctgccaaga
agttggtatg ggtgccttcc agcaagaatg gctttgaacc agctagcctc
300aaggaggagg tgggagaaga ggccattgta gagctggtag agaatgggaa
gaaggtgaag 360gtgaacaagg acgacatcca gaagatgaac ccacccaagt
tctccaaggt ggaggacatg 420gcagagctca cgtgcctcaa cgaagcttcg
gtgctgcaca acctcaagga gcgatactac 480tcagggctta tctacaccta
ttcaggcctg ttctgtgtgg tcatcaaccc ttataagaac 540ctgcccatct
actcagagga gatcgtggag atgtacaagg gcaagaagag gcacgagatg
600ccaccccaca tctacgccat cacagatact gcctaccgga gcatgatgca
ggaccgggaa 660gatcagtcca tcctgtgcac gggggagtct ggagcaggga
agacagagaa caccaagaaa 720gtcatccagt acctggcaca tgtggcctcc
tcacacaaga gcaagaagga ccagggggag 780ttggagcggc agctgctaca
ggccaaccct atcctagagg cctttggaaa cgccaagacg 840gtgaagaatg
acaactcctc tcgattcggt aaattcattc gtatcaactt tgatgtcaat
900ggctacattg ttggtgccaa cattgagact tatcttctgg agaaatctcg
tgctatccgc 960caagccaaag aggagcggac cttccacatc ttctactacc
tgctgtctgg ggccggagaa 1020cacctgaaga ctgatctcct gttggagcca
tacaacaaat accgcttcct gtccaacggg 1080cacgtcacca tccctgggca
gcaggacaag gacatgttcc aggagacaat ggaggccatg 1140agaattatgg
gtatcccaga ggatgagcag atgggcttgc tgcgggtcat ctctggggtc
1200cttcagcttg gcaacattgc cttcaagaag gagcggaaca ctgaccaggc
gtccatgccg 1260gacaacacag ctgctcaaaa ggtgtcccac ctcctgggga
tcaatgtgac cgacttcacc 1320agaggcatcc tcaccccacg catcaaggtg
ggcagagact atgtgcagaa ggcgcagact 1380aaagagcagg ctgactttgc
cattgaggcc ttggccaagg ctacctatga gcggatgttc 1440cgctggctgg
tgcttcgcat caacaaagct ctggacaaga ccaagaggca gggcgcctca
1500tttatcggga tcctggacat cgctggcttt gagatctttg atctgaactc
cttcgagcag 1560ctgtgcatca actacaccaa cgagaagctg cagcagctgt
tcaaccacac catgttcatc 1620ctggagcagg aggagtacca gcgagagggc
atcgagtgga acttcatcga cttcggcctg 1680gacctgcagc cctgcatcga
cctcattgag aagccggcgg gtcccccagg catcctggcc 1740ctgctagatg
aggagtgctg gtttcctaag gccactgaca agagcttcgt ggagaaggtg
1800gtgcaggagc agggcaccca ccccaagttc cagaagccca agcaactgaa
ggacaaggct 1860gatttctgca ttatccacta tgccggcaag gtggactata
aagctgacga gtggctgatg 1920aagaacatgg accccttgaa cgacaacatc
gccacgctgc ttcaccagtc ctcagacaag 1980tttgtctctg agctgtggaa
ggatgtggat cggatcattg gcttggacca agtggctgga 2040atgtccgaga
cagcactacc tggtgccttc aagacccgga agggcatgtt ccgtactgtc
2100ggacagctgt acaaggagca gctggccaag ctcatggcca cgttgaggaa
taccaacccc 2160aacttcgtgc gctgcatcat tcccaaccat gagaagaagg
ccggcaaact ggacccgcac 2220ttggtgctgg accagctgcg ctgcaatggc
gtccttgagg gcatccggat ctgccgccag 2280ggctttccca acagggtggt
cttccaggag ttccggcaga ggtatgagat cctcaccccc 2340aactccatcc
cgaagggctt catggatggc aagcaagcgt gtgtgctcat gatcaaagcc
2400ttggagcttg acagcaacct gtaccgcatc ggccagagca aagtgttctt
ccgggcagga 2460gtgctagccc acctggagga agagcgggac ctgaagatca
ccgatgtcat cattggcttc 2520caggcctgct gcaggggcta cctggccagg
aaggcctttg ccaagaggca gcaacagctg 2580accgccatga aggtcctaca
gaggaactgt gctgcgtacc tcaggctgcg caactggcag 2640tggtggaggc
tcttcaccaa ggtcaagccc ctgttgaact caataagaca tgaggatgag
2700ctgttagcca aggaggcgga actgacaaag gttcgagaga aacatctggc
tgcagagaac 2760aggctgacag agatggagac gatgcagtct cagctcatgg
cagagaagct gcagcttcag 2820gagcagctgc aggcggagac agagctgtgt
gccgaggctg aggagctccg ggcccgtctg 2880acagcgaaga agcaggagct
ggaggagatc tgccatgacc tggaggccag ggtggaggag 2940gaggaggagc
gctgccagta cctgcaggcc gagaagaaga agatgcagca gaacatccag
3000gaacttgagg agcagttgga ggaggaggag agcgcccggc agaagctgca
gcttgagaag 3060gtgaccaccg aggccaagct gaagaaactg gaggaggacc
agatcatcat ggaggaccag 3120aactgcaaac tggccaagga gaagaaactg
ctggaagaca gagtagctga attcactacc 3180aacctcatgg aagaggagga
gaagtccaag agcctggcca agctcaagaa caagcacgag 3240gcaatgatca
ccgacctgga agagcgcctc cgtagggagg agaagcagag gcaggagttg
3300gagaagaccc gtcgcaagct ggagggagac tccacagacc tcagtgacca
gattgctgag 3360ctccaggcgc agatagcaga gctcaagatg cagctggcca
agaaggagga ggagttgcag 3420gctgccttgg ccagagtgga agaagaagct
gctcagaaga atatggccct gaagaagatc 3480cgagaactgg aaactcagat
ctctgagctc caggaggacc tggagtcgga gcgagcctcc 3540aggaataaag
ccgagaagca gaaacgggat ctgggagagg agctggaggc gctgaagaca
3600gagctggagg acacgctgga ctccacggct gcccagcagg agctgaggtc
gaagcgtgag 3660caggaggtga gcatcctgaa gaagactctg gaggacgagg
ccaagaccca tgaggcccag 3720atccaggaga tgaggcagaa gcactcacag
gctgtggagg agctggcaga tcagttggag 3780cagacgaagc gggtaaaagc
tacccttgag aaggcgaagc agaccctgga gaatgagcgg 3840ggagagctgg
ccaatgaggt gaaggccctg ctgcaaggca agggcgactc agagcacaag
3900cgcaagaagg tggaggcgca gctgcaagaa ctgcaggtca agttcagcga
gggagagcgc 3960gtgcgaaccg aactggccga caaggtcacc aagctgcagg
ttgaactgga cagtgtgacc 4020ggtctcctta gccagtctga cagcaagtcc
agcaagctta cgaaggactt ctctgcgctg 4080gagtcccagc ttcaggacac
acaggagttg ctccaggagg agaaccggca gaagctgagc 4140ctgagcacca
agctcaagca gatggaggat gagaaaaact ccttcaggga gcagctggag
4200gaggaggagg aggccaagcg caacttggag aagcagatcg ccacgctcca
tgcccaggtg 4260accgacatga agaagaagat ggaggacggt gtagggtgcc
tggagactgc agaggaggcg 4320aagcggaggc ttcagaagga cttggaaggc
ctgagccagc ggcttgagga gaaggtggct 4380gcctacgata agctggagaa
gaccaagaca cggctgcagc aggagctgga cgacctgctg 4440gttgacctgg
accaccagcg gcagagcgtc tccaacctgg aaaagaagca gaagaagttc
4500gaccagctcc tagccgagga gaagaccatc tcggccaagt atgcagagga
gcgtgaccga 4560gctgaggctg aggcccgtga gaaggagaca aaggcgctat
cactggcccg ggcgcttgag 4620gaggccatgg agcagaaggc
agagctggag cggctcaaca agcagttccg cacggagatg 4680gaggacctca
tgagctccaa ggatgacgtg ggcaagagtg tccacgagct ggagaagtcc
4740aagcgggcct tggagcagca ggtggaggag atgaagaccc agctggagga
gctggaggat 4800gagctgcagg ccacggagga tgccaagctc cgcctggagg
tgaacctgca ggccatgaag 4860gcccagtttg agcgggatct gcagggccgg
gatgaacaga gcgaggagaa gaagaagcag 4920ctggtcagac aggtgcggga
gatggaggcg gagctggagg atgagaggaa gcagcgctcc 4980atggccatgg
ccgcacgcaa gaaactggag atggatctga aggacctgga ggcacacatt
5040gacacagcca ataagaaccg ggaagaggcc atcaaacagc tgcggaagct
tcaggcccag 5100atgaaggact gcatgcggga gctggacgac acgcgcgcct
cccgggagga gatcctggcg 5160caggccaagg agaatgagaa gaagctgaag
agcatggagg ccgagatgat tcagctgcag 5220gaggaactgg cagctgctga
gcgtgctaag cgtcaggccc aacaggaacg ggacgagctg 5280gctgatgaga
tcgccaacag cagtggcaaa ggggccctag cattagagga gaagcggcga
5340ctggaggccc gcattgccct gctggaggag gagctggagg aggaacaggg
caacacggag 5400ctgatcaacg atcggctgaa gaaggccaac ctgcagatcg
accaaataaa caccgacctg 5460aacctggaac gcagccacgc acagaagaat
gagaatgcgc gacagcagct ggaacgccag 5520aacaaggagc tcaaggccaa
gctgcaggaa atggagagtg ctgtcaagtc caaatacaag 5580gcctccatcg
cggccttgga ggccaaaatt gcacagctgg aggaacagct ggacaacgag
5640accaaggagc gccaggcagc ctccaagcag gtgcgccgga cggagaagaa
gctgaaggac 5700gtgctgctgc aggtggagga cgagcggagg aacgcggaac
agttcaagga ccaggctgac 5760aaggcgtcca cccgcctgaa gcagcttaaa
cggcagctag aggaggctga agaggaggcc 5820cagcgggcca atgcctcacg
ccggaagctg cagcgtgagc tggaagatgc cacagagacc 5880gctgatgcta
tgaaccgcga ggtcagctcc ctgaagaaca aactgaggcg tggggacctg
5940ccatttgtcg tgactcgccg aattgttcgg aaaggcactg gcgactgctc
agacgaggag 6000gtcgacggta aagcagatgg ggccgatgcc aaggcagctg
aataggagct tctcctgcag 6060cccaggcgga tggacaaacg gctctgcctc
cctcccccaa ccctccacac ccctgccttg 6120agactgctct gaccatgtcc
ccctcctccc aaggccttcc cgagggcatt ggcttcctct 6180gctgcagccc
ttccagtcct ccataccctt tgagaatctg ataccaaaga gtccaggctg
6240gctcaggccg gatgacccac agggtcttgt cctccttgcc tgaaagcacg
ggtggtgggc 6300aagaagggcg gccattggag taggcacaag agttttctat
gaatctattt tgtcttcaga 6360taaagatttt gatagctcag gcctctagta
gtgttaccct ccccgacctc ggctgtcccc 6420gtcccccgtc ccccctgctg
ttggcaatca cacacggtaa cctcatacct gccctatggc 6480ccccttccct
gggccctatt ggtccagaag gagcctctgt ctgggtgcag aacatggggc
6540actctgggaa tccccccact cccttctggg cagcactggt gcctctgctc
ctccgactgt 6600aaaccgtctc aagtgcaatg cccctcccct cccttgccaa
ggacagaccg tcctggcacc 6660ggggcaaacc agacagggca tcagggccac
tctagaaagg ccaacagcct tccggtggct 6720tctcccagca ctctagggga
ccaaatatat ttaatggtta agggacttgc agggcctggc 6780agccagaata
tccaagggct ggagcccact gtgcgctctg gtgcctctcc taggactggg
6840gccaagggtg gtcgagctgt gccacccact ctatagcttc aagtctgcct
tccacaagga 6900tgcttttgaa agaaaaaaaa aggttttatt tttcccttct
tgtagtaagt gctctagttc 6960tgggtgtctt cactgccttg ccctggaact
gtgtttagaa gagagtagct tgccctacaa 7020tgtctacact ggtcgctgag
ttccctgcgc actgcacctc actgtttgta aatgctgtga 7080ttaggttccc
ttatggcagg aaggcttttt ttttcttttt ttttttcttt tctttttttt
7140ttttttaaag gaaaaccagt caaatcatga agccacatac gctagagaag
ctgaatccag 7200gtcccaaagg cgctgtcata aaggagcaag tgggacccgc
accccttttt ttatataata 7260caagtgcctt agcatgtgtc gcagctgtca
ccactacagt aagctggttt acagatgttt 7320ccactgagcg tcacaataaa
gagtaccatg tccta 7355481960PRTMus musculus 48Met Ala Gln Gln Ala
Ala Asp Lys Tyr Leu Tyr Val Asp Lys Asn Phe 1 5 10 15 Ile Asn Asn
Pro Leu Ala Gln Ala Asp Trp Ala Ala Lys Lys Leu Val 20 25 30 Trp
Val Pro Ser Ser Lys Asn Gly Phe Glu Pro Ala Ser Leu Lys Glu 35 40
45 Glu Val Gly Glu Glu Ala Ile Val Glu Leu Val Glu Asn Gly Lys Lys
50 55 60 Val Lys Val Asn Lys Asp Asp Ile Gln Lys Met Asn Pro Pro
Lys Phe 65 70 75 80 Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu
Asn Glu Ala Ser 85 90 95 Val Leu His Asn Leu Lys Glu Arg Tyr Tyr
Ser Gly Leu Ile Tyr Thr 100 105 110 Tyr Ser Gly Leu Phe Cys Val Val
Ile Asn Pro Tyr Lys Asn Leu Pro 115 120 125 Ile Tyr Ser Glu Glu Ile
Val Glu Met Tyr Lys Gly Lys Lys Arg His 130 135 140 Glu Met Pro Pro
His Ile Tyr Ala Ile Thr Asp Thr Ala Tyr Arg Ser 145 150 155 160 Met
Met Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys Thr Gly Glu Ser 165 170
175 Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile Gln Tyr Leu Ala
180 185 190 His Val Ala Ser Ser His Lys Ser Lys Lys Asp Gln Gly Glu
Leu Glu 195 200 205 Arg Gln Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala
Phe Gly Asn Ala 210 215 220 Lys Thr Val Lys Asn Asp Asn Ser Ser Arg
Phe Gly Lys Phe Ile Arg 225 230 235 240 Ile Asn Phe Asp Val Asn Gly
Tyr Ile Val Gly Ala Asn Ile Glu Thr 245 250 255 Tyr Leu Leu Glu Lys
Ser Arg Ala Ile Arg Gln Ala Lys Glu Glu Arg 260 265 270 Thr Phe His
Ile Phe Tyr Tyr Leu Leu Ser Gly Ala Gly Glu His Leu 275 280 285 Lys
Thr Asp Leu Leu Leu Glu Pro Tyr Asn Lys Tyr Arg Phe Leu Ser 290 295
300 Asn Gly His Val Thr Ile Pro Gly Gln Gln Asp Lys Asp Met Phe Gln
305 310 315 320 Glu Thr Met Glu Ala Met Arg Ile Met Gly Ile Pro Glu
Asp Glu Gln 325 330 335 Met Gly Leu Leu Arg Val Ile Ser Gly Val Leu
Gln Leu Gly Asn Ile 340 345 350 Ala Phe Lys Lys Glu Arg Asn Thr Asp
Gln Ala Ser Met Pro Asp Asn 355 360 365 Thr Ala Ala Gln Lys Val Ser
His Leu Leu Gly Ile Asn Val Thr Asp 370 375 380 Phe Thr Arg Gly Ile
Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr 385 390 395 400 Val Gln
Lys Ala Gln Thr Lys Glu Gln Ala Asp Phe Ala Ile Glu Ala 405 410 415
Leu Ala Lys Ala Thr Tyr Glu Arg Met Phe Arg Trp Leu Val Leu Arg 420
425 430 Ile Asn Lys Ala Leu Asp Lys Thr Lys Arg Gln Gly Ala Ser Phe
Ile 435 440 445 Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Asp Leu
Asn Ser Phe 450 455 460 Glu Gln Leu Cys Ile Asn Tyr Thr Asn Glu Lys
Leu Gln Gln Leu Phe 465 470 475 480 Asn His Thr Met Phe Ile Leu Glu
Gln Glu Glu Tyr Gln Arg Glu Gly 485 490 495 Ile Glu Trp Asn Phe Ile
Asp Phe Gly Leu Asp Leu Gln Pro Cys Ile 500 505 510 Asp Leu Ile Glu
Lys Pro Ala Gly Pro Pro Gly Ile Leu Ala Leu Leu 515 520 525 Asp Glu
Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu 530 535 540
Lys Val Val Gln Glu Gln Gly Thr His Pro Lys Phe Gln Lys Pro Lys 545
550 555 560 Gln Leu Lys Asp Lys Ala Asp Phe Cys Ile Ile His Tyr Ala
Gly Lys 565 570 575 Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn
Met Asp Pro Leu 580 585 590 Asn Asp Asn Ile Ala Thr Leu Leu His Gln
Ser Ser Asp Lys Phe Val 595 600 605 Ser Glu Leu Trp Lys Asp Val Asp
Arg Ile Ile Gly Leu Asp Gln Val 610 615 620 Ala Gly Met Ser Glu Thr
Ala Leu Pro Gly Ala Phe Lys Thr Arg Lys 625 630 635 640 Gly Met Phe
Arg Thr Val Gly Gln Leu Tyr Lys Glu Gln Leu Ala Lys 645 650 655 Leu
Met Ala Thr Leu Arg Asn Thr Asn Pro Asn Phe Val Arg Cys Ile 660 665
670 Ile Pro Asn His Glu Lys Lys Ala Gly Lys Leu Asp Pro His Leu Val
675 680 685 Leu Asp Gln Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg
Ile Cys 690 695 700 Arg Gln Gly Phe Pro Asn Arg Val Val Phe Gln Glu
Phe Arg Gln Arg 705 710 715 720 Tyr Glu Ile Leu Thr Pro Asn Ser Ile
Pro Lys Gly Phe Met Asp Gly 725 730 735 Lys Gln Ala Cys Val Leu Met
Ile Lys Ala Leu Glu Leu Asp Ser Asn 740 745 750 Leu Tyr Arg Ile Gly
Gln Ser Lys Val Phe Phe Arg Ala Gly Val Leu 755 760 765 Ala His Leu
Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Val Ile Ile 770 775 780 Gly
Phe Gln Ala Cys Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala 785 790
795 800 Lys Arg Gln Gln Gln Leu Thr Ala Met Lys Val Leu Gln Arg Asn
Cys 805 810 815 Ala Ala Tyr Leu Arg Leu Arg Asn Trp Gln Trp Trp Arg
Leu Phe Thr 820 825 830 Lys Val Lys Pro Leu Leu Asn Ser Ile Arg His
Glu Asp Glu Leu Leu 835 840 845 Ala Lys Glu Ala Glu Leu Thr Lys Val
Arg Glu Lys His Leu Ala Ala 850 855 860 Glu Asn Arg Leu Thr Glu Met
Glu Thr Met Gln Ser Gln Leu Met Ala 865 870 875 880 Glu Lys Leu Gln
Leu Gln Glu Gln Leu Gln Ala Glu Thr Glu Leu Cys 885 890 895 Ala Glu
Ala Glu Glu Leu Arg Ala Arg Leu Thr Ala Lys Lys Gln Glu 900 905 910
Leu Glu Glu Ile Cys His Asp Leu Glu Ala Arg Val Glu Glu Glu Glu 915
920 925 Glu Arg Cys Gln Tyr Leu Gln Ala Glu Lys Lys Lys Met Gln Gln
Asn 930 935 940 Ile Gln Glu Leu Glu Glu Gln Leu Glu Glu Glu Glu Ser
Ala Arg Gln 945 950 955 960 Lys Leu Gln Leu Glu Lys Val Thr Thr Glu
Ala Lys Leu Lys Lys Leu 965 970 975 Glu Glu Asp Gln Ile Ile Met Glu
Asp Gln Asn Cys Lys Leu Ala Lys 980 985 990 Glu Lys Lys Leu Leu Glu
Asp Arg Val Ala Glu Phe Thr Thr Asn Leu 995 1000 1005 Met Glu Glu
Glu Glu Lys Ser Lys Ser Leu Ala Lys Leu Lys Asn 1010 1015 1020 Lys
His Glu Ala Met Ile Thr Asp Leu Glu Glu Arg Leu Arg Arg 1025 1030
1035 Glu Glu Lys Gln Arg Gln Glu Leu Glu Lys Thr Arg Arg Lys Leu
1040 1045 1050 Glu Gly Asp Ser Thr Asp Leu Ser Asp Gln Ile Ala Glu
Leu Gln 1055 1060 1065 Ala Gln Ile Ala Glu Leu Lys Met Gln Leu Ala
Lys Lys Glu Glu 1070 1075 1080 Glu Leu Gln Ala Ala Leu Ala Arg Val
Glu Glu Glu Ala Ala Gln 1085 1090 1095 Lys Asn Met Ala Leu Lys Lys
Ile Arg Glu Leu Glu Thr Gln Ile 1100 1105 1110 Ser Glu Leu Gln Glu
Asp Leu Glu Ser Glu Arg Ala Ser Arg Asn 1115 1120 1125 Lys Ala Glu
Lys Gln Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala 1130 1135 1140 Leu
Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Ala Gln 1145 1150
1155 Gln Glu Leu Arg Ser Lys Arg Glu Gln Glu Val Ser Ile Leu Lys
1160 1165 1170 Lys Thr Leu Glu Asp Glu Ala Lys Thr His Glu Ala Gln
Ile Gln 1175 1180 1185 Glu Met Arg Gln Lys His Ser Gln Ala Val Glu
Glu Leu Ala Asp 1190 1195 1200 Gln Leu Glu Gln Thr Lys Arg Val Lys
Ala Thr Leu Glu Lys Ala 1205 1210 1215 Lys Gln Thr Leu Glu Asn Glu
Arg Gly Glu Leu Ala Asn Glu Val 1220 1225 1230 Lys Ala Leu Leu Gln
Gly Lys Gly Asp Ser Glu His Lys Arg Lys 1235 1240 1245 Lys Val Glu
Ala Gln Leu Gln Glu Leu Gln Val Lys Phe Ser Glu 1250 1255 1260 Gly
Glu Arg Val Arg Thr Glu Leu Ala Asp Lys Val Thr Lys Leu 1265 1270
1275 Gln Val Glu Leu Asp Ser Val Thr Gly Leu Leu Ser Gln Ser Asp
1280 1285 1290 Ser Lys Ser Ser Lys Leu Thr Lys Asp Phe Ser Ala Leu
Glu Ser 1295 1300 1305 Gln Leu Gln Asp Thr Gln Glu Leu Leu Gln Glu
Glu Asn Arg Gln 1310 1315 1320 Lys Leu Ser Leu Ser Thr Lys Leu Lys
Gln Met Glu Asp Glu Lys 1325 1330 1335 Asn Ser Phe Arg Glu Gln Leu
Glu Glu Glu Glu Glu Ala Lys Arg 1340 1345 1350 Asn Leu Glu Lys Gln
Ile Ala Thr Leu His Ala Gln Val Thr Asp 1355 1360 1365 Met Lys Lys
Lys Met Glu Asp Gly Val Gly Cys Leu Glu Thr Ala 1370 1375 1380 Glu
Glu Ala Lys Arg Arg Leu Gln Lys Asp Leu Glu Gly Leu Ser 1385 1390
1395 Gln Arg Leu Glu Glu Lys Val Ala Ala Tyr Asp Lys Leu Glu Lys
1400 1405 1410 Thr Lys Thr Arg Leu Gln Gln Glu Leu Asp Asp Leu Leu
Val Asp 1415 1420 1425 Leu Asp His Gln Arg Gln Ser Val Ser Asn Leu
Glu Lys Lys Gln 1430 1435 1440 Lys Lys Phe Asp Gln Leu Leu Ala Glu
Glu Lys Thr Ile Ser Ala 1445 1450 1455 Lys Tyr Ala Glu Glu Arg Asp
Arg Ala Glu Ala Glu Ala Arg Glu 1460 1465 1470 Lys Glu Thr Lys Ala
Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala 1475 1480 1485 Met Glu Gln
Lys Ala Glu Leu Glu Arg Leu Asn Lys Gln Phe Arg 1490 1495 1500 Thr
Glu Met Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys 1505 1510
1515 Ser Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gln Gln
1520 1525 1530 Val Glu Glu Met Lys Thr Gln Leu Glu Glu Leu Glu Asp
Glu Leu 1535 1540 1545 Gln Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu
Val Asn Leu Gln 1550 1555 1560 Ala Met Lys Ala Gln Phe Glu Arg Asp
Leu Gln Gly Arg Asp Glu 1565 1570 1575 Gln Ser Glu Glu Lys Lys Lys
Gln Leu Val Arg Gln Val Arg Glu 1580 1585 1590 Met Glu Ala Glu Leu
Glu Asp Glu Arg Lys Gln Arg Ser Met Ala 1595 1600 1605 Met Ala Ala
Arg Lys Lys Leu Glu Met Asp Leu Lys Asp Leu Glu 1610 1615 1620 Ala
His Ile Asp Thr Ala Asn Lys Asn Arg Glu Glu Ala Ile Lys 1625 1630
1635 Gln Leu Arg Lys Leu Gln Ala Gln Met Lys Asp Cys Met Arg Glu
1640 1645 1650 Leu Asp Asp Thr Arg Ala Ser Arg Glu Glu Ile Leu Ala
Gln Ala 1655 1660 1665 Lys Glu Asn Glu Lys Lys Leu Lys Ser Met Glu
Ala Glu Met Ile 1670 1675 1680 Gln Leu Gln Glu Glu Leu Ala Ala Ala
Glu Arg Ala Lys Arg Gln 1685 1690 1695 Ala Gln Gln Glu Arg Asp Glu
Leu Ala Asp Glu Ile Ala Asn Ser 1700 1705 1710 Ser Gly Lys Gly Ala
Leu Ala Leu Glu Glu Lys Arg Arg Leu Glu 1715 1720 1725 Ala Arg Ile
Ala Leu Leu Glu Glu Glu Leu Glu Glu Glu Gln Gly 1730 1735 1740 Asn
Thr Glu Leu Ile Asn Asp Arg Leu Lys Lys Ala Asn Leu Gln 1745 1750
1755 Ile Asp Gln Ile Asn Thr Asp Leu Asn Leu Glu Arg Ser His Ala
1760 1765 1770 Gln Lys Asn Glu Asn Ala Arg Gln Gln Leu Glu Arg Gln
Asn Lys 1775 1780 1785 Glu Leu Lys Ala Lys Leu Gln Glu Met Glu Ser
Ala Val Lys Ser 1790 1795 1800 Lys Tyr Lys Ala Ser Ile Ala Ala Leu
Glu Ala Lys Ile Ala Gln 1805 1810 1815 Leu Glu Glu Gln Leu Asp Asn
Glu Thr Lys Glu Arg Gln Ala Ala 1820 1825 1830 Ser Lys Gln Val Arg
Arg Thr Glu Lys Lys Leu Lys Asp Val Leu 1835
1840 1845 Leu Gln Val Glu Asp Glu Arg Arg Asn Ala Glu Gln Phe Lys
Asp 1850 1855 1860 Gln Ala Asp Lys Ala Ser Thr Arg Leu Lys Gln Leu
Lys Arg Gln 1865 1870 1875 Leu Glu Glu Ala Glu Glu Glu Ala Gln Arg
Ala Asn Ala Ser Arg 1880 1885 1890 Arg Lys Leu Gln Arg Glu Leu Glu
Asp Ala Thr Glu Thr Ala Asp 1895 1900 1905 Ala Met Asn Arg Glu Val
Ser Ser Leu Lys Asn Lys Leu Arg Arg 1910 1915 1920 Gly Asp Leu Pro
Phe Val Val Thr Arg Arg Ile Val Arg Lys Gly 1925 1930 1935 Thr Gly
Asp Cys Ser Asp Glu Glu Val Asp Gly Lys Ala Asp Gly 1940 1945 1950
Ala Asp Ala Lys Ala Ala Glu 1955 1960 497474DNAHomo sapiens
49atacgactca ctatagggcg atcaggtgct ggaaagaagg ctaagcaagg ctgacctgct
60gcagctcccg cctcgtgcgc tcgccccacc cggccgccgc ccgagcgctc gagaaagtcc
120tctcgggaga agcagcgcct gttcccgggg cagatccagg ttcaggtcct
ggctataagt 180caccatggca cagcaagctg ccgataagta tctctatgtg
gataaaaact tcatcaacaa 240tccgctggcc caggccgact gggctgccaa
gaagctggta tgggtgcctt ccgacaagag 300tggctttgag ccagccagcc
tcaaggagga ggtgggcgaa gaggccatcg tggagctggt 360ggagaatggg
aagaaggtga aggtgaacaa ggatgacatc cagaagatga acccgcccaa
420gttctccaag gtggaggaca tggcagagct cacgtgcctc aacgaagcct
cggtgctgca 480caacctcaag gagcgttact actcagggct catctacacc
tattcaggcc tgttctgtgt 540ggtcatcaat ccttacaaga acctgcccat
ctactctgaa gagattgtgg aaatgtacaa 600gggcaagaag aggcacgaga
tgccccctca catctatgcc atcacagaca ccgcctacag 660gagtatgatg
caagaccgag aagatcaatc catcttgtgc actggtgaat ctggagctgg
720caagacggag aacaccaaga aggtcatcca gtatctggcg tacgtggcgt
cctcgcacaa 780gagcaagaag gaccagggcg agctggagcg gcagctgctg
caggccaacc ccatcctgga 840ggccttcggg aacgccaaga ccgtgaagaa
tgacaactcc tcccgcttcg gcaaattcat 900tcgcatcaac tttgatgtca
atggctacat tgttggagcc aacattgaga cttatctttt 960ggagaaatct
cgtgctatcc gccaagccaa ggaagaacgg accttccaca tcttctatta
1020tctcctgtct ggggctggag agcacctgaa gaccgatctc ctgttggagc
cgtacaacaa 1080ataccgcttc ctgtccaatg gacacgtcac catccccggg
cagcaggaca aggacatgtt 1140ccaggagacc atggaggcca tgaggattat
gggcatccca gaagaggagc aaatgggcct 1200gctgcgggtc atctcagggg
ttcttcagct cggcaacatc gtcttcaaga aggagcggaa 1260cactgaccag
gcgtccatgc ccgacaacac agctgcccaa aaggtgtccc atctcttggg
1320tatcaatgtg accgatttca ccagaggaat cctcaccccg cgcatcaagg
tgggacggga 1380ttacgtccag aaggcgcaga ctaaagagca ggctgacttt
gccatcgagg ccttggccaa 1440ggcgacctat gagcggatgt tccgctggct
ggtgctgcgc atcaacaagg ctctggacaa 1500gaccaagagg cagggcgcct
ccttcatcgg gatcctggac attgccggct tcgagatctt 1560tgatctgaac
tcgtttgagc agctgtgcat caattacacc aatgagaagc tgcagcagct
1620cttcaaccac accatgttca tcctggagca ggaggagtac cagcgcgagg
gcatcgagtg 1680gaacttcatc gactttggcc tcgacctgca gccctgcatc
gacctcattg agaagccagc 1740aggccccccg ggcattctgg ccctgctgga
cgaggagtgc tggttcccca aagccaccga 1800caagagcttc gtggagaagg
tgatgcagga gcagggcacc caccccaagt tccagaagcc 1860caagcagctg
aaggacaaag ctgatttctg cattatccac tatgccggca aggtggatta
1920caaagctgac gagtggctga tgaagaacat ggatcccctg aatgacaaca
tcgccacact 1980gctccaccag tcctctgaca agtttgtctc ggagctgtgg
aaggatgtgg accgcatcat 2040cggcctggac caggtggccg gcatgtcgga
gaccgcactg cccggggcct tcaagacgcg 2100gaagggcatg ttccgcactg
tggggcagct ttacaaggag cagctggcca agctgatggc 2160tacgctgagg
aacacgaacc ccaactttgt ccgctgcatc atccccaacc acgagaagaa
2220ggccggcaag ctggacccgc atctcgtgct ggaccagctg cgctgcaacg
gtgttctcga 2280gggcatccgt atctgccgcc agggcttccc caacagggtg
gtcttccagg agtttcggca 2340gagatatgag atcctgactc caaactccat
tcccaagggt ttcatggacg ggaagcaggc 2400gtgcgtgctc atgataaaag
ccctggagct cgacagcaat ctgtaccgca ttggccagag 2460caaagtcttc
ttccgtgccg gtgtgctggc ccacctggag gaggagcgag acctgaagat
2520caccgacgtc atcatagggt tccaggcctg ctgcaggggc tacctggcca
ggaaagcatt 2580tgccaagcgg cagcagcagc ttaccgccat gaaggtcctc
cagcggaact gcgctgccta 2640cctgaagctg cggaactggc agtggtggcg
gctcttcacc aaggtcaagc cgctgctgca 2700ggtgagccgg caggaggagg
agatgatggc caaggaggag gagctggtga aggtcagaga 2760gaagcagctg
gctgcggaga acaggctcac ggagatggag acgctgcagt ctcagctcat
2820ggcagagaaa ttgcagctgc aggagcagct ccaggcagaa accgagctgt
gtgccgaggc 2880tgaggagctc cgggcccgcc tgaccgccaa gaagcaggaa
ttagaagaga tctgccatga 2940cctagaggcc agggtggagg aggaggagga
gcgctgccag cacctgcagg cggagaagaa 3000gaagatgcag cagaacatcc
aggagcttga ggagcagctg gaggaggagg agagcgcccg 3060gcagaagctg
cagctggaga aggtgaccac cgaggcgaag ctgaaaaagc tggaggagga
3120gcagatcatc ctggaggacc agaactgcaa gctggccaag gaaaagaaac
tgctggaaga 3180cagaatagct gagttcacca ccaacctcac agaagaggag
gagaaatcta agagcctcgc 3240caagctcaag aacaagcatg aggcaatgat
cactgacttg gaagagcgcc tccgcaggga 3300ggagaagcag cgacaggagc
tggagaagac ccgccggaag ctggagggag actccacaga 3360cctcagcgac
cagatcgccg agctccaggc ccagatcgcg gagctcaaga tgcagctggc
3420caagaaagag gaggagctcc aggccgccct ggccagagtg gaagaggaag
ctgcccagaa 3480gaacatggcc ctcaagaaga tccgggagct ggaatctcag
atctctgaac tccaggaaga 3540cctggagtct gagcgtgctt ccaggaataa
agctgagaag cagaaacggg accttgggga 3600agagctagag gcgctgaaaa
cagagttgga ggacacgctg gattccacag ctgcccagca 3660ggagctcagg
tcaaaacgtg agcaggaggt gaacatcctg aagaagaccc tggaggagga
3720ggccaagacc cacgaggccc agatccagga gatgaggcag aagcactcac
aggccgtgga 3780ggagctggcg gagcagctgg agcagacgaa gcgggtgaaa
gcaaacctcg agaaggcaaa 3840gcagactctg gagaacgagc ggggggagct
ggccaacgag gtgaaggtgc tgctgcaggg 3900caaaggggac tcggagcaca
agcgcaagaa agtggaggcg cagctgcagg agctgcaggt 3960caagttcaac
gagggagagc gcgtgcgcac agagctggcc gacaaggtca ccaagctgca
4020ggtggagctg gacaacgtga ccgggcttct cagccagtcc gacagcaagt
ccagcaagct 4080caccaaggac ttctccgcgc tggagtccca gctgcaggac
actcaggagc tgctgcagga 4140ggagaaccgg cagaagctga gcctgagcac
caagctcaag caggtggagg acgagaagaa 4200ttccttccgg gagcagctgg
aggaggagga ggaggccaag cacaacctgg agaagcagat 4260cgccaccctc
catgcccagg tggccgacat gaaaaagaag atggaggaca gtgtggggtg
4320cctggaaact gctgaggagg tgaagaggaa gctccagaag gacctggagg
gcctgagcca 4380gcggcacgag gagaaggtgg ccgcctacga caagctggag
aagaccaaga cgcggctgca 4440gcaggagctg gacgacctgc tggtggacct
ggaccaccag cgccagagcg cgtgcaacct 4500ggagaagaag cagaagaagt
ttgaccagct cctggcggag gagaagacca tctctgccaa 4560gtatgcagag
gagcgcgacc gggctgaggc ggaggcccga gagaaggaga ccaaggctct
4620gtcgctggcc cgggccctgg aggaagccat ggagcagaag gcggagctgg
agcggctcaa 4680caagcagttc cgcacggaga tggaggacct tatgagctcc
aaggatgatg tgggcaagag 4740tgtccacgag ctggagaagt ccaagcgggc
cctagagcag caggtggagg agatgaagac 4800gcagctggaa gagctggagg
acgagctgca ggccaccgaa gatgccaagc tgcggttgga 4860ggtcaacctg
caggccatga aggcccagtt cgagcgggac ctgcagggcc gggacgagca
4920gagcgaggag aagaagaagc agctggtcag acaggtgcgg gagatggagg
cagagctgga 4980ggacgagagg aagcagcgct cgatggcagt ggccgcccgg
aagaagctgg agatggacct 5040gaaggacctg gaggcgcaca tcgactcggc
caacaagaac cgggacgaag ccatcaaaca 5100gctgcggaag ctgcaggccc
agatgaagga ctgcatgcgc gagctggatg acacccgcgc 5160ctctcgtgag
gagatcctgg cccaggccaa agagaacgag aagaagctga agagcatgga
5220ggccgagatg atccagttgc aggaggaact ggcagccgcg gagcgtgcca
agcgccaggc 5280ccagcaggag cgggatgagc tggctgacga gatcgccaac
agcagcggca aaggagccct 5340ggcgttagag gagaagcggc gtctggaggc
ccgcatcgcc cagctggagg aggagctgga 5400ggaggagcag ggcaacacgg
agctgatcaa cgaccggctg aagaaggcca acctgcagat 5460cgaccagatc
aacaccgacc tgaacctgga gcgcagccac gcccagaaga acgagaatgc
5520tcggcagcag ctggaacgcc agaacaagga gcttaaggtc aagctgcagg
agatggaggg 5580cactgtcaag tccaagtaca aggcctccat caccgccctc
gaggccaaga ttgcacagct 5640ggaggagcag ctggacaacg agaccaagga
gcgccaggca gcctgcaaac aggtgcgtcg 5700gaccgagaag aagctgaagg
atgtgctgct gcaggtggat gacgagcgga ggaacgccga 5760gcagtacaag
gaccaggccg acaaggcatc tacccgcctg aagcagctca agcggcagct
5820ggaggaggcc gaagaggagg cccagcgggc caacgcctcc cgccggaaac
tgcagcgcga 5880gctggaggac gccactgaga cggccgatgc catgaaccgc
gaagtcagct ccctaaagaa 5940caagctcagg cgcggggacc tgccgtttgt
cgtgccccgc cgaatggccc ggaaaggcgc 6000cggggatggc tccgacgaag
aggtagatgg caaagcggat ggggctgagg ccaaacctgc 6060cgaataagcc
tcttctcctg cagcctgaga tggatggaca gacagacacc acagcctccc
6120cttcccagac cccgcagcac gcctctcccc accttcttgg gactgctgtg
aacatgcctc 6180ctcctgccct ccgccccgtc cccccatccc gtttccctcc
aggtgttgtt gagggcattt 6240ggcttcctct gctgcatccc cttccagctc
cctcccctgc tcagaatctg ataccaaaga 6300gacagggccc gggcccaggc
agagagcgac cagcaggctc ctcagccctc tcttgccaaa 6360aagcacaaga
tgttgaggcg agcagggcag gcccccgggg aggggccaga gttttctatg
6420aatctatttt tcttcagact gaggcctttt ggtagtcgga gcccccgcag
tcgtcagcct 6480ccctgacgtc tgccaccagc gcccccactc ctcctccttt
ctttgctgtt tgcaatcaca 6540cgtggtgacc tcacacacct ctgccccttg
ggcctcccac tcccatggct ctgggcggtc 6600cagaaggagc aggccctggg
cctccacctc tgtgcagggc acagaaggct ggggtggggg 6660gaggagtgga
ttcctcccca ccctgtccca ggcagcgcca ctgtccgctg tctccctcct
6720gattctaaaa tgtctcaagt gcaatgcccc ctcccctcct ttaccgagga
cagcctgcct 6780ctgccacagc aaggctgtcg gggtcaagct ggaaaggcca
gcagccttcc agtggcttct 6840cccaacactc ttggggacca aatatattta
atggttaagg gacttgtccc aagtctgaca 6900gccagagcgt tagaggggcc
agcggccctc ccaggcgatc ttgtgtctac tctaggactg 6960ggcccgaggg
tggtttacct gcaccgttga ctcagtatag tttaaaaatc tgccacctgc
7020acaggtattt ttgaaagcaa aataaggttt tcttttttcc cctttcttgt
aataaatgat 7080aaaattccga gtctttctca ctgcctttgt ttagaagaga
gtagctcgtc ctcactggtc 7140tacactggtt gccgaattta cttgtattcc
taactgtttt gtatatgctg cattgagact 7200tacggcaaga aggcattttt
tttttttaaa ggaaacaaac tctcaaatca tgaagtgata 7260taaaagctgc
atatgcctac aaagctctga attcaggtcc cagttgctgt cacaaaggag
7320tgagtgaaac tcccacccta cccccttttt tatataataa aagtgcctta
gcatgtgttg 7380cagctgtcac cactacagta agctggttta cagatgtttt
ccactgagca tcacaataaa 7440gagaaccatg tgctaaaaaa aaaaaaaaaa aaaa
7474501960PRTHomo sapiens 50Met Ala Gln Gln Ala Ala Asp Lys Tyr Leu
Tyr Val Asp Lys Asn Phe 1 5 10 15 Ile Asn Asn Pro Leu Ala Gln Ala
Asp Trp Ala Ala Lys Lys Leu Val 20 25 30 Trp Val Pro Ser Asp Lys
Ser Gly Phe Glu Pro Ala Ser Leu Lys Glu 35 40 45 Glu Val Gly Glu
Glu Ala Ile Val Glu Leu Val Glu Asn Gly Lys Lys 50 55 60 Val Lys
Val Asn Lys Asp Asp Ile Gln Lys Met Asn Pro Pro Lys Phe 65 70 75 80
Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu Asn Glu Ala Ser 85
90 95 Val Leu His Asn Leu Lys Glu Arg Tyr Tyr Ser Gly Leu Ile Tyr
Thr 100 105 110 Tyr Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr Lys
Asn Leu Pro 115 120 125 Ile Tyr Ser Glu Glu Ile Val Glu Met Tyr Lys
Gly Lys Lys Arg His 130 135 140 Glu Met Pro Pro His Ile Tyr Ala Ile
Thr Asp Thr Ala Tyr Arg Ser 145 150 155 160 Met Met Gln Asp Arg Glu
Asp Gln Ser Ile Leu Cys Thr Gly Glu Ser 165 170 175 Gly Ala Gly Lys
Thr Glu Asn Thr Lys Lys Val Ile Gln Tyr Leu Ala 180 185 190 Tyr Val
Ala Ser Ser His Lys Ser Lys Lys Asp Gln Gly Glu Leu Glu 195 200 205
Arg Gln Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala 210
215 220 Lys Thr Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile
Arg 225 230 235 240 Ile Asn Phe Asp Val Asn Gly Tyr Ile Val Gly Ala
Asn Ile Glu Thr 245 250 255 Tyr Leu Leu Glu Lys Ser Arg Ala Ile Arg
Gln Ala Lys Glu Glu Arg 260 265 270 Thr Phe His Ile Phe Tyr Tyr Leu
Leu Ser Gly Ala Gly Glu His Leu 275 280 285 Lys Thr Asp Leu Leu Leu
Glu Pro Tyr Asn Lys Tyr Arg Phe Leu Ser 290 295 300 Asn Gly His Val
Thr Ile Pro Gly Gln Gln Asp Lys Asp Met Phe Gln 305 310 315 320 Glu
Thr Met Glu Ala Met Arg Ile Met Gly Ile Pro Glu Glu Glu Gln 325 330
335 Met Gly Leu Leu Arg Val Ile Ser Gly Val Leu Gln Leu Gly Asn Ile
340 345 350 Val Phe Lys Lys Glu Arg Asn Thr Asp Gln Ala Ser Met Pro
Asp Asn 355 360 365 Thr Ala Ala Gln Lys Val Ser His Leu Leu Gly Ile
Asn Val Thr Asp 370 375 380 Phe Thr Arg Gly Ile Leu Thr Pro Arg Ile
Lys Val Gly Arg Asp Tyr 385 390 395 400 Val Gln Lys Ala Gln Thr Lys
Glu Gln Ala Asp Phe Ala Ile Glu Ala 405 410 415 Leu Ala Lys Ala Thr
Tyr Glu Arg Met Phe Arg Trp Leu Val Leu Arg 420 425 430 Ile Asn Lys
Ala Leu Asp Lys Thr Lys Arg Gln Gly Ala Ser Phe Ile 435 440 445 Gly
Ile Leu Asp Ile Ala Gly Phe Glu Ile Phe Asp Leu Asn Ser Phe 450 455
460 Glu Gln Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gln Gln Leu Phe
465 470 475 480 Asn His Thr Met Phe Ile Leu Glu Gln Glu Glu Tyr Gln
Arg Glu Gly 485 490 495 Ile Glu Trp Asn Phe Ile Asp Phe Gly Leu Asp
Leu Gln Pro Cys Ile 500 505 510 Asp Leu Ile Glu Lys Pro Ala Gly Pro
Pro Gly Ile Leu Ala Leu Leu 515 520 525 Asp Glu Glu Cys Trp Phe Pro
Lys Ala Thr Asp Lys Ser Phe Val Glu 530 535 540 Lys Val Met Gln Glu
Gln Gly Thr His Pro Lys Phe Gln Lys Pro Lys 545 550 555 560 Gln Leu
Lys Asp Lys Ala Asp Phe Cys Ile Ile His Tyr Ala Gly Lys 565 570 575
Val Asp Tyr Lys Ala Asp Glu Trp Leu Met Lys Asn Met Asp Pro Leu 580
585 590 Asn Asp Asn Ile Ala Thr Leu Leu His Gln Ser Ser Asp Lys Phe
Val 595 600 605 Ser Glu Leu Trp Lys Asp Val Asp Arg Ile Ile Gly Leu
Asp Gln Val 610 615 620 Ala Gly Met Ser Glu Thr Ala Leu Pro Gly Ala
Phe Lys Thr Arg Lys 625 630 635 640 Gly Met Phe Arg Thr Val Gly Gln
Leu Tyr Lys Glu Gln Leu Ala Lys 645 650 655 Leu Met Ala Thr Leu Arg
Asn Thr Asn Pro Asn Phe Val Arg Cys Ile 660 665 670 Ile Pro Asn His
Glu Lys Lys Ala Gly Lys Leu Asp Pro His Leu Val 675 680 685 Leu Asp
Gln Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys 690 695 700
Arg Gln Gly Phe Pro Asn Arg Val Val Phe Gln Glu Phe Arg Gln Arg 705
710 715 720 Tyr Glu Ile Leu Thr Pro Asn Ser Ile Pro Lys Gly Phe Met
Asp Gly 725 730 735 Lys Gln Ala Cys Val Leu Met Ile Lys Ala Leu Glu
Leu Asp Ser Asn 740 745 750 Leu Tyr Arg Ile Gly Gln Ser Lys Val Phe
Phe Arg Ala Gly Val Leu 755 760 765 Ala His Leu Glu Glu Glu Arg Asp
Leu Lys Ile Thr Asp Val Ile Ile 770 775 780 Gly Phe Gln Ala Cys Cys
Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala 785 790 795 800 Lys Arg Gln
Gln Gln Leu Thr Ala Met Lys Val Leu Gln Arg Asn Cys 805 810 815 Ala
Ala Tyr Leu Lys Leu Arg Asn Trp Gln Trp Trp Arg Leu Phe Thr 820 825
830 Lys Val Lys Pro Leu Leu Gln Val Ser Arg Gln Glu Glu Glu Met Met
835 840 845 Ala Lys Glu Glu Glu Leu Val Lys Val Arg Glu Lys Gln Leu
Ala Ala 850 855 860 Glu Asn Arg Leu Thr Glu Met Glu Thr Leu Gln Ser
Gln Leu Met Ala 865 870 875 880 Glu Lys Leu Gln Leu Gln Glu Gln Leu
Gln Ala Glu Thr Glu Leu Cys 885 890 895 Ala Glu Ala Glu Glu Leu Arg
Ala Arg Leu Thr Ala Lys Lys Gln Glu 900 905 910 Leu Glu Glu Ile Cys
His Asp Leu Glu Ala Arg Val Glu Glu Glu Glu 915 920 925 Glu Arg Cys
Gln His Leu Gln Ala Glu Lys Lys Lys Met Gln Gln Asn 930 935 940 Ile
Gln Glu Leu Glu Glu Gln Leu Glu Glu Glu Glu Ser Ala Arg Gln 945 950
955 960 Lys Leu Gln Leu Glu Lys Val Thr Thr Glu Ala Lys Leu Lys Lys
Leu 965 970 975 Glu Glu Glu Gln Ile Ile Leu Glu Asp Gln Asn Cys Lys
Leu Ala Lys 980 985 990 Glu Lys Lys Leu Leu Glu Asp Arg Ile Ala Glu
Phe Thr Thr Asn Leu 995 1000 1005 Thr Glu Glu Glu Glu Lys Ser Lys
Ser Leu Ala Lys Leu Lys Asn 1010 1015 1020 Lys His Glu
Ala Met Ile Thr Asp Leu Glu Glu Arg Leu Arg Arg 1025 1030 1035 Glu
Glu Lys Gln Arg Gln Glu Leu Glu Lys Thr Arg Arg Lys Leu 1040 1045
1050 Glu Gly Asp Ser Thr Asp Leu Ser Asp Gln Ile Ala Glu Leu Gln
1055 1060 1065 Ala Gln Ile Ala Glu Leu Lys Met Gln Leu Ala Lys Lys
Glu Glu 1070 1075 1080 Glu Leu Gln Ala Ala Leu Ala Arg Val Glu Glu
Glu Ala Ala Gln 1085 1090 1095 Lys Asn Met Ala Leu Lys Lys Ile Arg
Glu Leu Glu Ser Gln Ile 1100 1105 1110 Ser Glu Leu Gln Glu Asp Leu
Glu Ser Glu Arg Ala Ser Arg Asn 1115 1120 1125 Lys Ala Glu Lys Gln
Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala 1130 1135 1140 Leu Lys Thr
Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Ala Gln 1145 1150 1155 Gln
Glu Leu Arg Ser Lys Arg Glu Gln Glu Val Asn Ile Leu Lys 1160 1165
1170 Lys Thr Leu Glu Glu Glu Ala Lys Thr His Glu Ala Gln Ile Gln
1175 1180 1185 Glu Met Arg Gln Lys His Ser Gln Ala Val Glu Glu Leu
Ala Glu 1190 1195 1200 Gln Leu Glu Gln Thr Lys Arg Val Lys Ala Asn
Leu Glu Lys Ala 1205 1210 1215 Lys Gln Thr Leu Glu Asn Glu Arg Gly
Glu Leu Ala Asn Glu Val 1220 1225 1230 Lys Val Leu Leu Gln Gly Lys
Gly Asp Ser Glu His Lys Arg Lys 1235 1240 1245 Lys Val Glu Ala Gln
Leu Gln Glu Leu Gln Val Lys Phe Asn Glu 1250 1255 1260 Gly Glu Arg
Val Arg Thr Glu Leu Ala Asp Lys Val Thr Lys Leu 1265 1270 1275 Gln
Val Glu Leu Asp Asn Val Thr Gly Leu Leu Ser Gln Ser Asp 1280 1285
1290 Ser Lys Ser Ser Lys Leu Thr Lys Asp Phe Ser Ala Leu Glu Ser
1295 1300 1305 Gln Leu Gln Asp Thr Gln Glu Leu Leu Gln Glu Glu Asn
Arg Gln 1310 1315 1320 Lys Leu Ser Leu Ser Thr Lys Leu Lys Gln Val
Glu Asp Glu Lys 1325 1330 1335 Asn Ser Phe Arg Glu Gln Leu Glu Glu
Glu Glu Glu Ala Lys His 1340 1345 1350 Asn Leu Glu Lys Gln Ile Ala
Thr Leu His Ala Gln Val Ala Asp 1355 1360 1365 Met Lys Lys Lys Met
Glu Asp Ser Val Gly Cys Leu Glu Thr Ala 1370 1375 1380 Glu Glu Val
Lys Arg Lys Leu Gln Lys Asp Leu Glu Gly Leu Ser 1385 1390 1395 Gln
Arg His Glu Glu Lys Val Ala Ala Tyr Asp Lys Leu Glu Lys 1400 1405
1410 Thr Lys Thr Arg Leu Gln Gln Glu Leu Asp Asp Leu Leu Val Asp
1415 1420 1425 Leu Asp His Gln Arg Gln Ser Ala Cys Asn Leu Glu Lys
Lys Gln 1430 1435 1440 Lys Lys Phe Asp Gln Leu Leu Ala Glu Glu Lys
Thr Ile Ser Ala 1445 1450 1455 Lys Tyr Ala Glu Glu Arg Asp Arg Ala
Glu Ala Glu Ala Arg Glu 1460 1465 1470 Lys Glu Thr Lys Ala Leu Ser
Leu Ala Arg Ala Leu Glu Glu Ala 1475 1480 1485 Met Glu Gln Lys Ala
Glu Leu Glu Arg Leu Asn Lys Gln Phe Arg 1490 1495 1500 Thr Glu Met
Glu Asp Leu Met Ser Ser Lys Asp Asp Val Gly Lys 1505 1510 1515 Ser
Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Gln Gln 1520 1525
1530 Val Glu Glu Met Lys Thr Gln Leu Glu Glu Leu Glu Asp Glu Leu
1535 1540 1545 Gln Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn
Leu Gln 1550 1555 1560 Ala Met Lys Ala Gln Phe Glu Arg Asp Leu Gln
Gly Arg Asp Glu 1565 1570 1575 Gln Ser Glu Glu Lys Lys Lys Gln Leu
Val Arg Gln Val Arg Glu 1580 1585 1590 Met Glu Ala Glu Leu Glu Asp
Glu Arg Lys Gln Arg Ser Met Ala 1595 1600 1605 Val Ala Ala Arg Lys
Lys Leu Glu Met Asp Leu Lys Asp Leu Glu 1610 1615 1620 Ala His Ile
Asp Ser Ala Asn Lys Asn Arg Asp Glu Ala Ile Lys 1625 1630 1635 Gln
Leu Arg Lys Leu Gln Ala Gln Met Lys Asp Cys Met Arg Glu 1640 1645
1650 Leu Asp Asp Thr Arg Ala Ser Arg Glu Glu Ile Leu Ala Gln Ala
1655 1660 1665 Lys Glu Asn Glu Lys Lys Leu Lys Ser Met Glu Ala Glu
Met Ile 1670 1675 1680 Gln Leu Gln Glu Glu Leu Ala Ala Ala Glu Arg
Ala Lys Arg Gln 1685 1690 1695 Ala Gln Gln Glu Arg Asp Glu Leu Ala
Asp Glu Ile Ala Asn Ser 1700 1705 1710 Ser Gly Lys Gly Ala Leu Ala
Leu Glu Glu Lys Arg Arg Leu Glu 1715 1720 1725 Ala Arg Ile Ala Gln
Leu Glu Glu Glu Leu Glu Glu Glu Gln Gly 1730 1735 1740 Asn Thr Glu
Leu Ile Asn Asp Arg Leu Lys Lys Ala Asn Leu Gln 1745 1750 1755 Ile
Asp Gln Ile Asn Thr Asp Leu Asn Leu Glu Arg Ser His Ala 1760 1765
1770 Gln Lys Asn Glu Asn Ala Arg Gln Gln Leu Glu Arg Gln Asn Lys
1775 1780 1785 Glu Leu Lys Val Lys Leu Gln Glu Met Glu Gly Thr Val
Lys Ser 1790 1795 1800 Lys Tyr Lys Ala Ser Ile Thr Ala Leu Glu Ala
Lys Ile Ala Gln 1805 1810 1815 Leu Glu Glu Gln Leu Asp Asn Glu Thr
Lys Glu Arg Gln Ala Ala 1820 1825 1830 Cys Lys Gln Val Arg Arg Thr
Glu Lys Lys Leu Lys Asp Val Leu 1835 1840 1845 Leu Gln Val Asp Asp
Glu Arg Arg Asn Ala Glu Gln Tyr Lys Asp 1850 1855 1860 Gln Ala Asp
Lys Ala Ser Thr Arg Leu Lys Gln Leu Lys Arg Gln 1865 1870 1875 Leu
Glu Glu Ala Glu Glu Glu Ala Gln Arg Ala Asn Ala Ser Arg 1880 1885
1890 Arg Lys Leu Gln Arg Glu Leu Glu Asp Ala Thr Glu Thr Ala Asp
1895 1900 1905 Ala Met Asn Arg Glu Val Ser Ser Leu Lys Asn Lys Leu
Arg Arg 1910 1915 1920 Gly Asp Leu Pro Phe Val Val Pro Arg Arg Met
Ala Arg Lys Gly 1925 1930 1935 Ala Gly Asp Gly Ser Asp Glu Glu Val
Asp Gly Lys Ala Asp Gly 1940 1945 1950 Ala Glu Ala Lys Pro Ala Glu
1955 1960 517666DNAHomo sapiens 51gtctttcctg ggagatgggc gcgcaaaccg
accagtgggt ctgggggcgg cagtgatggg 60cgtggagatg gcccaatgag ggtgggagtg
ggtggggcag gcgcgagcag cagtgctaaa 120ggagcccggc ggaggcagcg
gtgggtttgg aattgagacg ctggatctgt ggtcgctgct 180ggggacgtgt
gccggcgcca ccatcttcgg ctgaagaggc aattactttt gggtccttct
240gtttacaatg gcccagagaa ctggactgga ggatcccgag aggtatctct
ttgtggacag 300ggctgtcatc tacaaccctg ccactcaagc tgactggaca
gctaaaaagc tggtgtggat 360tccatcggaa cgccatggtt ttgaggcagc
tagtattaaa gaagagcggg gcgatgaggt 420tatggtggag ctggcagaga
atgggaagaa agcaatggtc aacaaagatg acattcagaa 480gatgaaccca
ccaaagttct ccaaggtgga ggatatggca gagctgacat gcttgaacga
540agcctctgtc ttacataatt tgaaggaccg ctactattca ggacttatct
atacttactc 600tggactcttc tgtgtggtga taaatcctta caagaacctt
ccaatttact ctgagaatat 660tattgaaatg tatagaggga agaaacgcca
tgagatgcca ccacacatct acgccatatc 720agagtctgct tacagatgca
tgcttcaaga tcgtgaggac cagtcaattc tatgcacggg 780tgaatcgggt
gccgggaaga cagaaaatac caagaaagtc attcagtacc ttgcccacgt
840tgcttcttct cacaaaggaa gaaaggacca taatattcct ggggaacttg
aacggcagct 900tttacaagca aatccaattc tggaatcctt tggaaatgcg
aagactgtga aaaatgataa 960ctcatctcgc tttggcaagt ttatccggat
caactttgat gtaactggct atattgttgg 1020ggccaacatt gaaacatacc
ttctggaaaa gtctcgtgct gttcgtcaag ctaaagatga 1080gcgtacattt
catatctttt atcagttgct ctctggagca ggggaacacc tgaaatccga
1140cttactcctg gaaggtttca acaactacag attcctctcc aatggctata
ttcctattcc 1200tggacagcaa gacaaggata acttccagga gaccatggaa
gccatgcaca tcatgggctt 1260ctctcacgaa gagatcctct caatgcttaa
agtcgtatct tcagtgctgc agtttggaaa 1320catctctttc aaaaaggaga
gaaacactga ccaagcctcc atgccggaga acacagtcgc 1380acagaagctc
tgccacctgc tcgggatgaa tgtgatggag ttcactcggg ctatcctcac
1440gcccaggatc aaggttggcc gggattacgt acagaaagcc cagaccaaag
agcaggctga 1500ttttgcagtg gaagcattgg caaaagctac ctatgagcgg
ttgtttcgct ggctcgttca 1560ccgcatcaat aaagcgctgg ataggaccaa
acgccaggga gcttccttca ttgggatcct 1620ggatattgct ggttttgaaa
tttttgagct gaactccttc gagcagctgt gcatcaacta 1680caccaacgag
aagctgcagc agctgttcaa ccacaccatg ttcatcctgg agcaggagga
1740gtaccagcga gagggcatcg agtggaactt tatcgacttc ggcctggacc
tgcagccctg 1800catcgacctg atagagagac ctgccaatcc ccctggcgtg
ctggccctcc tggatgaaga 1860atgctggttc cccaaagcta cagataaaac
atttgttgaa aagctggttc aggagcaagg 1920ttcccactcc aagtttcaga
agccgcgcca actgaaagac aaagccgact tctgcatcat 1980ccactacgcg
gggaaggtgg actataaggc agatgagtgg ctgatgaaga acatggaccc
2040gctgaatgac aacgtggcca ccctcctgca ccagtcctcg gacagatttg
tggctgagct 2100ttggaaggac gtggaccgaa ttgtaggtct ggatcaagtc
actgggatga ctgagaccgc 2160gtttggctct gcatacaaaa ccaagaaggg
catgttccga accgtcgggc agctctacaa 2220ggagtctctc accaagctga
tggcaactct ccgcaacacc aaccccaact tcgtccgctg 2280catcattcca
aatcacgaga agcgggctgg gaaactggac ccgcacctcg tgctcgatca
2340gcttcgctgt aacggcgtcc tggaagggat ccggatctgt cgccaggggt
tccccaaccg 2400gatagttttc caggaattca gacagagata tgagatccta
actcccaatg ctattcctaa 2460aggcttcatg gatggcaaac aggcgtgtga
gcgaatgatc cgagctttag aactggaccc 2520aaacctgtat agaattggac
agagcaagat atttttccga gctggagttt tggcgcactt 2580agaagaagaa
agagatttaa aaatcactga tatcatcatc tttttccaag ctgtatgcag
2640aggctacctc gcccgaaagg cctttgccaa gaaacagcaa caactaagtg
ccttaaaggt 2700cttgcagcgg aactgtgcgg cgtacctgaa gctgcgacac
tggcagtggt ggcgtgtctt 2760cacgaaggtg aagcctctcc tccaagtgac
ccgccaggag gaagaactcc aggcaaaaga 2820tgaggagctg ctgaaggtga
aagagaagca gacaaaagtg gaaggggagc ttgaggagat 2880ggagcggaag
caccagcagc tgctggaaga gaagaatatc ctggcagaac aactgcaagc
2940cgagaccgag ctcttcgctg aagcagaaga gatgagagca aggcttgctg
ccaaaaagca 3000ggaactggag gagattctcc atgacctcga gtccagggtg
gaggaggagg aagagcggaa 3060ccagatccta cagaatgaga agaagaagat
gcaggcgcac attcaggacc tagaagaaca 3120actggatgag gaggaggggg
cccggcaaaa gctgcagctg gagaaggtga cagcagaggc 3180taaaatcaag
aagatggaag aggaggttct gcttctcgaa gaccagaatt ccaaatttat
3240caaagaaaag aaactcatgg aagaccgaat tgctgagtgt tcctctcagc
tggctgaaga 3300ggaagaaaag gcaaaaaact tggccaaaat caggaataag
caagaagtga tgatctcgga 3360cttagaagaa cgcttgaaga aggaggagaa
aactcgacag gaactggaaa aggccaaacg 3420gaagctggat ggggaaacaa
ccgatctgca ggaccagatc gctgagctgc aggcacaggt 3480cgatgagctc
aaagtccagt tgaccaagaa ggaggaggag cttcaggggg cgctggccag
3540aggagatgat gagacactgc acaagaataa tgcacttaaa gttgcacggg
agctgcaggc 3600ccaaatcgca gagctccagg aagactttga gtctgaaaag
gcttcaagga acaaggctga 3660gaaacaaaaa cgggacttga gtgaggagct
ggaagctctg aagacagagc tggaggacac 3720cctagacacc acagcagctc
agcaggaact ccgcacaaaa cgtgagcagg aagtggcaga 3780gctgaagaag
gctcttgagg atgaaactaa gaaccacgaa gctcagatcc aggacatgag
3840acagaggcat gccacagcgc tggaggagct ttccgagcag ctggagcaag
cgaaaaggtt 3900caaagccaac ctggagaaga acaaacaggg cctggagaca
gacaacaagg agctggcgtg 3960tgaggtgaag gtgctgcagc aggtgaaggc
ggagtcagag cacaagagga agaagctgga 4020tgcccaggtc caggagctcc
atgccaaggt gtcagagggt gacaggctca gggtagagct 4080ggccgagaaa
gcaaacaagc tacagaatga gctggataat gtgtcaaccc tgctggaaga
4140agctgagaag aaaggtatta agtttgcgaa ggatgcagct ggtctcgagt
ctcaactaca 4200ggacacacag gagctccttc aggaagagac acggcagaaa
ctgaacctga gcagtcggat 4260ccggcagctg gaggaggaga agaacagcct
tcaggagcag caggaggagg aggaggaggc 4320caggaagaac ctggagaagc
aggtgttggc tctgcagtcc cagctggctg acaccaagaa 4380gaaagtggac
gatgacctgg ggacaatcga gagtttggag gaagccaaaa agaaactgct
4440caaggatgtg gaggcgctga gccagcggct ggaggagaag gtcctggcgt
atgacaagct 4500ggagaagacc aagaaccggc tgcaacaaga actggatgac
ctgacggtgg acctggacca 4560ccagcgccag atcgtctcca acttggagaa
gaaacagaag aagttcgacc agctgttggc 4620agaagaaaag ggcatctctg
ctcgctatgc agaagagcgg gaccgggctg aagctgaggc 4680cagagagaaa
gaaaccaaag cgctctccct ggcgcgggcc cttgaggagg ccttggaggc
4740gaaggaggaa ttcgagaggc agaacaagca gcttcgagca gacatggaag
acctgatgag 4800ctctaaagac gatgtgggga agaacgtcca cgagcttgag
aaatccaagc gagccttgga 4860gcagcaggtg gaggagatgc ggacccagct
ggaggagctg gaggacgagc tgcaggccac 4920tgaggatgcc aagctccgcc
tggaagtcaa catgcaggcc atgaaggccc agtttgagag 4980ggacctgcaa
acccgagatg agcagaatga agaaaagaag cggctgctgc ttaagcaggt
5040gcgggagctc gaggcagagc tggaggatga gcggaaacag cgggcactgg
ctgtggcgtc 5100aaagaagaag atggagatag acctgaagga cctggaggct
cagatcgagg ctgcgaacaa 5160agcccgggat gaagtgatca agcagcttcg
caaacttcag gcacagatga aggattacca 5220gcgtgaacta gaagaggctc
gagcatctag agatgagatt tttgctcaat ccaaagaaag 5280tgaaaagaaa
ctgaagagtc tagaagcaga aattcttcag ctgcaagagg agctggcctc
5340atccgagcga gcccgccgac acgcagagca ggagcgagac gagctggctg
atgagatcgc 5400caacagcgcc tctggaaagt ctgcgctgtt ggatgagaag
cggcgcctgg aagcgcggat 5460cgcacagctg gaagaggagc tggaggagga
gcagagcaac atggagctgc tcaatgaccg 5520cttccgcaag accacgctgc
aggtggacac actgaacaca gagctggcag cagagcgcag 5580cgctgcccag
aagagtgaca atgcccgcca gcagctggag cgacaaaaca aggagctgaa
5640ggccaagctg caggagctgg agggggcagt caagtccaag ttcaaggcta
ccatctcagc 5700cctggaagcc aagattgggc agctggagga gcagcttgag
caggaagcca aggagcgagc 5760agctgccaac aaactagtcc gtcgaacaga
gaagaaactg aaagaaatct tcatgcaggt 5820tgaagacgag cgtcggcatg
cggatcagta taaggagcag atggagaagg ctaatgccag 5880gatgaagcag
cttaaacgac agttggaaga ggctgaggaa gaggccacac gtgccaacgc
5940atctcggcgt aaactccaaa gggagctgga cgacgccact gaggccaatg
aaggcctgag 6000ccgcgaggtc agcactctca agaaccggct caggcggggc
ggtccaatca gcttttcttc 6060aagccgatct ggccggcgcc agctgcacat
tgagggggca tcgctagagc tgtcagatga 6120cgacacagaa agtaagacca
gtgatgtcaa tgacacacag ccaccccaat cagaataggc 6180acaggaggtc
agaggtgatg ctgaggacag gccagaactc atcccagcac cagtctgctt
6240gagccctgca ctcactgctc gggaatggca agctcccaga ttccttccag
gaaagtcaac 6300tgtgtcttaa ggctttgcgg cctgcgcaga ctatatcctg
cttcagacta gatacaattg 6360ccccttttta tatatacacc tccacaagac
atgcgtatta aacagattgt ctcatcgttg 6420catctatttt ccatgtattc
atcaagagac cattttatga cacattaaga agaaagaacc 6480tttttgaaac
aaactccagg ccctttgttg ccagtggctg ggcctaaggg ttgccccggg
6540accgtgctca gctgctctgc atgccctgtc ctactgacag gtaccttagt
tctgtgttca 6600tgtggccctg acccttcctt caaccacacc tggtctctta
gaacattgtg aacctaacct 6660gcacttgtgt ctctcatttc ctgtgaatag
tgatcactgt ctcagtgagc aaactgggag 6720aggggctttg gcggcttagg
ggtgggtttg gattggggaa gcagcatcca tttggggttc 6780tcctgcccat
ctcccaaggg gtgaccctgc ccctcaaatt catggtgtcc ccaccgtctc
6840aatgtgaata gtctcagagc tctgtgcaca gagaggacag tggccacaac
acataaggtg 6900ccccgggtgg cagccatcac agtaacttcc aggtggtctc
ctgagtgtct ggcttgataa 6960tgccctcaat tcaggagtga gcctctgtga
cccttggggt gctcgcagaa ggcctctcca 7020agcagtcaag ccctcttgca
aattcagcca ctgctttgag cccaaaacgg gaatattagt 7080tttatgtcgg
aggtgtgttc caagtttgtc aatgaggcta tagcctcaag aagatgccat
7140ctgcctgaat gttgacatgc cagcgggcgt gtgacccttc attttccctt
tcccttcctt 7200tggacagtgt tacaatgaac acttagcatt ctgtttttgg
ttgatagttg agcaaactga 7260cattacagaa agtgccttag acactacagt
actaagacaa tgttaaatat attatttgcc 7320tctataacaa cttaatgtat
taagttctga ctgtgcttca tatcatgtac ctctctagtg 7380aagtagatgc
gcaaacattc agtgacagca aatcagtgtt agtgacaagc cccgaccgtg
7440gcgatgtgct ggaaaacacg gaccttttgg gttaaaagct ttaacatctg
tgaggaagaa 7500ctggtcacat gggtttggaa tctttgattt cccctgtatg
aattgtactg gctgttgacc 7560accagacacc tgactgcaaa tatcttttct
tgtattccca tatttctaga caatgatttt 7620tgtaagacaa taaatttatt
cattatagaa aaaaaaaaaa aaaaaa 7666521976PRTMus musculus 52Met Ala
Gln Arg Thr Gly Leu Glu Asp Pro Glu Arg Tyr Leu Phe Val 1 5 10 15
Asp Arg Ala Val Ile Tyr Asn Pro Ala Thr Gln Ala Asp Trp Thr Ala 20
25 30 Lys Lys Leu Val Trp Ile Pro Ser Glu Arg His Gly Phe Glu Ala
Ala 35 40 45 Ser Ile Lys Glu Glu Arg Gly Asp Glu Val Met Val Glu
Leu Ala Glu 50 55 60 Asn Gly Lys Lys Ala Met Val Asn Lys Asp Asp
Ile Gln Lys Met Asn 65 70 75 80 Pro Pro Lys Phe Ser Lys Val Glu Asp
Met Ala Glu Leu Thr Cys Leu 85 90 95 Asn Glu Ala Ser Val Leu His
Asn Leu Lys Asp Arg Tyr Tyr Ser Gly 100 105 110 Leu Ile Tyr Thr Tyr
Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr 115 120 125 Lys Asn Leu
Pro Ile Tyr Ser Glu Asn Ile Ile Glu Met Tyr Arg Gly 130 135
140 Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ser Glu Ser
145 150 155 160 Ala Tyr Arg Cys Met Leu Gln Asp Arg Glu Asp Gln Ser
Ile Leu Cys 165 170 175 Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn
Thr Lys Lys Val Ile 180 185 190 Gln Tyr Leu Ala His Val Ala Ser Ser
His Lys Gly Arg Lys Asp His 195 200 205 Asn Ile Pro Gly Glu Leu Glu
Arg Gln Leu Leu Gln Ala Asn Pro Ile 210 215 220 Leu Glu Ser Phe Gly
Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser 225 230 235 240 Arg Phe
Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile 245 250 255
Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Val 260
265 270 Arg Gln Ala Lys Asp Glu Arg Thr Phe His Ile Phe Tyr Gln Leu
Leu 275 280 285 Ser Gly Ala Gly Glu His Leu Lys Ser Asp Leu Leu Leu
Glu Gly Phe 290 295 300 Asn Asn Tyr Arg Phe Leu Ser Asn Gly Tyr Ile
Pro Ile Pro Gly Gln 305 310 315 320 Gln Asp Lys Asp Asn Phe Gln Glu
Thr Met Glu Ala Met His Ile Met 325 330 335 Gly Phe Ser His Glu Glu
Ile Leu Ser Met Leu Lys Val Val Ser Ser 340 345 350 Val Leu Gln Phe
Gly Asn Ile Ser Phe Lys Lys Glu Arg Asn Thr Asp 355 360 365 Gln Ala
Ser Met Pro Glu Asn Thr Val Ala Gln Lys Leu Cys His Leu 370 375 380
Leu Gly Met Asn Val Met Glu Phe Thr Arg Ala Ile Leu Thr Pro Arg 385
390 395 400 Ile Lys Val Gly Arg Asp Tyr Val Gln Lys Ala Gln Thr Lys
Glu Gln 405 410 415 Ala Asp Phe Ala Val Glu Ala Leu Ala Lys Ala Thr
Tyr Glu Arg Leu 420 425 430 Phe Arg Trp Leu Val His Arg Ile Asn Lys
Ala Leu Asp Arg Thr Lys 435 440 445 Arg Gln Gly Ala Ser Phe Ile Gly
Ile Leu Asp Ile Ala Gly Phe Glu 450 455 460 Ile Phe Glu Leu Asn Ser
Phe Glu Gln Leu Cys Ile Asn Tyr Thr Asn 465 470 475 480 Glu Lys Leu
Gln Gln Leu Phe Asn His Thr Met Phe Ile Leu Glu Gln 485 490 495 Glu
Glu Tyr Gln Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly 500 505
510 Leu Asp Leu Gln Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro
515 520 525 Pro Gly Val Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro
Lys Ala 530 535 540 Thr Asp Lys Thr Phe Val Glu Lys Leu Val Gln Glu
Gln Gly Ser His 545 550 555 560 Ser Lys Phe Gln Lys Pro Arg Gln Leu
Lys Asp Lys Ala Asp Phe Cys 565 570 575 Ile Ile His Tyr Ala Gly Lys
Val Asp Tyr Lys Ala Asp Glu Trp Leu 580 585 590 Met Lys Asn Met Asp
Pro Leu Asn Asp Asn Val Ala Thr Leu Leu His 595 600 605 Gln Ser Ser
Asp Arg Phe Val Ala Glu Leu Trp Lys Asp Val Asp Arg 610 615 620 Ile
Val Gly Leu Asp Gln Val Thr Gly Met Thr Glu Thr Ala Phe Gly 625 630
635 640 Ser Ala Tyr Lys Thr Lys Lys Gly Met Phe Arg Thr Val Gly Gln
Leu 645 650 655 Tyr Lys Glu Ser Leu Thr Lys Leu Met Ala Thr Leu Arg
Asn Thr Asn 660 665 670 Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His
Glu Lys Arg Ala Gly 675 680 685 Lys Leu Asp Pro His Leu Val Leu Asp
Gln Leu Arg Cys Asn Gly Val 690 695 700 Leu Glu Gly Ile Arg Ile Cys
Arg Gln Gly Phe Pro Asn Arg Ile Val 705 710 715 720 Phe Gln Glu Phe
Arg Gln Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile 725 730 735 Pro Lys
Gly Phe Met Asp Gly Lys Gln Ala Cys Glu Arg Met Ile Arg 740 745 750
Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Ile Gly Gln Ser Lys Ile 755
760 765 Phe Phe Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp
Leu 770 775 780 Lys Ile Thr Asp Ile Ile Ile Phe Phe Gln Ala Val Cys
Arg Gly Tyr 785 790 795 800 Leu Ala Arg Lys Ala Phe Ala Lys Lys Gln
Gln Gln Leu Ser Ala Leu 805 810 815 Lys Val Leu Gln Arg Asn Cys Ala
Ala Tyr Leu Lys Leu Arg His Trp 820 825 830 Gln Trp Trp Arg Val Phe
Thr Lys Val Lys Pro Leu Leu Gln Val Thr 835 840 845 Arg Gln Glu Glu
Glu Leu Gln Ala Lys Asp Glu Glu Leu Leu Lys Val 850 855 860 Lys Glu
Lys Gln Thr Lys Val Glu Gly Glu Leu Glu Glu Met Glu Arg 865 870 875
880 Lys His Gln Gln Leu Leu Glu Glu Lys Asn Ile Leu Ala Glu Gln Leu
885 890 895 Gln Ala Glu Thr Glu Leu Phe Ala Glu Ala Glu Glu Met Arg
Ala Arg 900 905 910 Leu Ala Ala Lys Lys Gln Glu Leu Glu Glu Ile Leu
His Asp Leu Glu 915 920 925 Ser Arg Val Glu Glu Glu Glu Glu Arg Asn
Gln Ile Leu Gln Asn Glu 930 935 940 Lys Lys Lys Met Gln Ala His Ile
Gln Asp Leu Glu Glu Gln Leu Asp 945 950 955 960 Glu Glu Glu Gly Ala
Arg Gln Lys Leu Gln Leu Glu Lys Val Thr Ala 965 970 975 Glu Ala Lys
Ile Lys Lys Met Glu Glu Glu Val Leu Leu Leu Glu Asp 980 985 990 Gln
Asn Ser Lys Phe Ile Lys Glu Lys Lys Leu Met Glu Asp Arg Ile 995
1000 1005 Ala Glu Cys Ser Ser Gln Leu Ala Glu Glu Glu Glu Lys Ala
Lys 1010 1015 1020 Asn Leu Ala Lys Ile Arg Asn Lys Gln Glu Val Met
Ile Ser Asp 1025 1030 1035 Leu Glu Glu Arg Leu Lys Lys Glu Glu Lys
Thr Arg Gln Glu Leu 1040 1045 1050 Glu Lys Ala Lys Arg Lys Leu Asp
Gly Glu Thr Thr Asp Leu Gln 1055 1060 1065 Asp Gln Ile Ala Glu Leu
Gln Ala Gln Val Asp Glu Leu Lys Val 1070 1075 1080 Gln Leu Thr Lys
Lys Glu Glu Glu Leu Gln Gly Ala Leu Ala Arg 1085 1090 1095 Gly Asp
Asp Glu Thr Leu His Lys Asn Asn Ala Leu Lys Val Ala 1100 1105 1110
Arg Glu Leu Gln Ala Gln Ile Ala Glu Leu Gln Glu Asp Phe Glu 1115
1120 1125 Ser Glu Lys Ala Ser Arg Asn Lys Ala Glu Lys Gln Lys Arg
Asp 1130 1135 1140 Leu Ser Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu
Glu Asp Thr 1145 1150 1155 Leu Asp Thr Thr Ala Ala Gln Gln Glu Leu
Arg Thr Lys Arg Glu 1160 1165 1170 Gln Glu Val Ala Glu Leu Lys Lys
Ala Leu Glu Asp Glu Thr Lys 1175 1180 1185 Asn His Glu Ala Gln Ile
Gln Asp Met Arg Gln Arg His Ala Thr 1190 1195 1200 Ala Leu Glu Glu
Leu Ser Glu Gln Leu Glu Gln Ala Lys Arg Phe 1205 1210 1215 Lys Ala
Asn Leu Glu Lys Asn Lys Gln Gly Leu Glu Thr Asp Asn 1220 1225 1230
Lys Glu Leu Ala Cys Glu Val Lys Val Leu Gln Gln Val Lys Ala 1235
1240 1245 Glu Ser Glu His Lys Arg Lys Lys Leu Asp Ala Gln Val Gln
Glu 1250 1255 1260 Leu His Ala Lys Val Ser Glu Gly Asp Arg Leu Arg
Val Glu Leu 1265 1270 1275 Ala Glu Lys Ala Asn Lys Leu Gln Asn Glu
Leu Asp Asn Val Ser 1280 1285 1290 Thr Leu Leu Glu Glu Ala Glu Lys
Lys Gly Ile Lys Phe Ala Lys 1295 1300 1305 Asp Ala Ala Gly Leu Glu
Ser Gln Leu Gln Asp Thr Gln Glu Leu 1310 1315 1320 Leu Gln Glu Glu
Thr Arg Gln Lys Leu Asn Leu Ser Ser Arg Ile 1325 1330 1335 Arg Gln
Leu Glu Glu Glu Lys Asn Ser Leu Gln Glu Gln Gln Glu 1340 1345 1350
Glu Glu Glu Glu Ala Arg Lys Asn Leu Glu Lys Gln Val Leu Ala 1355
1360 1365 Leu Gln Ser Gln Leu Ala Asp Thr Lys Lys Lys Val Asp Asp
Asp 1370 1375 1380 Leu Gly Thr Ile Glu Ser Leu Glu Glu Ala Lys Lys
Lys Leu Leu 1385 1390 1395 Lys Asp Val Glu Ala Leu Ser Gln Arg Leu
Glu Glu Lys Val Leu 1400 1405 1410 Ala Tyr Asp Lys Leu Glu Lys Thr
Lys Asn Arg Leu Gln Gln Glu 1415 1420 1425 Leu Asp Asp Leu Thr Val
Asp Leu Asp His Gln Arg Gln Ile Val 1430 1435 1440 Ser Asn Leu Glu
Lys Lys Gln Lys Lys Phe Asp Gln Leu Leu Ala 1445 1450 1455 Glu Glu
Lys Gly Ile Ser Ala Arg Tyr Ala Glu Glu Arg Asp Arg 1460 1465 1470
Ala Glu Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu 1475
1480 1485 Ala Arg Ala Leu Glu Glu Ala Leu Glu Ala Lys Glu Glu Phe
Glu 1490 1495 1500 Arg Gln Asn Lys Gln Leu Arg Ala Asp Met Glu Asp
Leu Met Ser 1505 1510 1515 Ser Lys Asp Asp Val Gly Lys Asn Val His
Glu Leu Glu Lys Ser 1520 1525 1530 Lys Arg Ala Leu Glu Gln Gln Val
Glu Glu Met Arg Thr Gln Leu 1535 1540 1545 Glu Glu Leu Glu Asp Glu
Leu Gln Ala Thr Glu Asp Ala Lys Leu 1550 1555 1560 Arg Leu Glu Val
Asn Met Gln Ala Met Lys Ala Gln Phe Glu Arg 1565 1570 1575 Asp Leu
Gln Thr Arg Asp Glu Gln Asn Glu Glu Lys Lys Arg Leu 1580 1585 1590
Leu Leu Lys Gln Val Arg Glu Leu Glu Ala Glu Leu Glu Asp Glu 1595
1600 1605 Arg Lys Gln Arg Ala Leu Ala Val Ala Ser Lys Lys Lys Met
Glu 1610 1615 1620 Ile Asp Leu Lys Asp Leu Glu Ala Gln Ile Glu Ala
Ala Asn Lys 1625 1630 1635 Ala Arg Asp Glu Val Ile Lys Gln Leu Arg
Lys Leu Gln Ala Gln 1640 1645 1650 Met Lys Asp Tyr Gln Arg Glu Leu
Glu Glu Ala Arg Ala Ser Arg 1655 1660 1665 Asp Glu Ile Phe Ala Gln
Ser Lys Glu Ser Glu Lys Lys Leu Lys 1670 1675 1680 Ser Leu Glu Ala
Glu Ile Leu Gln Leu Gln Glu Glu Leu Ala Ser 1685 1690 1695 Ser Glu
Arg Ala Arg Arg His Ala Glu Gln Glu Arg Asp Glu Leu 1700 1705 1710
Ala Asp Glu Ile Ala Asn Ser Ala Ser Gly Lys Ser Ala Leu Leu 1715
1720 1725 Asp Glu Lys Arg Arg Leu Glu Ala Arg Ile Ala Gln Leu Glu
Glu 1730 1735 1740 Glu Leu Glu Glu Glu Gln Ser Asn Met Glu Leu Leu
Asn Asp Arg 1745 1750 1755 Phe Arg Lys Thr Thr Leu Gln Val Asp Thr
Leu Asn Thr Glu Leu 1760 1765 1770 Ala Ala Glu Arg Ser Ala Ala Gln
Lys Ser Asp Asn Ala Arg Gln 1775 1780 1785 Gln Leu Glu Arg Gln Asn
Lys Glu Leu Lys Ala Lys Leu Gln Glu 1790 1795 1800 Leu Glu Gly Ala
Val Lys Ser Lys Phe Lys Ala Thr Ile Ser Ala 1805 1810 1815 Leu Glu
Ala Lys Ile Gly Gln Leu Glu Glu Gln Leu Glu Gln Glu 1820 1825 1830
Ala Lys Glu Arg Ala Ala Ala Asn Lys Leu Val Arg Arg Thr Glu 1835
1840 1845 Lys Lys Leu Lys Glu Ile Phe Met Gln Val Glu Asp Glu Arg
Arg 1850 1855 1860 His Ala Asp Gln Tyr Lys Glu Gln Met Glu Lys Ala
Asn Ala Arg 1865 1870 1875 Met Lys Gln Leu Lys Arg Gln Leu Glu Glu
Ala Glu Glu Glu Ala 1880 1885 1890 Thr Arg Ala Asn Ala Ser Arg Arg
Lys Leu Gln Arg Glu Leu Asp 1895 1900 1905 Asp Ala Thr Glu Ala Asn
Glu Gly Leu Ser Arg Glu Val Ser Thr 1910 1915 1920 Leu Lys Asn Arg
Leu Arg Arg Gly Gly Pro Ile Ser Phe Ser Ser 1925 1930 1935 Ser Arg
Ser Gly Arg Arg Gln Leu His Ile Glu Gly Ala Ser Leu 1940 1945 1950
Glu Leu Ser Asp Asp Asp Thr Glu Ser Lys Thr Ser Asp Val Asn 1955
1960 1965 Asp Thr Gln Pro Pro Gln Ser Glu 1970 1975 537619DNAHomo
sapiens 53actgaggcgc tggatctgtg gtcgcggctg gggacgtgcg cccgcgccac
catcttcggc 60tgaagaggca attgcttttg gatcgttcca tttacaatgg cgcagagaac
tggactcgag 120gatccagaga ggtatctctt tgtggacagg gctgtcatct
acaaccctgc cactcaagct 180gattggacag ctaaaaagct agtgtggatt
ccatcagaac gccatggttt tgaggcagct 240agtatcaaag aagaacgggg
agatgaagtt atggtggagt tggcagagaa tggaaagaaa 300gcaatggtca
acaaagatga tattcagaag atgaacccac ctaagttttc caaggtggag
360gatatggcag aattgacatg cttgaatgaa gcttccgttt tacataatct
gaaggatcgc 420tactattcag gactaatcta tacttattct ggactcttct
gtgtagttat aaacccttac 480aagaatcttc caatttactc tgagaatatt
attgaaatgt acagagggaa gaagcgtcat 540gagatgcctc cacacatcta
tgctatatct gaatctgctt acagatgcat gcttcaagat 600cgtgaggacc
agtcaattct ttgcacgggt gagtcaggtg ctgggaagac agaaaataca
660aagaaagtta ttcagtacct tgcccatgtt gcttcttcac ataaaggaag
aaaggaccat 720aatattcctg gggaacttga acggcagctt ttgcaagcaa
atccaattct ggaatcattt 780ggaaatgcga agactgtgaa aaatgataac
tcatctcgtt ttggcaaatt tattcggatc 840aactttgatg taactggcta
tatcgttggg gccaacattg aaacatacct tctggaaaag 900tctcgtgctg
ttcgtcaagc aaaagatgaa cgtacttttc atatctttta ccagttgtta
960tctggagcag gagaacacct aaagtctgat ttgcttcttg aaggatttaa
taactacagg 1020tttctctcca atggctatat tcctattccg ggacagcaag
acaaagataa tttccaggag 1080accatggaag caatgcacat aatgggcttc
tcccatgaag agattctgtc aatgcttaaa 1140gtagtatctt cagtgctaca
gtttggaaat atttctttca aaaaggagag aaatactgat 1200caagcttcca
tgccagaaaa tacagttgcg cagaagctct gccatcttct tgggatgaat
1260gtgatggagt ttactcgggc catcctgact ccccggatca aggtcggccg
agactatgtg 1320caaaaagccc agaccaaaga acaggcagat tttgcagtag
aagcattggc aaaagctacc 1380tatgagcggc tctttcgctg gctcgttcat
cgcatcaata aagctctgga taggaccaaa 1440cgtcagggag catctttcat
tggaatcctg gatattgctg gatttgaaat ttttgagctg 1500aactcctttg
aacaactttg catcaactac accaatgaga agctgcagca gctgttcaac
1560cacaccatgt ttatcctaga acaagaggaa taccagcgcg aaggcatcga
gtggaacttc 1620atcgatttcg ggctggatct gcagccatgc atcgacctaa
tagagagacc tgcgaaccct 1680cctggtgtac tggccctttt ggatgaagaa
tgctggttcc ctaaagccac agataaaacc 1740tttgttgaaa aactggttca
agagcaaggt tcccactcca agtttcagaa acctcgacaa 1800ttaaaagaca
aagctgattt ttgcattata cattatgcag ggaaggtgga ctataaggca
1860gatgagtggc tgatgaagaa tatggacccc ctgaatgaca acgtggccac
ccttttgcac 1920cagtcatcag acagatttgt ggcagagctt tggaaagatg
tggaccgtat cgtgggtctg 1980gatcaagtca ctggtatgac tgagacagct
tttggctccg catataaaac caagaagggc 2040atgtttcgta ccgttgggca
actctacaaa gaatctctca ccaagctgat ggcaactctc 2100cgaaacacca
accctaactt tgttcgttgt atcattccaa atcacgagaa gagggctgga
2160aaattggatc cacacctagt cctagatcag cttcgctgta atggtgtcct
ggaagggatc 2220cgaatctgtc gccagggctt ccctaaccga atagttttcc
aggaattcag acagagatat 2280gagatcctaa ctccaaatgc tattcctaaa
ggttttatgg atggtaaaca ggcctgtgaa 2340cgaatgatcc gggctttaga
attggaccca aacttgtaca gaattggaca gagcaagata 2400tttttcagag
ctggagttct ggcacactta gaggaagaaa gagatttaaa aatcaccgat
2460atcattatct tcttccaggc cgtttgcaga ggttacctgg ccagaaaggc
ctttgccaag 2520aagcagcagc aactaagtgc cttaaaggtc ttgcagcgga
actgtgccgc gtacctgaaa 2580ttacggcact ggcagtggtg gcgagtcttc
acaaaggtga agccgcttct acaagtgact 2640cgccaggagg aagaacttca
ggccaaagat gaagagctgt tgaaggtgaa ggagaagcag 2700acgaaggtgg
aaggagagct ggaggagatg gagcggaagc
accagcagct tttagaagag 2760aagaatatcc ttgcagaaca actacaagca
gagactgagc tctttgctga agcagaagag 2820atgagggcaa gacttgctgc
taaaaagcag gaattagaag agattctaca tgacttggag 2880tctagggttg
aagaagaaga agaaagaaac caaatcctcc aaaatgaaaa gaaaaaaatg
2940caagcacata ttcaggacct ggaagaacag ctagacgagg aggaaggggc
tcggcaaaag 3000ctgcagctgg aaaaggtgac agcagaggcc aagatcaaga
agatggaaga ggagattctg 3060cttctcgagg accaaaattc caagttcatc
aaagaaaaga aactcatgga agatcgcatt 3120gctgagtgtt cctctcagct
ggctgaagag gaagaaaagg cgaaaaactt ggccaaaatc 3180aggaataagc
aagaagtgat gatctcagat ttagaagaac gcttaaagaa ggaagaaaag
3240actcgtcagg aactggaaaa ggccaaaaga aaactcgacg gggagacgac
cgacctgcag 3300gaccagatcg cagagctgca ggcgcagatt gatgagctca
agctgcagct ggccaagaag 3360gaggaggagc tgcagggcgc actggccaga
ggtgatgatg aaacactcca taagaacaat 3420gcccttaaag ttgtgcgaga
gctacaagcc caaattgctg aacttcagga agactttgaa 3480tccgagaagg
cttcacggaa caaggccgaa aagcagaaaa gggacttgag tgaggaactg
3540gaagctctga aaacagagct ggaggacacg ctggacacca cggcagccca
gcaggaacta 3600cgtacaaaac gtgaacaaga agtggcagag ctgaagaaag
ctcttgagga ggaaactaag 3660aaccatgaag ctcaaatcca ggacatgaga
caaagacacg caacagccct ggaggagctc 3720tcagagcagc tggaacaggc
caagcggttc aaagcaaatc tagagaagaa caagcagggc 3780ctggagacag
ataacaagga gctggcgtgt gaggtgaagg tcctgcagca ggtcaaggct
3840gagtctgagc acaagaggaa gaagctcgac gcgcaggtcc aggagctcca
tgccaaggtc 3900tctgaaggcg acaggctcag ggtggagctg gcggagaaag
caagtaagct gcagaatgag 3960ctagataatg tctccaccct tctggaagaa
gcagagaaga agggtattaa atttgctaag 4020gatgcagcta gtcttgagtc
tcaactacag gatacacagg agcttcttca ggaggagaca 4080cgccagaaac
taaacctgag cagtcggatc cggcagctgg aagaggagaa gaacagtctt
4140caggagcagc aggaggagga ggaggaggcc aggaagaacc tggagaagca
agtgctggcc 4200ctgcagtccc agttggctga taccaagaag aaagtagatg
acgacctggg aacaattgaa 4260agtctggaag aagccaagaa gaagcttctg
aaggacgcgg aggccctgag ccagcgcctg 4320gaggagaagg cactggcgta
tgacaaactg gagaagacca agaaccgcct gcagcaggag 4380ctggacgacc
tcacggtgga cctggaccac cagcgccagg tcgcctccaa cttggagaag
4440aagcagaaga agtttgacca gctgttagca gaagagaaga gcatctctgc
tcgctatgcc 4500gaagagcggg accgggccga agccgaggcc agagagaaag
aaaccaaagc cctgtcactg 4560gcccgggccc tcgaggaagc cctggaggcc
aaggaggagt ttgagaggca gaacaagcag 4620ctccgagcag acatggaaga
cctcatgagc tccaaagatg atgtgggaaa aaacgttcac 4680gaacttgaaa
aatccaaacg ggccctagag cagcaggtgg aggaaatgag gacccagctg
4740gaggagctgg aagacgaact ccaggccacg gaagatgcca agcttcgtct
ggaggtcaac 4800atgcaggcca tgaaggcgca gttcgagaga gacctgcaaa
ccagggatga gcagaatgaa 4860gagaagaagc ggctgctgat caaacaggtg
cgggagctcg aggcggagct ggaggatgag 4920aggaaacagc gggcgcttgc
tgtagcttca aagaaaaaga tggagataga cctgaaggac 4980ctcgaagccc
aaatcgaggc tgcgaacaaa gctcgggatg aggtgattaa gcagctccgc
5040aagctccagg ctcagatgaa ggattaccaa cgtgaattag aagaagctcg
tgcatccaga 5100gatgagattt ttgctcaatc caaagagagt gaaaagaaat
tgaagagtct ggaagcagaa 5160atccttcaat tgcaggagga acttgcctca
tctgagcgag cccgccgaca cgccgagcag 5220gagagagatg agctggcgga
cgagatcacc aacagcgcct ctggcaagtc cgcgctgctg 5280gatgagaagc
ggcgtctgga agctcggatc gcacagctgg aggaggagct ggaagaggag
5340cagagcaaca tggagctgct caacgaccgc ttccgcaaga ccactctaca
ggtggacaca 5400ctgaacgccg agctagcagc cgagcgcagc gccgcccaga
agagtgacaa tgcacgccag 5460caactggagc ggcagaacaa ggagctgaag
gccaagctgc aggaactcga gggtgctgtc 5520aagtctaagt tcaaggccac
catctcagcc ctggaggcca agattgggca gctggaggag 5580cagcttgagc
aggaagccaa ggaacgagca gccgccaaca aattagtccg tcgcactgag
5640aagaagctga aagaaatctt catgcaggtt gaggatgagc gtcgacacgc
ggaccagtat 5700aaagagcaga tggagaaggc caacgctcgg atgaagcagc
ttaaacgcca gctggaggaa 5760gcagaagaag aagcgacgcg tgccaacgca
tctcggcgta aactccagcg ggaactggat 5820gatgccaccg aggccaacga
gggcctgagc cgcgaggtca gcaccctgaa gaaccggctg 5880aggcggggtg
gccccatcag cttctcttcc agccgatctg gccggcgcca gctgcacctt
5940gaaggagctt ccctggagct ctccgacgat gacacagaaa gtaagaccag
tgatgtcaac 6000gagacgcagc caccccagtc agagtaaagt tgcaggaagc
cagaggaggc aatacagtgg 6060gacagttagg aatgcacccg gggcctcctg
cagatttcgg aaattggcaa gctacgggat 6120tccttcctga aagatcaact
gtgtcttaag gctctccagc ctatgcatac tgtatcctgc 6180ttcagactta
ggtacaattg ctcccctttt tatatataga cacacacagg acacatatat
6240taaacagatt gtttcatcat tgcatctatt ttccatatag tcatcaagag
accattttat 6300aaaacatggt aagacccttt ttaaaacaaa ctccaggccc
ttggttgcgg gtcgctgggt 6360tattggggca gcgccgtggt cgtcactcag
tcgctctgca tgctctctgt catacagaca 6420ggtaacctag ttctgtgttc
acgtggcccc cgactcctca gccacatcaa gtctcctaga 6480ccactgtgga
ctctaaactg cacttgtctc tctcatttcc ttcaaataat gatcaatgct
6540atttcagtga gcaaactgtg aaaggggctt tggaaagagt aggaggggtg
ggctggatcg 6600gaagcaacac ccatttgggg ttaccatgtc catcccccaa
ggggggccct gcccctcgag 6660tcgatggtgt cccgcatcta ctcatgtgaa
ctggccttgg cgagggctgg tctgtgcata 6720gaagggatag tggccacact
gcagctgagg ccccaggtgg cagccatgga tcatgtagac 6780ttccagatgg
tctcccgaac cgcctggctc tgccggcgcc ctcctcacgt caggagcaag
6840cagccgtgga cccctaagcc gagctggtgg aaggcccctc cctgtcgcca
gccgggccct 6900catgctgacc ttgcaaattc agccgctgct ttgagcccaa
aatgggaata ttggttttgt 6960gtccgaggct tgttccaagt ttgtcaatga
ggtttatgga gcctccagaa cagatgccat 7020cttcctgaat gttgacatgc
cagtgggtgt gactccttca tttttccttc tcccttccct 7080ttggacagtg
ttacagtgaa cacttagcat cctgtttttg gttggtagtt aagcaaactg
7140acattacgga aagtgcctta gacactacag tactaagaca atgttgaata
tatcattcgc 7200ctctataaca atttaatgta ttcagttttg actgtgcttc
atatcatgta cctctctagt 7260caaagtggta ttacagacat tcagtgacaa
tgaatcagtg ttaattctaa atccttgatc 7320ctctgcaatg tgcttgaaaa
cacaaacctt ttgggttaaa agctttaaca tctattagga 7380agaatttgtc
ctgtgggttt ggaatcttgg attttccccc tttatgaact gtactggctg
7440ttgaccacca gacacctgac cgcaaatatc ttttcttgta ttcccatatt
tctagacaat 7500gatttttgta agacaataaa tttattcatt atagatattt
gcgcctgctc tgtttacttg 7560aagaaaaaag cacccgtgga gaataaagag
acctcaataa acaagaataa tcatgtgaa 7619541976PRTHomo sapiens 54Met Ala
Gln Arg Thr Gly Leu Glu Asp Pro Glu Arg Tyr Leu Phe Val 1 5 10 15
Asp Arg Ala Val Ile Tyr Asn Pro Ala Thr Gln Ala Asp Trp Thr Ala 20
25 30 Lys Lys Leu Val Trp Ile Pro Ser Glu Arg His Gly Phe Glu Ala
Ala 35 40 45 Ser Ile Lys Glu Glu Arg Gly Asp Glu Val Met Val Glu
Leu Ala Glu 50 55 60 Asn Gly Lys Lys Ala Met Val Asn Lys Asp Asp
Ile Gln Lys Met Asn 65 70 75 80 Pro Pro Lys Phe Ser Lys Val Glu Asp
Met Ala Glu Leu Thr Cys Leu 85 90 95 Asn Glu Ala Ser Val Leu His
Asn Leu Lys Asp Arg Tyr Tyr Ser Gly 100 105 110 Leu Ile Tyr Thr Tyr
Ser Gly Leu Phe Cys Val Val Ile Asn Pro Tyr 115 120 125 Lys Asn Leu
Pro Ile Tyr Ser Glu Asn Ile Ile Glu Met Tyr Arg Gly 130 135 140 Lys
Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ser Glu Ser 145 150
155 160 Ala Tyr Arg Cys Met Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu
Cys 165 170 175 Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys
Lys Val Ile 180 185 190 Gln Tyr Leu Ala His Val Ala Ser Ser His Lys
Gly Arg Lys Asp His 195 200 205 Asn Ile Pro Gly Glu Leu Glu Arg Gln
Leu Leu Gln Ala Asn Pro Ile 210 215 220 Leu Glu Ser Phe Gly Asn Ala
Lys Thr Val Lys Asn Asp Asn Ser Ser 225 230 235 240 Arg Phe Gly Lys
Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile 245 250 255 Val Gly
Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Val 260 265 270
Arg Gln Ala Lys Asp Glu Arg Thr Phe His Ile Phe Tyr Gln Leu Leu 275
280 285 Ser Gly Ala Gly Glu His Leu Lys Ser Asp Leu Leu Leu Glu Gly
Phe 290 295 300 Asn Asn Tyr Arg Phe Leu Ser Asn Gly Tyr Ile Pro Ile
Pro Gly Gln 305 310 315 320 Gln Asp Lys Asp Asn Phe Gln Glu Thr Met
Glu Ala Met His Ile Met 325 330 335 Gly Phe Ser His Glu Glu Ile Leu
Ser Met Leu Lys Val Val Ser Ser 340 345 350 Val Leu Gln Phe Gly Asn
Ile Ser Phe Lys Lys Glu Arg Asn Thr Asp 355 360 365 Gln Ala Ser Met
Pro Glu Asn Thr Val Ala Gln Lys Leu Cys His Leu 370 375 380 Leu Gly
Met Asn Val Met Glu Phe Thr Arg Ala Ile Leu Thr Pro Arg 385 390 395
400 Ile Lys Val Gly Arg Asp Tyr Val Gln Lys Ala Gln Thr Lys Glu Gln
405 410 415 Ala Asp Phe Ala Val Glu Ala Leu Ala Lys Ala Thr Tyr Glu
Arg Leu 420 425 430 Phe Arg Trp Leu Val His Arg Ile Asn Lys Ala Leu
Asp Arg Thr Lys 435 440 445 Arg Gln Gly Ala Ser Phe Ile Gly Ile Leu
Asp Ile Ala Gly Phe Glu 450 455 460 Ile Phe Glu Leu Asn Ser Phe Glu
Gln Leu Cys Ile Asn Tyr Thr Asn 465 470 475 480 Glu Lys Leu Gln Gln
Leu Phe Asn His Thr Met Phe Ile Leu Glu Gln 485 490 495 Glu Glu Tyr
Gln Arg Glu Gly Ile Glu Trp Asn Phe Ile Asp Phe Gly 500 505 510 Leu
Asp Leu Gln Pro Cys Ile Asp Leu Ile Glu Arg Pro Ala Asn Pro 515 520
525 Pro Gly Val Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe Pro Lys Ala
530 535 540 Thr Asp Lys Thr Phe Val Glu Lys Leu Val Gln Glu Gln Gly
Ser His 545 550 555 560 Ser Lys Phe Gln Lys Pro Arg Gln Leu Lys Asp
Lys Ala Asp Phe Cys 565 570 575 Ile Ile His Tyr Ala Gly Lys Val Asp
Tyr Lys Ala Asp Glu Trp Leu 580 585 590 Met Lys Asn Met Asp Pro Leu
Asn Asp Asn Val Ala Thr Leu Leu His 595 600 605 Gln Ser Ser Asp Arg
Phe Val Ala Glu Leu Trp Lys Asp Val Asp Arg 610 615 620 Ile Val Gly
Leu Asp Gln Val Thr Gly Met Thr Glu Thr Ala Phe Gly 625 630 635 640
Ser Ala Tyr Lys Thr Lys Lys Gly Met Phe Arg Thr Val Gly Gln Leu 645
650 655 Tyr Lys Glu Ser Leu Thr Lys Leu Met Ala Thr Leu Arg Asn Thr
Asn 660 665 670 Pro Asn Phe Val Arg Cys Ile Ile Pro Asn His Glu Lys
Arg Ala Gly 675 680 685 Lys Leu Asp Pro His Leu Val Leu Asp Gln Leu
Arg Cys Asn Gly Val 690 695 700 Leu Glu Gly Ile Arg Ile Cys Arg Gln
Gly Phe Pro Asn Arg Ile Val 705 710 715 720 Phe Gln Glu Phe Arg Gln
Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile 725 730 735 Pro Lys Gly Phe
Met Asp Gly Lys Gln Ala Cys Glu Arg Met Ile Arg 740 745 750 Ala Leu
Glu Leu Asp Pro Asn Leu Tyr Arg Ile Gly Gln Ser Lys Ile 755 760 765
Phe Phe Arg Ala Gly Val Leu Ala His Leu Glu Glu Glu Arg Asp Leu 770
775 780 Lys Ile Thr Asp Ile Ile Ile Phe Phe Gln Ala Val Cys Arg Gly
Tyr 785 790 795 800 Leu Ala Arg Lys Ala Phe Ala Lys Lys Gln Gln Gln
Leu Ser Ala Leu 805 810 815 Lys Val Leu Gln Arg Asn Cys Ala Ala Tyr
Leu Lys Leu Arg His Trp 820 825 830 Gln Trp Trp Arg Val Phe Thr Lys
Val Lys Pro Leu Leu Gln Val Thr 835 840 845 Arg Gln Glu Glu Glu Leu
Gln Ala Lys Asp Glu Glu Leu Leu Lys Val 850 855 860 Lys Glu Lys Gln
Thr Lys Val Glu Gly Glu Leu Glu Glu Met Glu Arg 865 870 875 880 Lys
His Gln Gln Leu Leu Glu Glu Lys Asn Ile Leu Ala Glu Gln Leu 885 890
895 Gln Ala Glu Thr Glu Leu Phe Ala Glu Ala Glu Glu Met Arg Ala Arg
900 905 910 Leu Ala Ala Lys Lys Gln Glu Leu Glu Glu Ile Leu His Asp
Leu Glu 915 920 925 Ser Arg Val Glu Glu Glu Glu Glu Arg Asn Gln Ile
Leu Gln Asn Glu 930 935 940 Lys Lys Lys Met Gln Ala His Ile Gln Asp
Leu Glu Glu Gln Leu Asp 945 950 955 960 Glu Glu Glu Gly Ala Arg Gln
Lys Leu Gln Leu Glu Lys Val Thr Ala 965 970 975 Glu Ala Lys Ile Lys
Lys Met Glu Glu Glu Ile Leu Leu Leu Glu Asp 980 985 990 Gln Asn Ser
Lys Phe Ile Lys Glu Lys Lys Leu Met Glu Asp Arg Ile 995 1000 1005
Ala Glu Cys Ser Ser Gln Leu Ala Glu Glu Glu Glu Lys Ala Lys 1010
1015 1020 Asn Leu Ala Lys Ile Arg Asn Lys Gln Glu Val Met Ile Ser
Asp 1025 1030 1035 Leu Glu Glu Arg Leu Lys Lys Glu Glu Lys Thr Arg
Gln Glu Leu 1040 1045 1050 Glu Lys Ala Lys Arg Lys Leu Asp Gly Glu
Thr Thr Asp Leu Gln 1055 1060 1065 Asp Gln Ile Ala Glu Leu Gln Ala
Gln Ile Asp Glu Leu Lys Leu 1070 1075 1080 Gln Leu Ala Lys Lys Glu
Glu Glu Leu Gln Gly Ala Leu Ala Arg 1085 1090 1095 Gly Asp Asp Glu
Thr Leu His Lys Asn Asn Ala Leu Lys Val Val 1100 1105 1110 Arg Glu
Leu Gln Ala Gln Ile Ala Glu Leu Gln Glu Asp Phe Glu 1115 1120 1125
Ser Glu Lys Ala Ser Arg Asn Lys Ala Glu Lys Gln Lys Arg Asp 1130
1135 1140 Leu Ser Glu Glu Leu Glu Ala Leu Lys Thr Glu Leu Glu Asp
Thr 1145 1150 1155 Leu Asp Thr Thr Ala Ala Gln Gln Glu Leu Arg Thr
Lys Arg Glu 1160 1165 1170 Gln Glu Val Ala Glu Leu Lys Lys Ala Leu
Glu Glu Glu Thr Lys 1175 1180 1185 Asn His Glu Ala Gln Ile Gln Asp
Met Arg Gln Arg His Ala Thr 1190 1195 1200 Ala Leu Glu Glu Leu Ser
Glu Gln Leu Glu Gln Ala Lys Arg Phe 1205 1210 1215 Lys Ala Asn Leu
Glu Lys Asn Lys Gln Gly Leu Glu Thr Asp Asn 1220 1225 1230 Lys Glu
Leu Ala Cys Glu Val Lys Val Leu Gln Gln Val Lys Ala 1235 1240 1245
Glu Ser Glu His Lys Arg Lys Lys Leu Asp Ala Gln Val Gln Glu 1250
1255 1260 Leu His Ala Lys Val Ser Glu Gly Asp Arg Leu Arg Val Glu
Leu 1265 1270 1275 Ala Glu Lys Ala Ser Lys Leu Gln Asn Glu Leu Asp
Asn Val Ser 1280 1285 1290 Thr Leu Leu Glu Glu Ala Glu Lys Lys Gly
Ile Lys Phe Ala Lys 1295 1300 1305 Asp Ala Ala Ser Leu Glu Ser Gln
Leu Gln Asp Thr Gln Glu Leu 1310 1315 1320 Leu Gln Glu Glu Thr Arg
Gln Lys Leu Asn Leu Ser Ser Arg Ile 1325 1330 1335 Arg Gln Leu Glu
Glu Glu Lys Asn Ser Leu Gln Glu Gln Gln Glu 1340 1345 1350 Glu Glu
Glu Glu Ala Arg Lys Asn Leu Glu Lys Gln Val Leu Ala 1355 1360 1365
Leu Gln Ser Gln Leu Ala Asp Thr Lys Lys Lys Val Asp Asp Asp 1370
1375 1380 Leu Gly Thr Ile Glu Ser Leu Glu Glu Ala Lys Lys Lys Leu
Leu 1385 1390 1395 Lys Asp Ala Glu Ala Leu Ser Gln Arg Leu Glu Glu
Lys Ala Leu 1400 1405 1410 Ala Tyr Asp Lys Leu Glu Lys Thr Lys Asn
Arg Leu Gln Gln Glu 1415 1420 1425 Leu Asp Asp Leu Thr Val Asp Leu
Asp His Gln Arg Gln Val Ala 1430 1435 1440 Ser Asn Leu Glu Lys Lys
Gln Lys Lys Phe Asp Gln Leu Leu Ala 1445 1450 1455 Glu Glu Lys Ser
Ile Ser Ala Arg Tyr Ala Glu Glu Arg Asp Arg 1460 1465 1470 Ala Glu
Ala Glu Ala Arg Glu Lys Glu Thr Lys Ala Leu Ser Leu 1475 1480 1485
Ala Arg Ala Leu Glu Glu Ala Leu Glu Ala Lys Glu Glu Phe Glu 1490
1495 1500 Arg Gln Asn Lys Gln Leu Arg Ala Asp Met Glu Asp Leu Met
Ser 1505 1510 1515 Ser Lys Asp Asp Val Gly Lys Asn Val His Glu Leu
Glu Lys Ser 1520 1525
1530 Lys Arg Ala Leu Glu Gln Gln Val Glu Glu Met Arg Thr Gln Leu
1535 1540 1545 Glu Glu Leu Glu Asp Glu Leu Gln Ala Thr Glu Asp Ala
Lys Leu 1550 1555 1560 Arg Leu Glu Val Asn Met Gln Ala Met Lys Ala
Gln Phe Glu Arg 1565 1570 1575 Asp Leu Gln Thr Arg Asp Glu Gln Asn
Glu Glu Lys Lys Arg Leu 1580 1585 1590 Leu Ile Lys Gln Val Arg Glu
Leu Glu Ala Glu Leu Glu Asp Glu 1595 1600 1605 Arg Lys Gln Arg Ala
Leu Ala Val Ala Ser Lys Lys Lys Met Glu 1610 1615 1620 Ile Asp Leu
Lys Asp Leu Glu Ala Gln Ile Glu Ala Ala Asn Lys 1625 1630 1635 Ala
Arg Asp Glu Val Ile Lys Gln Leu Arg Lys Leu Gln Ala Gln 1640 1645
1650 Met Lys Asp Tyr Gln Arg Glu Leu Glu Glu Ala Arg Ala Ser Arg
1655 1660 1665 Asp Glu Ile Phe Ala Gln Ser Lys Glu Ser Glu Lys Lys
Leu Lys 1670 1675 1680 Ser Leu Glu Ala Glu Ile Leu Gln Leu Gln Glu
Glu Leu Ala Ser 1685 1690 1695 Ser Glu Arg Ala Arg Arg His Ala Glu
Gln Glu Arg Asp Glu Leu 1700 1705 1710 Ala Asp Glu Ile Thr Asn Ser
Ala Ser Gly Lys Ser Ala Leu Leu 1715 1720 1725 Asp Glu Lys Arg Arg
Leu Glu Ala Arg Ile Ala Gln Leu Glu Glu 1730 1735 1740 Glu Leu Glu
Glu Glu Gln Ser Asn Met Glu Leu Leu Asn Asp Arg 1745 1750 1755 Phe
Arg Lys Thr Thr Leu Gln Val Asp Thr Leu Asn Ala Glu Leu 1760 1765
1770 Ala Ala Glu Arg Ser Ala Ala Gln Lys Ser Asp Asn Ala Arg Gln
1775 1780 1785 Gln Leu Glu Arg Gln Asn Lys Glu Leu Lys Ala Lys Leu
Gln Glu 1790 1795 1800 Leu Glu Gly Ala Val Lys Ser Lys Phe Lys Ala
Thr Ile Ser Ala 1805 1810 1815 Leu Glu Ala Lys Ile Gly Gln Leu Glu
Glu Gln Leu Glu Gln Glu 1820 1825 1830 Ala Lys Glu Arg Ala Ala Ala
Asn Lys Leu Val Arg Arg Thr Glu 1835 1840 1845 Lys Lys Leu Lys Glu
Ile Phe Met Gln Val Glu Asp Glu Arg Arg 1850 1855 1860 His Ala Asp
Gln Tyr Lys Glu Gln Met Glu Lys Ala Asn Ala Arg 1865 1870 1875 Met
Lys Gln Leu Lys Arg Gln Leu Glu Glu Ala Glu Glu Glu Ala 1880 1885
1890 Thr Arg Ala Asn Ala Ser Arg Arg Lys Leu Gln Arg Glu Leu Asp
1895 1900 1905 Asp Ala Thr Glu Ala Asn Glu Gly Leu Ser Arg Glu Val
Ser Thr 1910 1915 1920 Leu Lys Asn Arg Leu Arg Arg Gly Gly Pro Ile
Ser Phe Ser Ser 1925 1930 1935 Ser Arg Ser Gly Arg Arg Gln Leu His
Leu Glu Gly Ala Ser Leu 1940 1945 1950 Glu Leu Ser Asp Asp Asp Thr
Glu Ser Lys Thr Ser Asp Val Asn 1955 1960 1965 Glu Thr Gln Pro Pro
Gln Ser Glu 1970 1975 556442DNAMus musculus 55ccttttctgt ccaggccgag
gcctctggac cgccctgggc gccgaccatg gctgcagtga 60ccatgtccgt gtctgggagg
aaggtagcct ccaggccagg cccggtgcct gaggcagccc 120aatcgttcct
ctacgcgccc cggacgccaa atgtaggtgg ccctggaggg ccacaggtgg
180agtggacagc ccggcgcatg gtgtgggtgc cctcggaact gcatgggttc
gaggcagcag 240ccctgcggga tgaaggggag gaggaggcag aagtggagct
ggcggagagt gggcgccgcc 300tgcggctgcc cagggaccag atccagcgca
tgaacccacc caagttcagc aaggcagaag 360atatggctga gctcacctgc
ctcaacgagg cctcggtcct gcacaacctg cgagaacgct 420actactccgg
gctcatttat acctactctg gcctcttctg tgtggtcatt aacccataca
480agcagctgcc catctacacg gaggccattg ttgaaatgta ccggggcaag
aagcgccatg 540aggtgccacc tcacgtgtat gctgtgacgg agggcgcgta
ccgcagcatg cttcaggatc 600gtgaggatca atccattctc tgcacgggag
agtctggcgc tgggaagacg gagaacacca 660agaaggtcat ccagtacctg
gcccatgtgg catcatctcc aaagggcagg aaggagcctg 720gtgtccctgc
ctccgtcagc accatgtctt atggggagct agagcgtcag cttcttcaag
780ccaaccccat cctagaggcc tttggcaatg ccaagacagt gaagaacgac
aactcttccc 840gatttggcaa attcatccgc atcaactttg atattgctgg
ctacatcgtg ggagcaaaca 900tcgagaccta tctgttggag aagtcccggg
ccatcagaca ggccaaggat gaatgcagct 960tccatatctt ctaccagctg
ctagggggcg ctggggagca gctaaaagct gacctccttc 1020tggagccctg
ttcccattat cgcttcctga ccaatgggcc ctcatcgtcc ccgggccagg
1080agcgtgagtt attccaggag accctggagt ccctgcgtgt gctgggcctc
ctcccagaag 1140agatcactgc catgctgcgc actgtctctg ctgtcctcca
gtttggcaac attgtcctga 1200agaaagagcg caatacggac caagccacca
tgcctgacaa cacagctgcc cagaagcttt 1260gccgcctctt gggactcgga
gtgaccgact tctccagagc ccttctcaca ccccgcatca 1320aagtgggccg
agattatgtt cagaaagcac aaaccaagga gcaggctgac tttgcgctgg
1380aggctctggc caaagctacc tatgagcgcc tgttccgctg gctggttctg
cggctcaacc 1440gtgccctgga cagaagcccg cggcagggtg cctccttcct
gggcatcctg gacatcgcgg 1500gctttgagat cttccagctg aactccttcg
agcagctgtg catcaactac accaacgaga 1560agctacagca gctattcaac
cacaccatgt tcgtgctgga gcaggaggag taccagcgag 1620agggcatccc
ctggaccttc ctagacttcg ggttggacct gcaaccttgc atcgacctca
1680ttgagcgtcc ggccaaccct ccaggtctcc tggccctgct ggacgaggag
tgctggttcc 1740ccaaggccac ggacaagtct tttgtggaga aggtcgccca
ggagcagggc agccacccca 1800aattccagcg ccccaggaac ctgcgagatc
aggccgactt cagcgtcctg cactatgccg 1860gcaaggttga ctacaaagcc
agtgagtggc tgatgaagaa catggaccca ctgaatgaca 1920atgtggccgc
cttgcttcac cagagcacgg atcgtctcac agctgagatc tggaaggatg
1980tggagggcat cgtggggctg gagcaagtaa gcagccttgg agatggccca
ccgggaggcc 2040gcccccgccg tggaatgttc cggactgtgg ggcagctcta
caaagaatcc ctgagccgcc 2100tcatggccac gctcagcaac accaacccta
gttttgtccg ctgcatcgtt cccaatcatg 2160agaagagggc tggaaagctg
gagccgcgcc tggtgctgga ccaactccgt tgtaacgggg 2220tcctcgaggg
tatacgcatc tgtcgccaag gcttccccaa ccgcatcctc ttccaggagt
2280tccgacagcg ctatgaaatc ctcaccccga acgctattcc caagggcttc
atggacggca 2340aacaggcctg tgagaagatg atccaggccc tggagctaga
ccccaacctg taccgtgttg 2400gccaaagcaa gatcttcttc cgggcagggg
tcctggccca gctggaggag gagcgggacc 2460tgaaagtcac cgacatcata
gtgtctttcc aggcagcggc acggggctac ctggcccgta 2520gggctttcca
gagacggcag cagcagcaga gtgctctgag ggtgatgcag agaaactgtg
2580ctgcctacct caagctcagg aactggcagt ggtggaggct gttcatcaag
gtgaagcccc 2640tgctgcaggt gacacggcag gatgaggtgc tgcaggcgcg
cgcccaggag ctgcagaaag 2700ttcaggagct gcagcagcag agcgctcgtg
aagtggggga actgcagggt cgagtggcac 2760agctagagga ggagcgcacg
cgcctggctg agcagcttcg agcagaagcc gagctctgct 2820ctgaggccga
ggagacgcgg gcgcgactgg ctgcccggaa gcaggagctg gagctggtgg
2880tgacagagct ggaggcacga gtgggcgagg aagaagagtg cagccggcag
ctgcagagtg 2940agaagaagag gctgcagcag catatccagg agctagagag
ccacctggaa gctgaggagg 3000gtgcccggca gaagctacag ctggagaagg
tgaccacaga ggccaagatg aagaaatttg 3060aggaggacct gctgctcctg
gaggaccaga attccaagct gagcaaggag cggaggctgc 3120tggaggagcg
gctggctgag ttctcctcac aggcagcaga agaggaagag aaagtcaaaa
3180gtctcaacaa gctgaggctc aaatatgaag ccacaatctc agacatggaa
gaccggctga 3240agaaggagga gaagggacgc caggaactag agaagctgaa
gcgacggctg gacggggaga 3300gctcagagct tcaggagcag atggtggagc
agaagcagag ggcagaggaa ctgctcgcac 3360agctgggccg caaggaggat
gagctgcagg ccgccctgct cagggcagag gaagagggtg 3420gtgcccgtgc
ccagttgctc aagtccctgc gagaggcaca ggctggcctt gctgaggctc
3480aggaggacct ggaagctgag cgggtagcca gggccaaggc ggagaagcag
cgccgggacc 3540tgggcgagga gttggaggcc ctacgtgggg agctcgagga
cactctggat tccaccaacg 3600cccagcagga gctgcggtcc aagagggagc
aggaggtgac agagctgaag aaagcattgg 3660aagaggagtc ccgtgcccat
gaggtgtcca tgcaggagct gagacagagg catagccagg 3720cactggtgga
gatggccgag cagttggagc aagcccggag gggcaaaggt gtgtgggaga
3780agactcggct atccctggag gctgaggtgt ccgagctgaa ggccgagctg
agcagcctgc 3840agacctcgag acaggagggt gagcagaaga ggcgccgcct
ggagtcccag ctacaggagg 3900tccagggccg atccagtgat tcggagcggg
ctcggtctga ggctgctgag aagctgcaga 3960gagcccaggc ggaacttgag
agcgtgtcca cagccctgag tgaggcggag tccaaagcca 4020tcaggctggg
caaggagctg agcagtgcag agtcccagct gcatgacacc caggaactgc
4080ttcaggagga gaccagggca aagctggcct tggggtcccg tgtgcgtgcc
ctagaggccg 4140aggcggcggg gcttcgggag cagatggaag aggaggtggt
tgccagggaa cgggctggcc 4200gggagctgca gagcacgcag gcccagctct
ctgaatggcg gcgccgccag gaagaagagg 4260ctgcggtgct ggaggctggg
gaggaggctc ggcgccgtgc agcccgggag gcagagaccc 4320tgacccagcg
cctggcagaa aagactgagg ctgtagaacg actggagcga gcccggcgcc
4380gactgcagca ggagttggac gatgccactg tggatctggg gcagcagaag
cagctcctga 4440gcacactgga gaagaagcag cggaaatttg accagctcct
ggcagaggag aaggctgcag 4500ttctacgggc tgtggaagac cgtgaacgga
tagaggccga aggccgggag cgagaggccc 4560gggccctgtc gctgacccgg
gccctggaag aggagcagga ggcccgggag gagctggaga 4620ggcagaaccg
tgctctgagg gctgagctgg aagcactgct gagcagcaag gatgacgtgg
4680gcaagaacgt gcacgagctg gagcgagccc gtaaggcggc tgaacaggca
gccagtgacc 4740tgcggacaca ggtgacagaa ttggaggatg agctgacagc
cgcagaggat gccaagctgc 4800gcctggaggt gactgtgcag gctctgaagg
ctcaacatga acgcgacctg cagggccgcg 4860atgatgccgg tgaggagagg
cggaggcagc tggccaagca gctaagagac gcagaggtag 4920agcgcgatga
ggaacggaag cagagggcac tggctatggc tgcccgcaag aagctggagc
4980tggaactgga ggagttgaag gcgcagacat ctgctgctgg gcagggcaag
gaagaggcag 5040tgaagcagct gaagaagatg caggtccaga tgaaggagct
gtggcgggag gtagaggaga 5100cgcgtagctc ccgcgacgag atgtttaccc
tgagcaggga aaatgagaag aagctcaagg 5160ggctggaagc tgaggtgctg
cgtctgcaag aggaacttgc tgcctcagac cgagcccgga 5220ggcaggccca
gcaagacaga gacgagatgg cagaggaggt ggccagtggc aatcttagca
5280aggcagccac cctggaggaa aaacggcagc tggaggggcg actgagccag
ttggaagagg 5340agctggagga agaacagaac aactcggagc tgctcaagga
ccattaccga aagctagtgc 5400tacaggtcga gtccctcacc acagaactgt
ctgccgaacg aagtttctca gccaaggccg 5460agagtggacg gcagcagctg
gagcggcaga tccaggaact gcgggcccgc ttgggtgaag 5520aggatgctgg
agcccgagcc aggcagaaaa tgctgatcgc tgctctggag tctaaactgg
5580cccaggcaga ggagcagctg gagcaggaga gcagggagcg catcctctct
ggcaagctgg 5640tacgcagagc tgagaagcgg ctgaaggagg tagttcttca
ggtggatgaa gagcgcaggg 5700tggctgacca ggtccgggac cagctggaga
aaagcaacct ccggctgaag cagctcaaga 5760ggcagctgga ggaggcagag
gaggaggcat ctcgggcaca ggctggtcgg aggcggctgc 5820agcgggagct
ggaggacgtc actgagtctg cagaatccat gaaccgggag gtgaccacgc
5880tgaggaacag gctccggcgt ggcccactta cattcaccac acggactgtg
cgccaggtgt 5940tccggctgga agagggcgtg gcttctgacg aggaagaggc
tgaaggagct gaacctggct 6000ctgcaccagg ccaggagccg gaggctccgc
cccctgccac accccaatga tccagtctgt 6060cctagatgcc ccaaggacag
agccctttcc agtgcccctc ctggtttgca ctttgaaatg 6120gcactgtcct
ctggcacttt ctggcattga tgaaccctcc tgggacccca ggacccctgc
6180ccactggggg ccccaaacca aggagctggg tgggagggag gccatgatgg
tctctcttgt 6240tagagaaaca aaattgaacg tggatgtcaa gaatgtcctg
tctgcaccta ttttcagcag 6300gcctgtcccc tggagagggc aggcagggtg
cttccatccc ctctcagtat cttgccctct 6360tttttggggg gaagtggggt
gtctgtgtgc tcatagggta atgctcatgg cccctcatgc 6420tccagacact
aaagaaataa aa 6442562000PRTMus musculus 56Met Ala Ala Val Thr Met
Ser Val Ser Gly Arg Lys Val Ala Ser Arg 1 5 10 15 Pro Gly Pro Val
Pro Glu Ala Ala Gln Ser Phe Leu Tyr Ala Pro Arg 20 25 30 Thr Pro
Asn Val Gly Gly Pro Gly Gly Pro Gln Val Glu Trp Thr Ala 35 40 45
Arg Arg Met Val Trp Val Pro Ser Glu Leu His Gly Phe Glu Ala Ala 50
55 60 Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala Glu Val Glu Leu Ala
Glu 65 70 75 80 Ser Gly Arg Arg Leu Arg Leu Pro Arg Asp Gln Ile Gln
Arg Met Asn 85 90 95 Pro Pro Lys Phe Ser Lys Ala Glu Asp Met Ala
Glu Leu Thr Cys Leu 100 105 110 Asn Glu Ala Ser Val Leu His Asn Leu
Arg Glu Arg Tyr Tyr Ser Gly 115 120 125 Leu Ile Tyr Thr Tyr Ser Gly
Leu Phe Cys Val Val Ile Asn Pro Tyr 130 135 140 Lys Gln Leu Pro Ile
Tyr Thr Glu Ala Ile Val Glu Met Tyr Arg Gly 145 150 155 160 Lys Lys
Arg His Glu Val Pro Pro His Val Tyr Ala Val Thr Glu Gly 165 170 175
Ala Tyr Arg Ser Met Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys 180
185 190 Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val
Ile 195 200 205 Gln Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly Arg
Lys Glu Pro 210 215 220 Gly Val Pro Ala Ser Val Ser Thr Met Ser Tyr
Gly Glu Leu Glu Arg 225 230 235 240 Gln Leu Leu Gln Ala Asn Pro Ile
Leu Glu Ala Phe Gly Asn Ala Lys 245 250 255 Thr Val Lys Asn Asp Asn
Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile 260 265 270 Asn Phe Asp Ile
Ala Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr 275 280 285 Leu Leu
Glu Lys Ser Arg Ala Ile Arg Gln Ala Lys Asp Glu Cys Ser 290 295 300
Phe His Ile Phe Tyr Gln Leu Leu Gly Gly Ala Gly Glu Gln Leu Lys 305
310 315 320 Ala Asp Leu Leu Leu Glu Pro Cys Ser His Tyr Arg Phe Leu
Thr Asn 325 330 335 Gly Pro Ser Ser Ser Pro Gly Gln Glu Arg Glu Leu
Phe Gln Glu Thr 340 345 350 Leu Glu Ser Leu Arg Val Leu Gly Leu Leu
Pro Glu Glu Ile Thr Ala 355 360 365 Met Leu Arg Thr Val Ser Ala Val
Leu Gln Phe Gly Asn Ile Val Leu 370 375 380 Lys Lys Glu Arg Asn Thr
Asp Gln Ala Thr Met Pro Asp Asn Thr Ala 385 390 395 400 Ala Gln Lys
Leu Cys Arg Leu Leu Gly Leu Gly Val Thr Asp Phe Ser 405 410 415 Arg
Ala Leu Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Tyr Val Gln 420 425
430 Lys Ala Gln Thr Lys Glu Gln Ala Asp Phe Ala Leu Glu Ala Leu Ala
435 440 445 Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Leu Val Leu Arg
Leu Asn 450 455 460 Arg Ala Leu Asp Arg Ser Pro Arg Gln Gly Ala Ser
Phe Leu Gly Ile 465 470 475 480 Leu Asp Ile Ala Gly Phe Glu Ile Phe
Gln Leu Asn Ser Phe Glu Gln 485 490 495 Leu Cys Ile Asn Tyr Thr Asn
Glu Lys Leu Gln Gln Leu Phe Asn His 500 505 510 Thr Met Phe Val Leu
Glu Gln Glu Glu Tyr Gln Arg Glu Gly Ile Pro 515 520 525 Trp Thr Phe
Leu Asp Phe Gly Leu Asp Leu Gln Pro Cys Ile Asp Leu 530 535 540 Ile
Glu Arg Pro Ala Asn Pro Pro Gly Leu Leu Ala Leu Leu Asp Glu 545 550
555 560 Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys
Val 565 570 575 Ala Gln Glu Gln Gly Ser His Pro Lys Phe Gln Arg Pro
Arg Asn Leu 580 585 590 Arg Asp Gln Ala Asp Phe Ser Val Leu His Tyr
Ala Gly Lys Val Asp 595 600 605 Tyr Lys Ala Ser Glu Trp Leu Met Lys
Asn Met Asp Pro Leu Asn Asp 610 615 620 Asn Val Ala Ala Leu Leu His
Gln Ser Thr Asp Arg Leu Thr Ala Glu 625 630 635 640 Ile Trp Lys Asp
Val Glu Gly Ile Val Gly Leu Glu Gln Val Ser Ser 645 650 655 Leu Gly
Asp Gly Pro Pro Gly Gly Arg Pro Arg Arg Gly Met Phe Arg 660 665 670
Thr Val Gly Gln Leu Tyr Lys Glu Ser Leu Ser Arg Leu Met Ala Thr 675
680 685 Leu Ser Asn Thr Asn Pro Ser Phe Val Arg Cys Ile Val Pro Asn
His 690 695 700 Glu Lys Arg Ala Gly Lys Leu Glu Pro Arg Leu Val Leu
Asp Gln Leu 705 710 715 720 Arg Cys Asn Gly Val Leu Glu Gly Ile Arg
Ile Cys Arg Gln Gly Phe 725 730 735 Pro Asn Arg Ile Leu Phe Gln Glu
Phe Arg Gln Arg Tyr Glu Ile Leu 740 745 750 Thr Pro Asn Ala Ile Pro
Lys Gly Phe Met Asp Gly Lys Gln Ala Cys 755 760 765 Glu Lys Met Ile
Gln Ala Leu Glu Leu Asp Pro Asn Leu Tyr Arg Val 770 775 780 Gly Gln
Ser Lys Ile Phe Phe Arg Ala Gly Val Leu Ala Gln Leu Glu 785 790 795
800 Glu Glu Arg Asp Leu Lys Val Thr Asp Ile Ile Val Ser Phe Gln Ala
805 810 815 Ala Ala Arg Gly Tyr Leu Ala Arg Arg Ala Phe Gln Arg Arg
Gln Gln 820 825 830 Gln Gln Ser Ala Leu Arg Val Met Gln Arg Asn Cys
Ala Ala Tyr
Leu 835 840 845 Lys Leu Arg Asn Trp Gln Trp Trp Arg Leu Phe Ile Lys
Val Lys Pro 850 855 860 Leu Leu Gln Val Thr Arg Gln Asp Glu Val Leu
Gln Ala Arg Ala Gln 865 870 875 880 Glu Leu Gln Lys Val Gln Glu Leu
Gln Gln Gln Ser Ala Arg Glu Val 885 890 895 Gly Glu Leu Gln Gly Arg
Val Ala Gln Leu Glu Glu Glu Arg Thr Arg 900 905 910 Leu Ala Glu Gln
Leu Arg Ala Glu Ala Glu Leu Cys Ser Glu Ala Glu 915 920 925 Glu Thr
Arg Ala Arg Leu Ala Ala Arg Lys Gln Glu Leu Glu Leu Val 930 935 940
Val Thr Glu Leu Glu Ala Arg Val Gly Glu Glu Glu Glu Cys Ser Arg 945
950 955 960 Gln Leu Gln Ser Glu Lys Lys Arg Leu Gln Gln His Ile Gln
Glu Leu 965 970 975 Glu Ser His Leu Glu Ala Glu Glu Gly Ala Arg Gln
Lys Leu Gln Leu 980 985 990 Glu Lys Val Thr Thr Glu Ala Lys Met Lys
Lys Phe Glu Glu Asp Leu 995 1000 1005 Leu Leu Leu Glu Asp Gln Asn
Ser Lys Leu Ser Lys Glu Arg Arg 1010 1015 1020 Leu Leu Glu Glu Arg
Leu Ala Glu Phe Ser Ser Gln Ala Ala Glu 1025 1030 1035 Glu Glu Glu
Lys Val Lys Ser Leu Asn Lys Leu Arg Leu Lys Tyr 1040 1045 1050 Glu
Ala Thr Ile Ser Asp Met Glu Asp Arg Leu Lys Lys Glu Glu 1055 1060
1065 Lys Gly Arg Gln Glu Leu Glu Lys Leu Lys Arg Arg Leu Asp Gly
1070 1075 1080 Glu Ser Ser Glu Leu Gln Glu Gln Met Val Glu Gln Lys
Gln Arg 1085 1090 1095 Ala Glu Glu Leu Leu Ala Gln Leu Gly Arg Lys
Glu Asp Glu Leu 1100 1105 1110 Gln Ala Ala Leu Leu Arg Ala Glu Glu
Glu Gly Gly Ala Arg Ala 1115 1120 1125 Gln Leu Leu Lys Ser Leu Arg
Glu Ala Gln Ala Gly Leu Ala Glu 1130 1135 1140 Ala Gln Glu Asp Leu
Glu Ala Glu Arg Val Ala Arg Ala Lys Ala 1145 1150 1155 Glu Lys Gln
Arg Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu Arg 1160 1165 1170 Gly
Glu Leu Glu Asp Thr Leu Asp Ser Thr Asn Ala Gln Gln Glu 1175 1180
1185 Leu Arg Ser Lys Arg Glu Gln Glu Val Thr Glu Leu Lys Lys Ala
1190 1195 1200 Leu Glu Glu Glu Ser Arg Ala His Glu Val Ser Met Gln
Glu Leu 1205 1210 1215 Arg Gln Arg His Ser Gln Ala Leu Val Glu Met
Ala Glu Gln Leu 1220 1225 1230 Glu Gln Ala Arg Arg Gly Lys Gly Val
Trp Glu Lys Thr Arg Leu 1235 1240 1245 Ser Leu Glu Ala Glu Val Ser
Glu Leu Lys Ala Glu Leu Ser Ser 1250 1255 1260 Leu Gln Thr Ser Arg
Gln Glu Gly Glu Gln Lys Arg Arg Arg Leu 1265 1270 1275 Glu Ser Gln
Leu Gln Glu Val Gln Gly Arg Ser Ser Asp Ser Glu 1280 1285 1290 Arg
Ala Arg Ser Glu Ala Ala Glu Lys Leu Gln Arg Ala Gln Ala 1295 1300
1305 Glu Leu Glu Ser Val Ser Thr Ala Leu Ser Glu Ala Glu Ser Lys
1310 1315 1320 Ala Ile Arg Leu Gly Lys Glu Leu Ser Ser Ala Glu Ser
Gln Leu 1325 1330 1335 His Asp Thr Gln Glu Leu Leu Gln Glu Glu Thr
Arg Ala Lys Leu 1340 1345 1350 Ala Leu Gly Ser Arg Val Arg Ala Leu
Glu Ala Glu Ala Ala Gly 1355 1360 1365 Leu Arg Glu Gln Met Glu Glu
Glu Val Val Ala Arg Glu Arg Ala 1370 1375 1380 Gly Arg Glu Leu Gln
Ser Thr Gln Ala Gln Leu Ser Glu Trp Arg 1385 1390 1395 Arg Arg Gln
Glu Glu Glu Ala Ala Val Leu Glu Ala Gly Glu Glu 1400 1405 1410 Ala
Arg Arg Arg Ala Ala Arg Glu Ala Glu Thr Leu Thr Gln Arg 1415 1420
1425 Leu Ala Glu Lys Thr Glu Ala Val Glu Arg Leu Glu Arg Ala Arg
1430 1435 1440 Arg Arg Leu Gln Gln Glu Leu Asp Asp Ala Thr Val Asp
Leu Gly 1445 1450 1455 Gln Gln Lys Gln Leu Leu Ser Thr Leu Glu Lys
Lys Gln Arg Lys 1460 1465 1470 Phe Asp Gln Leu Leu Ala Glu Glu Lys
Ala Ala Val Leu Arg Ala 1475 1480 1485 Val Glu Asp Arg Glu Arg Ile
Glu Ala Glu Gly Arg Glu Arg Glu 1490 1495 1500 Ala Arg Ala Leu Ser
Leu Thr Arg Ala Leu Glu Glu Glu Gln Glu 1505 1510 1515 Ala Arg Glu
Glu Leu Glu Arg Gln Asn Arg Ala Leu Arg Ala Glu 1520 1525 1530 Leu
Glu Ala Leu Leu Ser Ser Lys Asp Asp Val Gly Lys Asn Val 1535 1540
1545 His Glu Leu Glu Arg Ala Arg Lys Ala Ala Glu Gln Ala Ala Ser
1550 1555 1560 Asp Leu Arg Thr Gln Val Thr Glu Leu Glu Asp Glu Leu
Thr Ala 1565 1570 1575 Ala Glu Asp Ala Lys Leu Arg Leu Glu Val Thr
Val Gln Ala Leu 1580 1585 1590 Lys Ala Gln His Glu Arg Asp Leu Gln
Gly Arg Asp Asp Ala Gly 1595 1600 1605 Glu Glu Arg Arg Arg Gln Leu
Ala Lys Gln Leu Arg Asp Ala Glu 1610 1615 1620 Val Glu Arg Asp Glu
Glu Arg Lys Gln Arg Ala Leu Ala Met Ala 1625 1630 1635 Ala Arg Lys
Lys Leu Glu Leu Glu Leu Glu Glu Leu Lys Ala Gln 1640 1645 1650 Thr
Ser Ala Ala Gly Gln Gly Lys Glu Glu Ala Val Lys Gln Leu 1655 1660
1665 Lys Lys Met Gln Val Gln Met Lys Glu Leu Trp Arg Glu Val Glu
1670 1675 1680 Glu Thr Arg Ser Ser Arg Asp Glu Met Phe Thr Leu Ser
Arg Glu 1685 1690 1695 Asn Glu Lys Lys Leu Lys Gly Leu Glu Ala Glu
Val Leu Arg Leu 1700 1705 1710 Gln Glu Glu Leu Ala Ala Ser Asp Arg
Ala Arg Arg Gln Ala Gln 1715 1720 1725 Gln Asp Arg Asp Glu Met Ala
Glu Glu Val Ala Ser Gly Asn Leu 1730 1735 1740 Ser Lys Ala Ala Thr
Leu Glu Glu Lys Arg Gln Leu Glu Gly Arg 1745 1750 1755 Leu Ser Gln
Leu Glu Glu Glu Leu Glu Glu Glu Gln Asn Asn Ser 1760 1765 1770 Glu
Leu Leu Lys Asp His Tyr Arg Lys Leu Val Leu Gln Val Glu 1775 1780
1785 Ser Leu Thr Thr Glu Leu Ser Ala Glu Arg Ser Phe Ser Ala Lys
1790 1795 1800 Ala Glu Ser Gly Arg Gln Gln Leu Glu Arg Gln Ile Gln
Glu Leu 1805 1810 1815 Arg Ala Arg Leu Gly Glu Glu Asp Ala Gly Ala
Arg Ala Arg Gln 1820 1825 1830 Lys Met Leu Ile Ala Ala Leu Glu Ser
Lys Leu Ala Gln Ala Glu 1835 1840 1845 Glu Gln Leu Glu Gln Glu Ser
Arg Glu Arg Ile Leu Ser Gly Lys 1850 1855 1860 Leu Val Arg Arg Ala
Glu Lys Arg Leu Lys Glu Val Val Leu Gln 1865 1870 1875 Val Asp Glu
Glu Arg Arg Val Ala Asp Gln Val Arg Asp Gln Leu 1880 1885 1890 Glu
Lys Ser Asn Leu Arg Leu Lys Gln Leu Lys Arg Gln Leu Glu 1895 1900
1905 Glu Ala Glu Glu Glu Ala Ser Arg Ala Gln Ala Gly Arg Arg Arg
1910 1915 1920 Leu Gln Arg Glu Leu Glu Asp Val Thr Glu Ser Ala Glu
Ser Met 1925 1930 1935 Asn Arg Glu Val Thr Thr Leu Arg Asn Arg Leu
Arg Arg Gly Pro 1940 1945 1950 Leu Thr Phe Thr Thr Arg Thr Val Arg
Gln Val Phe Arg Leu Glu 1955 1960 1965 Glu Gly Val Ala Ser Asp Glu
Glu Glu Ala Glu Gly Ala Glu Pro 1970 1975 1980 Gly Ser Ala Pro Gly
Gln Glu Pro Glu Ala Pro Pro Pro Ala Thr 1985 1990 1995 Pro Gln 2000
576377DNAMus musculus 57ccgaccatgg ctgcagtgac catgtccgtg tctgggagga
aggtagcctc caggccaggc 60ccggtgcctg aggcagccca atcgttcctc tacgcgcccc
ggacgccaaa tgtaggtggc 120cctggagggc cacaggtgga gtggacagcc
cggcgcatgg tgtgggtgcc ctcggaactg 180catgggttcg aggcagcagc
cctgcgggat gaaggggagg aggaggcaga agtggagctg 240gcggagagtg
ggcgccgcct gcggctgccc agggaccaga tccagcgcat gaacccaccc
300aagttcagca aggcagaaga tatggctgag ctcacctgcc tcaacgaggc
ctcggtcctg 360cacaacctgc gagaacgcta ctactccggg ctcatttata
cctactctgg cctcttctgt 420gtggtcatta acccatacaa gcagctgccc
atctacacgg aggccattgt tgaaatgtac 480cggggcaaga agcgccatga
ggtgccacct cacgtgtatg ctgtgacgga gggcgcgtac 540cgcagcatgc
ttcaggatcg tgaggatcaa tccattctct gcacgggaga gtctggcgct
600gggaagacgg agaacaccaa gaaggtcatc cagtacctgg cccatgtggc
atcatctcca 660aagggcagga aggagcctgg tgtccctggg gagctagagc
gtcagcttct tcaagccaac 720cccatcctag aggcctttgg caatgccaag
acagtgaaga acgacaactc ttcccgattt 780ggcaaattca tccgcatcaa
ctttgatatt gctggctaca tcgtgggagc aaacatcgag 840acctatctgt
tggagaagtc ccgggccatc agacaggcca aggatgaatg cagcttccat
900atcttctacc agctgctagg gggcgctggg gagcagctaa aagctgacct
ccttctggag 960ccctgttccc attatcgctt cctgaccaat gggccctcat
cgtccccggg ccaggagcgt 1020gagttattcc aggagaccct ggagtccctg
cgtgtgctgg gcctcctccc agaagagatc 1080actgccatgc tgcgcactgt
ctctgctgtc ctccagtttg gcaacattgt cctgaagaaa 1140gagcgcaata
cggaccaagc caccatgcct gacaacacag ctgcccagaa gctttgccgc
1200ctcttgggac tcggagtgac cgacttctcc agagcccttc tcacaccccg
catcaaagtg 1260ggccgagatt atgttcagaa agcacaaacc aaggagcagg
ctgactttgc gctggaggct 1320ctggccaaag ctacctatga gcgcctgttc
cgctggctgg ttctgcggct caaccgtgcc 1380ctggacagaa gcccgcggca
gggtgcctcc ttcctgggca tcctggacat cgcgggcttt 1440gagatcttcc
agctgaactc cttcgagcag ctgtgcatca actacaccaa cgagaagcta
1500cagcagctat tcaaccacac catgttcgtg ctggagcagg aggagtacca
gcgagagggc 1560atcccctgga ccttcctaga cttcgggttg gacctgcaac
cttgcatcga cctcattgag 1620cgtccggcca accctccagg tctcctggcc
ctgctggacg aggagtgctg gttccccaag 1680gccacggaca agtcttttgt
ggagaaggtc gcccaggagc agggcagcca ccccaaattc 1740cagcgcccca
ggaacctgcg agatcaggcc gacttcagcg tcctgcacta tgccggcaag
1800gttgactaca aagccagtga gtggctgatg aagaacatgg acccactgaa
tgacaatgtg 1860gccgccttgc ttcaccagag cacggatcgt ctcacagctg
agatctggaa ggatgtggag 1920ggcatcgtgg ggctggagca agtaagcagc
cttggagatg gcccaccggg aggccgcccc 1980cgccgtggaa tgttccggac
tgtggggcag ctctacaaag aatccctgag ccgcctcatg 2040gccacgctca
gcaacaccaa ccctagtttt gtccgctgca tcgttcccaa tcatgagaag
2100agggctggaa agctggagcc gcgcctggtg ctggaccaac tccgttgtaa
cggggtcctc 2160gagggtatac gcatctgtcg ccaaggcttc cccaaccgca
tcctcttcca ggagttccga 2220cagcgctatg aaatcctcac cccgaacgct
attcccaagg gcttcatgga cggcaaacag 2280gcctgtgaga agatgatcca
ggccctggag ctagacccca acctgtaccg tgttggccaa 2340agcaagatct
tcttccgggc aggggtcctg gcccagctgg aggaggagcg ggacctgaaa
2400gtcaccgaca tcatagtgtc tttccaggca gcggcacggg gctacctggc
ccgtagggct 2460ttccagagac ggcagcagca gcagagtgct ctgagggtga
tgcagagaaa ctgtgctgcc 2520tacctcaagc tcaggaactg gcagtggtgg
aggctgttca tcaaggtgaa gcccctgctg 2580caggtgacac ggcaggatga
ggtgctgcag gcgcgcgccc aggagctgca gaaagttcag 2640gagctgcagc
agcagagcgc tcgtgaagtg ggggaactgc agggtcgagt ggcacagcta
2700gaggaggagc gcacgcgcct ggctgagcag cttcgagcag aagccgagct
ctgctctgag 2760gccgaggaga cgcgggcgcg actggctgcc cggaagcagg
agctggagct ggtggtgaca 2820gagctggagg cacgagtggg cgaggaagaa
gagtgcagcc ggcagctgca gagtgagaag 2880aagaggctgc agcagcatat
ccaggagcta gagagccacc tggaagctga ggagggtgcc 2940cggcagaagc
tacagctgga gaaggtgacc acagaggcca agatgaagaa atttgaggag
3000gacctgctgc tcctggagga ccagaattcc aagctgagca aggagcggag
gctgctggag 3060gagcggctgg ctgagttctc ctcacaggca gcagaagagg
aagagaaagt caaaagtctc 3120aacaagctga ggctcaaata tgaagccaca
atctcagaca tggaagaccg gctgaagaag 3180gaggagaagg gacgccagga
actagagaag ctgaagcgac ggctggacgg ggagagctca 3240gagcttcagg
agcagatggt ggagcagaag cagagggcag aggaactgct cgcacagctg
3300ggccgcaagg aggatgagct gcaggccgcc ctgctcaggg cagaggaaga
gggtggtgcc 3360cgtgcccagt tgctcaagtc cctgcgagag gcacaggctg
gccttgctga ggctcaggag 3420gacctggaag ctgagcgggt agccagggcc
aaggcggaga agcagcgccg ggacctgggc 3480gaggagttgg aggccctacg
tggggagctc gaggacactc tggattccac caacgcccag 3540caggagctgc
ggtccaagag ggagcaggag gtgacagagc tgaagaaagc attggaagag
3600gagtcccgtg cccatgaggt gtccatgcag gagctgagac agaggcatag
ccaggcactg 3660gtggagatgg ccgagcagtt ggagcaagcc cggaggggca
aaggtgtgtg ggagaagact 3720cggctatccc tggaggctga ggtgtccgag
ctgaaggccg agctgagcag cctgcagacc 3780tcgagacagg agggtgagca
gaagaggcgc cgcctggagt cccagctaca ggaggtccag 3840ggccgatcca
gtgattcgga gcgggctcgg tctgaggctg ctgagaagct gcagagagcc
3900caggcggaac ttgagagcgt gtccacagcc ctgagtgagg cggagtccaa
agccatcagg 3960ctgggcaagg agctgagcag tgcagagtcc cagctgcatg
acacccagga actgcttcag 4020gaggagacca gggcaaagct ggccttgggg
tcccgtgtgc gtgccctaga ggccgaggcg 4080gcggggcttc gggagcagat
ggaagaggag gtggttgcca gggaacgggc tggccgggag 4140ctgcagagca
cgcaggccca gctctctgaa tggcggcgcc gccaggaaga agaggccgcg
4200gtgctggagg ctggggagga ggctcggcgc cgtgcagccc gggaggcaga
gaccctgacc 4260cagcgcctgg cagaaaagac tgaggctgta gaacgactgg
agcgagcccg gcgccgactg 4320cagcaggagt tggacgatgc cactgtggat
ctggggcagc agaagcagct cctgagcaca 4380ctggagaaga agcagcggaa
atttgaccag ctcctggcag aggagaaggc tgcagttcta 4440cgggctgtgg
aagaccgtga acggatagag gccgaaggcc gggagcgaga ggcccgggcc
4500ctgtcgctga cccgggccct ggaagaggag caggaggccc gggaggagct
ggagaggcag 4560aaccgtgctc tgagggctga gctggaagca ctgctgagca
gcaaggatga cgtgggcaag 4620aacgtgcacg agctggagcg agcccgtaag
gcggctgaac aggcagccag tgacctgcgg 4680acacaggtga cagaattgga
ggatgagctg acagccgcag aggatgccaa gctgcgcctg 4740gaggtgactg
tgcaggctct gaaggctcaa catgaacgcg acctgcaggg ccgcgatgat
4800gccggtgagg agaggcggag gcagctggcc aagcagctaa gagacgcaga
ggtagagcgc 4860gatgaggaac ggaagcagag ggcactggct atggctgccc
gcaagaagct ggagctggaa 4920ctggaggagt tgaaggcgca gacatctgct
gctgggcagg gcaaggaaga ggcagtgaag 4980cagctgaaga agatgcaggt
ccagatgaag gagctgtggc gggaggtaga ggagacgcgt 5040agctcccgcg
acgagatgtt taccctgagc agggaaaatg agaagaagct caaggggctg
5100gaagctgagg tgctgcgtct gcaagaggaa cttgctgcct cagaccgagc
ccggaggcag 5160gcccagcaag acagagacga gatggcagag gaggtggcca
gtggcaatct tagcaaggca 5220gccaccctgg aggaaaaacg gcagctggag
gggcgactga gccagttgga agaggagctg 5280gaggaagaac agaacaactc
ggagctgctc aaggaccatt accgaaagct agtgctacag 5340gtcgagtccc
tcaccacaga actgtctgcc gaacgaagtt tctcagccaa ggccgagagt
5400ggacggcagc agctggagcg gcagatccag gaactgcggg cccgcttggg
tgaagaggat 5460gctggagccc gagccaggca gaaaatgctg atcgctgctc
tggagtctaa actggcccag 5520gcagaggagc agctggagca ggagagcagg
gagcgcatcc tctctggcaa gctggtacgc 5580agagctgaga agcggctgaa
ggaggtagtt cttcaggtgg atgaagagcg cagggtggct 5640gaccaggtcc
gggaccagct ggagaaaagc aacctccggc tgaagcagct caagaggcag
5700ctggaggagg cagaggagga ggcatctcgg gcacaggctg gtcggaggcg
gctgcagcgg 5760gagctggagg acgtcactga gtctgcagaa tccatgaacc
gggaggtgac cacgctgagg 5820aacaggctcc ggcgtggccc acttacattc
accacacgga ctgtgcgcca ggtgttccgg 5880ctggaagagg gcgtggcttc
tgacgaggaa gaggctgaag gagctgaacc tggctctgca 5940ccaggccagg
agccggaggc tccgccccct gccacacccc aatgatccag tctgtcctag
6000atgccccaag gacagagccc tttccagtgc ccctcctggt ttgcactttg
aaatggcact 6060gtcctctggc actttctggc attgatgaac cctcctggga
ccccaggacc cctgcccact 6120gggggcccca aaccaaggag ctgggtggga
gggaggccat gatggtctct cttgttagag 6180aaacaaaatt gaacgtggat
gtcaagaatg tcctgtctgc acctattttc agcaggcctg 6240tcccctggag
agggcaggca gggtgcttcc atcccctctc agtatcttgc cctctttttt
6300ggggggaagt ggggtgtctg tgtgctcata gggtaatgct catggcccct
catgctccag 6360acactaaaga aataaaa 6377581992PRTMus musculus 58Met
Ala Ala Val Thr Met Ser Val Ser Gly Arg Lys Val Ala Ser Arg 1 5 10
15 Pro Gly Pro Val Pro Glu Ala Ala Gln Ser Phe Leu Tyr Ala Pro Arg
20 25 30 Thr Pro Asn Val Gly Gly Pro Gly Gly Pro Gln Val Glu Trp
Thr Ala 35 40 45 Arg Arg Met Val Trp Val Pro Ser Glu Leu His Gly
Phe Glu Ala Ala 50 55 60 Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala
Glu Val Glu Leu Ala Glu 65 70 75 80 Ser Gly Arg Arg Leu Arg Leu Pro
Arg Asp Gln Ile Gln Arg Met Asn 85 90 95 Pro Pro Lys Phe Ser Lys
Ala Glu Asp Met Ala Glu Leu Thr Cys Leu
100 105 110 Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Tyr
Ser Gly 115 120 125 Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val
Ile Asn Pro Tyr 130 135 140 Lys Gln Leu Pro Ile Tyr Thr Glu Ala Ile
Val Glu Met Tyr Arg Gly 145 150 155 160 Lys Lys Arg His Glu Val Pro
Pro His Val Tyr Ala Val Thr Glu Gly 165 170 175 Ala Tyr Arg Ser Met
Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys 180 185 190 Thr Gly Glu
Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile 195 200 205 Gln
Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly Arg Lys Glu Pro 210 215
220 Gly Val Pro Gly Glu Leu Glu Arg Gln Leu Leu Gln Ala Asn Pro Ile
225 230 235 240 Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp
Asn Ser Ser 245 250 255 Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp
Ile Ala Gly Tyr Ile 260 265 270 Val Gly Ala Asn Ile Glu Thr Tyr Leu
Leu Glu Lys Ser Arg Ala Ile 275 280 285 Arg Gln Ala Lys Asp Glu Cys
Ser Phe His Ile Phe Tyr Gln Leu Leu 290 295 300 Gly Gly Ala Gly Glu
Gln Leu Lys Ala Asp Leu Leu Leu Glu Pro Cys 305 310 315 320 Ser His
Tyr Arg Phe Leu Thr Asn Gly Pro Ser Ser Ser Pro Gly Gln 325 330 335
Glu Arg Glu Leu Phe Gln Glu Thr Leu Glu Ser Leu Arg Val Leu Gly 340
345 350 Leu Leu Pro Glu Glu Ile Thr Ala Met Leu Arg Thr Val Ser Ala
Val 355 360 365 Leu Gln Phe Gly Asn Ile Val Leu Lys Lys Glu Arg Asn
Thr Asp Gln 370 375 380 Ala Thr Met Pro Asp Asn Thr Ala Ala Gln Lys
Leu Cys Arg Leu Leu 385 390 395 400 Gly Leu Gly Val Thr Asp Phe Ser
Arg Ala Leu Leu Thr Pro Arg Ile 405 410 415 Lys Val Gly Arg Asp Tyr
Val Gln Lys Ala Gln Thr Lys Glu Gln Ala 420 425 430 Asp Phe Ala Leu
Glu Ala Leu Ala Lys Ala Thr Tyr Glu Arg Leu Phe 435 440 445 Arg Trp
Leu Val Leu Arg Leu Asn Arg Ala Leu Asp Arg Ser Pro Arg 450 455 460
Gln Gly Ala Ser Phe Leu Gly Ile Leu Asp Ile Ala Gly Phe Glu Ile 465
470 475 480 Phe Gln Leu Asn Ser Phe Glu Gln Leu Cys Ile Asn Tyr Thr
Asn Glu 485 490 495 Lys Leu Gln Gln Leu Phe Asn His Thr Met Phe Val
Leu Glu Gln Glu 500 505 510 Glu Tyr Gln Arg Glu Gly Ile Pro Trp Thr
Phe Leu Asp Phe Gly Leu 515 520 525 Asp Leu Gln Pro Cys Ile Asp Leu
Ile Glu Arg Pro Ala Asn Pro Pro 530 535 540 Gly Leu Leu Ala Leu Leu
Asp Glu Glu Cys Trp Phe Pro Lys Ala Thr 545 550 555 560 Asp Lys Ser
Phe Val Glu Lys Val Ala Gln Glu Gln Gly Ser His Pro 565 570 575 Lys
Phe Gln Arg Pro Arg Asn Leu Arg Asp Gln Ala Asp Phe Ser Val 580 585
590 Leu His Tyr Ala Gly Lys Val Asp Tyr Lys Ala Ser Glu Trp Leu Met
595 600 605 Lys Asn Met Asp Pro Leu Asn Asp Asn Val Ala Ala Leu Leu
His Gln 610 615 620 Ser Thr Asp Arg Leu Thr Ala Glu Ile Trp Lys Asp
Val Glu Gly Ile 625 630 635 640 Val Gly Leu Glu Gln Val Ser Ser Leu
Gly Asp Gly Pro Pro Gly Gly 645 650 655 Arg Pro Arg Arg Gly Met Phe
Arg Thr Val Gly Gln Leu Tyr Lys Glu 660 665 670 Ser Leu Ser Arg Leu
Met Ala Thr Leu Ser Asn Thr Asn Pro Ser Phe 675 680 685 Val Arg Cys
Ile Val Pro Asn His Glu Lys Arg Ala Gly Lys Leu Glu 690 695 700 Pro
Arg Leu Val Leu Asp Gln Leu Arg Cys Asn Gly Val Leu Glu Gly 705 710
715 720 Ile Arg Ile Cys Arg Gln Gly Phe Pro Asn Arg Ile Leu Phe Gln
Glu 725 730 735 Phe Arg Gln Arg Tyr Glu Ile Leu Thr Pro Asn Ala Ile
Pro Lys Gly 740 745 750 Phe Met Asp Gly Lys Gln Ala Cys Glu Lys Met
Ile Gln Ala Leu Glu 755 760 765 Leu Asp Pro Asn Leu Tyr Arg Val Gly
Gln Ser Lys Ile Phe Phe Arg 770 775 780 Ala Gly Val Leu Ala Gln Leu
Glu Glu Glu Arg Asp Leu Lys Val Thr 785 790 795 800 Asp Ile Ile Val
Ser Phe Gln Ala Ala Ala Arg Gly Tyr Leu Ala Arg 805 810 815 Arg Ala
Phe Gln Arg Arg Gln Gln Gln Gln Ser Ala Leu Arg Val Met 820 825 830
Gln Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg Asn Trp Gln Trp Trp 835
840 845 Arg Leu Phe Ile Lys Val Lys Pro Leu Leu Gln Val Thr Arg Gln
Asp 850 855 860 Glu Val Leu Gln Ala Arg Ala Gln Glu Leu Gln Lys Val
Gln Glu Leu 865 870 875 880 Gln Gln Gln Ser Ala Arg Glu Val Gly Glu
Leu Gln Gly Arg Val Ala 885 890 895 Gln Leu Glu Glu Glu Arg Thr Arg
Leu Ala Glu Gln Leu Arg Ala Glu 900 905 910 Ala Glu Leu Cys Ser Glu
Ala Glu Glu Thr Arg Ala Arg Leu Ala Ala 915 920 925 Arg Lys Gln Glu
Leu Glu Leu Val Val Thr Glu Leu Glu Ala Arg Val 930 935 940 Gly Glu
Glu Glu Glu Cys Ser Arg Gln Leu Gln Ser Glu Lys Lys Arg 945 950 955
960 Leu Gln Gln His Ile Gln Glu Leu Glu Ser His Leu Glu Ala Glu Glu
965 970 975 Gly Ala Arg Gln Lys Leu Gln Leu Glu Lys Val Thr Thr Glu
Ala Lys 980 985 990 Met Lys Lys Phe Glu Glu Asp Leu Leu Leu Leu Glu
Asp Gln Asn Ser 995 1000 1005 Lys Leu Ser Lys Glu Arg Arg Leu Leu
Glu Glu Arg Leu Ala Glu 1010 1015 1020 Phe Ser Ser Gln Ala Ala Glu
Glu Glu Glu Lys Val Lys Ser Leu 1025 1030 1035 Asn Lys Leu Arg Leu
Lys Tyr Glu Ala Thr Ile Ser Asp Met Glu 1040 1045 1050 Asp Arg Leu
Lys Lys Glu Glu Lys Gly Arg Gln Glu Leu Glu Lys 1055 1060 1065 Leu
Lys Arg Arg Leu Asp Gly Glu Ser Ser Glu Leu Gln Glu Gln 1070 1075
1080 Met Val Glu Gln Lys Gln Arg Ala Glu Glu Leu Leu Ala Gln Leu
1085 1090 1095 Gly Arg Lys Glu Asp Glu Leu Gln Ala Ala Leu Leu Arg
Ala Glu 1100 1105 1110 Glu Glu Gly Gly Ala Arg Ala Gln Leu Leu Lys
Ser Leu Arg Glu 1115 1120 1125 Ala Gln Ala Gly Leu Ala Glu Ala Gln
Glu Asp Leu Glu Ala Glu 1130 1135 1140 Arg Val Ala Arg Ala Lys Ala
Glu Lys Gln Arg Arg Asp Leu Gly 1145 1150 1155 Glu Glu Leu Glu Ala
Leu Arg Gly Glu Leu Glu Asp Thr Leu Asp 1160 1165 1170 Ser Thr Asn
Ala Gln Gln Glu Leu Arg Ser Lys Arg Glu Gln Glu 1175 1180 1185 Val
Thr Glu Leu Lys Lys Ala Leu Glu Glu Glu Ser Arg Ala His 1190 1195
1200 Glu Val Ser Met Gln Glu Leu Arg Gln Arg His Ser Gln Ala Leu
1205 1210 1215 Val Glu Met Ala Glu Gln Leu Glu Gln Ala Arg Arg Gly
Lys Gly 1220 1225 1230 Val Trp Glu Lys Thr Arg Leu Ser Leu Glu Ala
Glu Val Ser Glu 1235 1240 1245 Leu Lys Ala Glu Leu Ser Ser Leu Gln
Thr Ser Arg Gln Glu Gly 1250 1255 1260 Glu Gln Lys Arg Arg Arg Leu
Glu Ser Gln Leu Gln Glu Val Gln 1265 1270 1275 Gly Arg Ser Ser Asp
Ser Glu Arg Ala Arg Ser Glu Ala Ala Glu 1280 1285 1290 Lys Leu Gln
Arg Ala Gln Ala Glu Leu Glu Ser Val Ser Thr Ala 1295 1300 1305 Leu
Ser Glu Ala Glu Ser Lys Ala Ile Arg Leu Gly Lys Glu Leu 1310 1315
1320 Ser Ser Ala Glu Ser Gln Leu His Asp Thr Gln Glu Leu Leu Gln
1325 1330 1335 Glu Glu Thr Arg Ala Lys Leu Ala Leu Gly Ser Arg Val
Arg Ala 1340 1345 1350 Leu Glu Ala Glu Ala Ala Gly Leu Arg Glu Gln
Met Glu Glu Glu 1355 1360 1365 Val Val Ala Arg Glu Arg Ala Gly Arg
Glu Leu Gln Ser Thr Gln 1370 1375 1380 Ala Gln Leu Ser Glu Trp Arg
Arg Arg Gln Glu Glu Glu Ala Ala 1385 1390 1395 Val Leu Glu Ala Gly
Glu Glu Ala Arg Arg Arg Ala Ala Arg Glu 1400 1405 1410 Ala Glu Thr
Leu Thr Gln Arg Leu Ala Glu Lys Thr Glu Ala Val 1415 1420 1425 Glu
Arg Leu Glu Arg Ala Arg Arg Arg Leu Gln Gln Glu Leu Asp 1430 1435
1440 Asp Ala Thr Val Asp Leu Gly Gln Gln Lys Gln Leu Leu Ser Thr
1445 1450 1455 Leu Glu Lys Lys Gln Arg Lys Phe Asp Gln Leu Leu Ala
Glu Glu 1460 1465 1470 Lys Ala Ala Val Leu Arg Ala Val Glu Asp Arg
Glu Arg Ile Glu 1475 1480 1485 Ala Glu Gly Arg Glu Arg Glu Ala Arg
Ala Leu Ser Leu Thr Arg 1490 1495 1500 Ala Leu Glu Glu Glu Gln Glu
Ala Arg Glu Glu Leu Glu Arg Gln 1505 1510 1515 Asn Arg Ala Leu Arg
Ala Glu Leu Glu Ala Leu Leu Ser Ser Lys 1520 1525 1530 Asp Asp Val
Gly Lys Asn Val His Glu Leu Glu Arg Ala Arg Lys 1535 1540 1545 Ala
Ala Glu Gln Ala Ala Ser Asp Leu Arg Thr Gln Val Thr Glu 1550 1555
1560 Leu Glu Asp Glu Leu Thr Ala Ala Glu Asp Ala Lys Leu Arg Leu
1565 1570 1575 Glu Val Thr Val Gln Ala Leu Lys Ala Gln His Glu Arg
Asp Leu 1580 1585 1590 Gln Gly Arg Asp Asp Ala Gly Glu Glu Arg Arg
Arg Gln Leu Ala 1595 1600 1605 Lys Gln Leu Arg Asp Ala Glu Val Glu
Arg Asp Glu Glu Arg Lys 1610 1615 1620 Gln Arg Ala Leu Ala Met Ala
Ala Arg Lys Lys Leu Glu Leu Glu 1625 1630 1635 Leu Glu Glu Leu Lys
Ala Gln Thr Ser Ala Ala Gly Gln Gly Lys 1640 1645 1650 Glu Glu Ala
Val Lys Gln Leu Lys Lys Met Gln Val Gln Met Lys 1655 1660 1665 Glu
Leu Trp Arg Glu Val Glu Glu Thr Arg Ser Ser Arg Asp Glu 1670 1675
1680 Met Phe Thr Leu Ser Arg Glu Asn Glu Lys Lys Leu Lys Gly Leu
1685 1690 1695 Glu Ala Glu Val Leu Arg Leu Gln Glu Glu Leu Ala Ala
Ser Asp 1700 1705 1710 Arg Ala Arg Arg Gln Ala Gln Gln Asp Arg Asp
Glu Met Ala Glu 1715 1720 1725 Glu Val Ala Ser Gly Asn Leu Ser Lys
Ala Ala Thr Leu Glu Glu 1730 1735 1740 Lys Arg Gln Leu Glu Gly Arg
Leu Ser Gln Leu Glu Glu Glu Leu 1745 1750 1755 Glu Glu Glu Gln Asn
Asn Ser Glu Leu Leu Lys Asp His Tyr Arg 1760 1765 1770 Lys Leu Val
Leu Gln Val Glu Ser Leu Thr Thr Glu Leu Ser Ala 1775 1780 1785 Glu
Arg Ser Phe Ser Ala Lys Ala Glu Ser Gly Arg Gln Gln Leu 1790 1795
1800 Glu Arg Gln Ile Gln Glu Leu Arg Ala Arg Leu Gly Glu Glu Asp
1805 1810 1815 Ala Gly Ala Arg Ala Arg Gln Lys Met Leu Ile Ala Ala
Leu Glu 1820 1825 1830 Ser Lys Leu Ala Gln Ala Glu Glu Gln Leu Glu
Gln Glu Ser Arg 1835 1840 1845 Glu Arg Ile Leu Ser Gly Lys Leu Val
Arg Arg Ala Glu Lys Arg 1850 1855 1860 Leu Lys Glu Val Val Leu Gln
Val Asp Glu Glu Arg Arg Val Ala 1865 1870 1875 Asp Gln Val Arg Asp
Gln Leu Glu Lys Ser Asn Leu Arg Leu Lys 1880 1885 1890 Gln Leu Lys
Arg Gln Leu Glu Glu Ala Glu Glu Glu Ala Ser Arg 1895 1900 1905 Ala
Gln Ala Gly Arg Arg Arg Leu Gln Arg Glu Leu Glu Asp Val 1910 1915
1920 Thr Glu Ser Ala Glu Ser Met Asn Arg Glu Val Thr Thr Leu Arg
1925 1930 1935 Asn Arg Leu Arg Arg Gly Pro Leu Thr Phe Thr Thr Arg
Thr Val 1940 1945 1950 Arg Gln Val Phe Arg Leu Glu Glu Gly Val Ala
Ser Asp Glu Glu 1955 1960 1965 Glu Ala Glu Gly Ala Glu Pro Gly Ser
Ala Pro Gly Gln Glu Pro 1970 1975 1980 Glu Ala Pro Pro Pro Ala Thr
Pro Gln 1985 1990 596786DNAHomo sapiens 59ctctttctcc ccaggccgaa
gcctcgggac ggccctggaa gccgaccatg gcagccgtga 60ccatgtcggt gcccgggcgg
aaggcgcccc ccaggccggg cccagtgccc gaggcggccc 120agccgttcct
gttcacgccc cgcgggccca gcgcgggtgg cgggcctggc tcgggcacct
180ccccgcaggt ggagtggacg gcccggcgtc tcgtgtgggt gccttcggag
cttcacgggt 240tcgaggcggc ggcgctgcgg gacgaaggcg aggaggaggc
ggaggtggag ctggcggaga 300gcgggaggcg gctgcgactg ccgcgggacc
agatccagcg catgaacccg cccaagttca 360gcaaggccga ggacatggcc
gagctgacct gcctcaacga ggcctcggtc ctgcacaacc 420tccgggagcg
gtactactcc ggcctcatct acacgtactc cggccttttc tgtgtggtca
480tcaacccgta caagcagctt cccatctaca cagaagccat tgtggagatg
taccggggca 540agaagcgcca cgaggtgcca ccccacgtgt acgcagtgac
cgagggggcc tatcggagca 600tgctgcagga tcgtgaggac cagtccattc
tctgcactgg agagtctgga gctgggaaga 660cggaaaacac caagaaggtc
atccagtacc tcgcccacgt ggcatcgtct ccaaagggca 720ggaaggagcc
gggtgtcccc ggtgagctgg agcggcagct gcttcaggcc aaccccatcc
780tagaggcctt tggcaatgcc aagacagtga agaatgacaa ctcctcccga
ttcggcaaat 840tcatccgcat caactttgat gttgccgggt acatcgtggg
cgccaacatt gagacctacc 900tgctggagaa gtcgcgggcc atccgccagg
ccaaggacga gtgcagcttc cacatcttct 960accagctgct ggggggcgct
ggagagcagc tcaaagccga cctcctcctc gagccctgct 1020cccactaccg
gttcctgacc aacgggccgt catcctctcc cggccaggag cgggaactct
1080tccaggagac gctggagtcg ctgcgggtcc tgggattcag ccacgaggaa
atcatctcca 1140tgctgcggat ggtctcagca gttctccagt ttggcaacat
tgccttgaag agagaacgga 1200acaccgatca agccaccatg cctgacaaca
cagctgcaca gaagctctgc cgcctcttgg 1260gactgggggt gacggatttc
tcccgagcct tgctcacccc tcgcatcaaa gttggccgag 1320actatgtgca
gaaagcccag actaaggaac aggctgactt cgcgctggag gccctggcca
1380aggccaccta cgagcgcctc ttccgctggc tggttctgcg cctcaaccgg
gccttggacc 1440gcagcccccg ccaaggcgcc tccttcctgg gcatcctgga
catcgcgggc tttgagatct 1500tccagctgaa ctccttcgag cagctctgca
tcaactacac caacgagaag ctgcagcagc 1560tcttcaacca caccatgttc
gtgctggagc aggaggagta ccagcgtgag ggcatcccct 1620ggaccttcct
cgactttggc ctcgacctgc agccctgcat cgacctcatc gagcggccgg
1680ccaacccccc tggactcctg gccctgctgg atgaggagtg ctggttcccg
aaggccacag 1740acaagtcgtt tgtggagaag gtagcccagg agcagggcgg
ccaccccaag ttccagcggc 1800cgaggcacct gcgggatcag gccgacttca
gtgttctcca ctacgcgggc aaggtcgact 1860acaaggccaa cgagtggctg
atgaaaaaca tggaccctct gaatgacaac gtcgcagcct 1920tgctccacca
gagcacagac cggctgacgg cagagatctg gaaagacgtg gagggcatcg
1980tggggctgga acaggtgagc agcctgggcg acggcccacc aggtggccgc
ccccgtcggg 2040gtatgttccg gacagtggga cagctctaca aggagtccct
gagccgcctc atggccacac 2100tcagcaacac caaccccagt tttgtccggt
gcattgtccc caaccacgag aagagggccg 2160ggaagctgga gccacggctg
gtgctggacc agcttcgctg caacggggtc ctggagggca 2220tccgcatctg
tcgccagggc ttccccaacc gcatcctctt ccaggagttc cggcagcgat
2280acgagatcct gacacccaat gccatcccca agggcttcat ggatgggaag
caggcctgtg 2340aaaagatgat ccaggcgctg gaactggacc ccaacctcta
ccgcgtggga cagagcaaga 2400tcttcttccg ggctggggtc ctggcccagc
tggaagagga gcgagacctg aaggtcaccg 2460acatcatcgt ctccttccag
gcagctgccc ggggatacct ggctcgcagg gccttccaga 2520agcgccagca
gcagcagagc gccctgaggg tgatgcagcg gaactgcgcg gcctacctca
2580agctgagaca ctggcagtgg tggcggctgt ttaccaaggt gaagccactg
ctgcaggtga 2640cgcggcagga tgaggtgctg caggcacggg cccaggagct
gcagaaagtg caggagctac 2700agcagcagag cgcccgcgaa gttggggagc
tccagggccg agtggcacag ctggaagagg 2760agcgcgcccg cctggcagag
caattgcgag cagaggcaga actgtgtgca gaggccgagg 2820agacgcgggg
gaggctggca gcccgcaagc aggagctgga gctggtggtg tcagagctgg
2880aggctcgcgt gggcgaggag gaggagtgca gccgtcaaat gcaaaccgag
aagaagaggc 2940tacagcagca catacaggag ctagaggccc accttgaggc
tgaggagggt gcgcggcaga 3000agctgcagct ggagaaggtg acgacagagg
caaaaatgaa gaaatttgaa gaggacctgc 3060tgctcctgga agaccagaat
tccaagctga gcaagagcgg aagctgctgg aagatcgtct 3120ggccgagttc
tcatcccagg cagctgagga ggaggagaag gtcaagagcc tcaataagct
3180acggctcaaa tatgaggcca caatcgcaga catggaggga ccgcctacgg
aaggaggaga 3240agggtcgcca ggagctggag aagctgaagc ggaggctgga
tggggagagc tcagagctgc 3300aggagcagat ggtggagcag caacagcggg
cagaggagct gcgggcccag ctgggccgga 3360aggaggagga gctgcaggct
gccctggcca gggcagaaga cgagggtggg gcccgggccc 3420agctgctgaa
atccctgcgg gaggctcaag cagccctggc cgaggcccag gaggacctgg
3480agtctgagcg tgtggccagg accaaggcgg agaagcagcg ccgggacctg
ggcgaggagc 3540tggaggcgct gcggggcgag ctggaggaca cgctggactc
caccaacgca cagcaggagc 3600tccggtccaa gagggaacag gaggtgacgg
agctgaagaa gactctggag gaggagactc 3660gcatccacga ggcggcagtg
caggagctga ggcagcgcca cggccaggcc ctgggggagc 3720tggcggagca
gctggagcag gcccggaggg gcaaaggtgc atgggagaag acccggctgg
3780ccctggaggc cgaggtgtcc gagctgcggg cagaactgag cagcctgcag
actgcacgtc 3840aggagggtga gcagcggagg cgccgcctgg agttacagct
gcaggaggtg cagggccggg 3900ctggtgatgg ggagagggca cgagcggagg
ctgctgagaa gctgcagcga gcccaggctg 3960aactggagaa tgtgtctggg
gcgctgaacg aggctgagtc caaaaccatc cgtcttagca 4020aggagctgag
cagcacagaa gcccagctgc acgatgccca ggagctgctg caggaggaga
4080ccagggcgaa attggccttg gggtcccggg tgcgagccat ggaggctgag
gcagccgggc 4140tgcgtgagca gctggaggag gaggcagctg ccagggaacg
ggcgggccgt gaactgcaga 4200ctgcccaggc ccagctttcc gagtggcggc
ggcgccagga ggaggaggca ggggcactgg 4260aggcagggga ggaggcacgg
cgccgggcag cccgggaggc cgaggccctg acccagcgcc 4320tggcagaaaa
gacagagacc gtggatcggc tggagcgggg ccgccgccgg ctgcagcagg
4380agctggacga cgccaccatg gacctggagc agcagcggca gcttgtgagc
accctggaga 4440agaagcagcg caagtttgac cagcttctgg cagaggagaa
ggcagctgta cttcgggcag 4500tggaggaacg tgagcgggcc gaggcagagg
gccgggagcg tgaggctcgg gccctgtcac 4560tgacacgggc actggaggag
gagcaggagg cacgtgagga gctggagcgg cagaaccggg 4620ccctgcgggc
tgagctggag gcactgctga gcagcaagga tgacgtcggc aagagcgtgc
4680atgagctgga acgagcctgc cgggtagcag aacaggcagc caatgatctg
cgagcacagg 4740tgacagaact ggaggatgag ctgacagcgg ccgaggatgc
caagctgcgt ctggaggtga 4800ctgtgcaggc tctcaagact cagcatgagc
gtgacctgca gggccgtgat gaggctggtg 4860aagagaggcg gaggcagctg
gccaagcagc tgagagatgc agaggtggag cgggatgagg 4920agcggaagca
gcgcactctg gccgtggctg cccgcaagaa gctggaggga gagctggagg
4980agctgaaggc tcagatggcc tctgccggcc agggcaagga ggaggcggtg
aagcagcttc 5040gcaagatgca ggcccagatg aaggagctat ggcgggaggt
ggaggagaca cgcacctccc 5100gggaggagat cttctcccag aatcgggaaa
gtgaaaagcg cctcaagggc ctggaggctg 5160aggtgctgcg gctgcaggag
gaactggccg cctcggaccg tgctcggcgg caggcccagc 5220aggaccggga
tgagatggca gatgaggtgg ccaatggtaa ccttagcaag gcagccattc
5280tggaggagaa gcgtcagctg gaggggcgcc tggggcagtt ggaggaagag
ctggaggagg 5340agcagagcaa ctcagagctg ctcaatgacc gctaccgcaa
gctgctcctg caggtagagt 5400cactgaccac agagctgtca gctgagcgca
gtttctcagc caaggcagag agcgggcggc 5460agcagctgga acggcagatc
caggagctac ggggacgcct gggtgaggag gatgctgggg 5520cccgtgcccg
ccacaagatg accattgctg cccttgagtc taagttggcc caggctgagg
5580agcagctaga gcaagagacc agagagcgca tcctctctgg aaagctggtg
cgcagagctg 5640agaagcggct taaagaggtg gtgctccagg tggaggagga
gcggagggtg gctgaccagc 5700tccgggacca gctggagaag ggaaaccttc
gagtcaagca gctgaagcgg cagctggagg 5760aggccgagga ggaggcatcc
cgggctcagg ctggccgccg gaggctgcag cgtgagctgg 5820aagatgtcac
agagtcggcc gagtccatga accgtgaagt gaccacactg aggaaccggc
5880ttcgacgcgg ccccctcacc ttcaccaccc gcacggtgcg ccaggtcttc
cgactagagg 5940agggcgtggc atccgacgag gaggcagagg aagcacagcc
tgggtctggg ccatccccgg 6000agcctgaggg gtccccacca gcccaccccc
agtgacccta ccctgtcccc agatgcacta 6060acagatgggg cccagccccc
ttcctccctg gaccccacgg gcccctgtcc caggaacccc 6120gccctctgac
ttcttgccct ttggaaatgg tgcagcactc tggcatttat cacccccacc
6180tgggtcccct gcaacctccc atcaaaggat gacccctaaa cacagaggag
cggggcaggc 6240agggaggcaa ggactggagc taccttgctt gttgggggac
tgggtacagt tggcaagctg 6300tgtttccatc agctccctgt cctcctttct
tccctcgtta ttgatctata gacattagga 6360agggagtgag acggctcctc
caccatcctc agccagtgca acccattccc tctgcttctc 6420tctctctctc
tctctctccc tccctctcct tccctaccct ctcaccatct ttcttggcct
6480ctctgagggt ctctctgtgc atctttttag gaatctcgct ctcactctct
acgtagccac 6540tctccttccc ccatttctgc gtccacccct gaactcctga
gcgacagaag ccccaggcct 6600ccaccagcct tgaacccttg caaaggggca
ggacaagggg acccctctca ctcctgctgc 6660tgcccatgct ctgccctccc
ttctggttgc tctgagggtt cggagcttcc ctctgggact 6720aaaggagtgt
cctttaccct cccagcctcc aggctctggc agaaataaac tccaacccga 6780ctggac
6786601995PRTHomo sapiens 60Met Ala Ala Val Thr Met Ser Val Pro Gly
Arg Lys Ala Pro Pro Arg 1 5 10 15 Pro Gly Pro Val Pro Glu Ala Ala
Gln Pro Phe Leu Phe Thr Pro Arg 20 25 30 Gly Pro Ser Ala Gly Gly
Gly Pro Gly Ser Gly Thr Ser Pro Gln Val 35 40 45 Glu Trp Thr Ala
Arg Arg Leu Val Trp Val Pro Ser Glu Leu His Gly 50 55 60 Phe Glu
Ala Ala Ala Leu Arg Asp Glu Gly Glu Glu Glu Ala Glu Val 65 70 75 80
Glu Leu Ala Glu Ser Gly Arg Arg Leu Arg Leu Pro Arg Asp Gln Ile 85
90 95 Gln Arg Met Asn Pro Pro Lys Phe Ser Lys Ala Glu Asp Met Ala
Glu 100 105 110 Leu Thr Cys Leu Asn Glu Ala Ser Val Leu His Asn Leu
Arg Glu Arg 115 120 125 Tyr Tyr Ser Gly Leu Ile Tyr Thr Tyr Ser Gly
Leu Phe Cys Val Val 130 135 140 Ile Asn Pro Tyr Lys Gln Leu Pro Ile
Tyr Thr Glu Ala Ile Val Glu 145 150 155 160 Met Tyr Arg Gly Lys Lys
Arg His Glu Val Pro Pro His Val Tyr Ala 165 170 175 Val Thr Glu Gly
Ala Tyr Arg Ser Met Leu Gln Asp Arg Glu Asp Gln 180 185 190 Ser Ile
Leu Cys Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr 195 200 205
Lys Lys Val Ile Gln Tyr Leu Ala His Val Ala Ser Ser Pro Lys Gly 210
215 220 Arg Lys Glu Pro Gly Val Pro Gly Glu Leu Glu Arg Gln Leu Leu
Gln 225 230 235 240 Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys
Thr Val Lys Asn 245 250 255 Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile
Arg Ile Asn Phe Asp Val 260 265 270 Ala Gly Tyr Ile Val Gly Ala Asn
Ile Glu Thr Tyr Leu Leu Glu Lys 275 280 285 Ser Arg Ala Ile Arg Gln
Ala Lys Asp Glu Cys Ser Phe His Ile Phe 290 295 300 Tyr Gln Leu Leu
Gly Gly Ala Gly Glu Gln Leu Lys Ala Asp Leu Leu 305 310 315 320 Leu
Glu Pro Cys Ser His Tyr Arg Phe Leu Thr Asn Gly Pro Ser Ser 325 330
335 Ser Pro Gly Gln Glu Arg Glu Leu Phe Gln Glu Thr Leu Glu Ser Leu
340 345 350 Arg Val Leu Gly Phe Ser His Glu Glu Ile Ile Ser Met Leu
Arg Met 355 360 365 Val Ser Ala Val Leu Gln Phe Gly Asn Ile Ala Leu
Lys Arg Glu Arg 370 375 380 Asn Thr Asp Gln Ala Thr Met Pro Asp Asn
Thr Ala Ala Gln Lys Leu 385 390 395 400 Cys Arg Leu Leu Gly Leu Gly
Val Thr Asp Phe Ser Arg Ala Leu Leu 405 410 415 Thr Pro Arg Ile Lys
Val Gly Arg Asp Tyr Val Gln Lys Ala Gln Thr 420 425 430 Lys Glu Gln
Ala Asp Phe Ala Leu Glu Ala Leu Ala Lys Ala Thr Tyr 435 440 445 Glu
Arg Leu Phe Arg Trp Leu Val Leu Arg Leu Asn Arg Ala Leu Asp 450 455
460 Arg Ser Pro Arg Gln Gly Ala Ser Phe Leu Gly Ile Leu Asp Ile Ala
465 470 475 480 Gly Phe Glu Ile Phe Gln Leu Asn Ser Phe Glu Gln Leu
Cys Ile Asn 485 490 495 Tyr Thr Asn Glu Lys Leu Gln Gln Leu Phe Asn
His Thr Met Phe Val 500 505 510 Leu Glu Gln Glu Glu Tyr Gln Arg Glu
Gly Ile Pro Trp Thr Phe Leu 515 520 525 Asp Phe Gly Leu Asp Leu Gln
Pro Cys Ile Asp Leu Ile Glu Arg Pro 530 535 540 Ala Asn Pro Pro Gly
Leu Leu Ala Leu Leu Asp Glu Glu Cys Trp Phe 545 550 555 560 Pro Lys
Ala Thr Asp Lys Ser Phe Val Glu Lys Val Ala Gln Glu Gln 565 570 575
Gly Gly His Pro Lys Phe Gln Arg Pro Arg His Leu Arg Asp Gln Ala 580
585 590 Asp Phe Ser Val Leu His Tyr Ala Gly Lys Val Asp Tyr Lys Ala
Asn 595 600 605 Glu Trp Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn
Val Ala Ala 610 615 620 Leu Leu His Gln Ser Thr Asp Arg Leu Thr Ala
Glu Ile Trp Lys Asp 625 630 635 640 Val Glu Gly Ile Val Gly Leu Glu
Gln Val Ser Ser Leu Gly Asp Gly 645 650 655 Pro Pro Gly Gly Arg Pro
Arg Arg Gly Met Phe Arg Thr Val Gly Gln 660 665 670 Leu Tyr Lys Glu
Ser Leu Ser Arg Leu Met Ala Thr Leu Ser Asn Thr 675 680 685 Asn Pro
Ser Phe Val Arg Cys Ile Val Pro Asn His Glu Lys Arg Ala 690 695 700
Gly Lys Leu Glu Pro Arg Leu Val Leu Asp Gln Leu Arg Cys Asn Gly 705
710 715 720 Val Leu Glu Gly Ile Arg Ile Cys Arg Gln Gly Phe Pro Asn
Arg Ile 725 730 735 Leu Phe Gln Glu Phe Arg Gln Arg Tyr Glu Ile Leu
Thr Pro Asn Ala 740 745 750 Ile Pro Lys Gly Phe Met Asp Gly Lys Gln
Ala Cys Glu Lys Met Ile 755 760 765 Gln Ala Leu Glu Leu Asp Pro Asn
Leu Tyr Arg Val Gly Gln Ser Lys 770 775 780 Ile Phe Phe Arg Ala Gly
Val Leu Ala Gln Leu Glu Glu Glu Arg Asp 785 790 795 800 Leu Lys Val
Thr Asp Ile Ile Val Ser Phe Gln Ala Ala Ala Arg Gly 805 810 815 Tyr
Leu Ala Arg Arg Ala Phe Gln Lys Arg Gln Gln Gln Gln Ser Ala 820 825
830 Leu Arg Val Met Gln Arg Asn Cys Ala Ala Tyr Leu Lys Leu Arg His
835 840 845 Trp Gln Trp Trp Arg Leu Phe Thr Lys Val Lys Pro Leu Leu
Gln Val 850 855 860 Thr Arg Gln Asp Glu Val Leu Gln Ala Arg Ala Gln
Glu Leu Gln Lys 865 870 875 880 Val Gln Glu Leu Gln Gln Gln Ser Ala
Arg Glu Val Gly Glu Leu Gln 885 890 895 Gly Arg Val Ala Gln Leu Glu
Glu Glu Arg Ala Arg Leu Ala Glu Gln 900 905 910 Leu Arg Ala Glu Ala
Glu Leu Cys Ala Glu Ala Glu Glu Thr Arg Gly 915 920 925 Arg Leu Ala
Ala Arg Lys Gln Glu Leu Glu Leu Val Val Ser Glu Leu 930 935 940 Glu
Ala Arg Val Gly Glu Glu Glu Glu Cys Ser Arg Gln Met Gln Thr 945 950
955 960 Glu Lys Lys Arg Leu Gln Gln His Ile Gln Glu Leu Glu Ala His
Leu 965 970 975 Glu Ala Glu Glu Gly Ala Arg Gln Lys Leu Gln Leu Glu
Lys Val Thr 980 985 990 Thr Glu Ala Lys Met Lys Lys Phe Glu Glu Asp
Leu Leu Leu Leu Glu 995 1000 1005 Asp Gln Asn Ser Lys Leu Ser Lys
Ser Gly Ser Cys Trp Lys Ile 1010 1015 1020 Val Trp Pro Ser Ser His
Pro Arg Gln Leu Arg Arg Arg Arg Arg 1025 1030 1035 Ser Arg Ala Ser
Ile Ser Tyr Gly Ser Asn Met Arg Pro Gln Ser 1040 1045 1050 Gln Thr
Trp Arg Asp Arg Leu Arg Lys Glu Glu Lys Gly Arg Gln 1055 1060 1065
Glu Leu Glu Lys Leu Lys Arg Arg Leu Asp Gly Glu Ser Ser Glu 1070
1075 1080 Leu Gln Glu Gln Met Val Glu Gln Gln Gln Arg Ala Glu Glu
Leu 1085 1090 1095 Arg Ala Gln Leu Gly Arg Lys Glu Glu Glu Leu Gln
Ala Ala Leu 1100 1105 1110 Ala Arg Ala Glu Asp Glu Gly Gly Ala Arg
Ala Gln Leu Leu Lys 1115 1120 1125 Ser Leu Arg Glu Ala Gln Ala Ala
Leu Ala Glu Ala Gln Glu Asp 1130 1135 1140 Leu Glu Ser Glu Arg Val
Ala Arg Thr Lys Ala Glu Lys Gln Arg 1145 1150 1155 Arg Asp Leu Gly
Glu Glu Leu Glu Ala Leu Arg Gly Glu Leu Glu 1160 1165 1170 Asp Thr
Leu Asp Ser Thr Asn Ala Gln Gln Glu Leu Arg Ser Lys 1175 1180 1185
Arg Glu Gln Glu Val Thr Glu Leu Lys Lys Thr Leu Glu Glu Glu 1190
1195 1200 Thr Arg Ile His Glu Ala Ala Val Gln Glu Leu Arg Gln Arg
His 1205 1210 1215 Gly Gln Ala Leu Gly Glu Leu Ala Glu Gln Leu Glu
Gln Ala Arg 1220 1225 1230 Arg Gly Lys Gly Ala Trp Glu Lys Thr Arg
Leu Ala Leu Glu Ala 1235 1240 1245 Glu Val Ser Glu Leu Arg Ala Glu
Leu Ser Ser Leu Gln Thr Ala 1250 1255 1260 Arg Gln Glu Gly Glu Gln
Arg Arg Arg Arg Leu Glu Leu Gln Leu 1265 1270 1275 Gln Glu Val Gln
Gly Arg Ala Gly Asp Gly Glu Arg Ala Arg Ala 1280 1285 1290 Glu Ala
Ala Glu Lys Leu Gln Arg Ala Gln Ala Glu Leu Glu Asn 1295 1300 1305
Val Ser Gly Ala Leu Asn Glu Ala Glu Ser Lys Thr Ile Arg Leu 1310
1315 1320 Ser Lys Glu Leu Ser Ser Thr Glu Ala Gln Leu His Asp Ala
Gln 1325 1330 1335 Glu Leu Leu Gln Glu Glu Thr Arg Ala Lys Leu Ala
Leu Gly Ser 1340 1345 1350 Arg Val Arg Ala Met Glu Ala Glu Ala Ala
Gly Leu Arg Glu Gln 1355 1360 1365 Leu Glu Glu Glu Ala Ala Ala Arg
Glu Arg Ala Gly Arg Glu Leu 1370 1375 1380 Gln Thr Ala Gln Ala Gln
Leu Ser Glu Trp Arg Arg Arg Gln Glu 1385 1390 1395 Glu Glu Ala Gly
Ala Leu Glu Ala Gly Glu Glu Ala Arg Arg Arg 1400 1405 1410 Ala Ala
Arg Glu Ala Glu Ala Leu Thr Gln Arg Leu Ala Glu Lys 1415 1420 1425
Thr Glu Thr Val Asp Arg Leu Glu Arg Gly Arg Arg Arg Leu Gln 1430
1435 1440 Gln Glu Leu Asp Asp Ala Thr Met Asp Leu Glu Gln Gln Arg
Gln 1445 1450 1455 Leu Val Ser Thr Leu Glu Lys Lys Gln Arg Lys Phe
Asp Gln Leu 1460 1465 1470 Leu Ala Glu Glu Lys Ala Ala Val Leu Arg
Ala Val Glu Glu Arg 1475 1480 1485 Glu Arg Ala Glu Ala Glu Gly Arg
Glu Arg Glu Ala Arg Ala Leu 1490 1495 1500 Ser Leu Thr Arg Ala Leu
Glu Glu Glu Gln Glu Ala Arg Glu Glu 1505 1510 1515 Leu Glu Arg Gln
Asn Arg Ala Leu Arg Ala Glu Leu Glu Ala Leu 1520 1525 1530 Leu Ser
Ser Lys Asp Asp Val Gly Lys Ser Val His Glu Leu Glu 1535 1540 1545
Arg Ala Cys Arg Val Ala Glu Gln Ala Ala Asn Asp Leu Arg Ala 1550
1555 1560 Gln Val Thr Glu Leu Glu Asp Glu Leu Thr Ala Ala Glu Asp
Ala 1565 1570 1575 Lys Leu Arg Leu Glu Val Thr Val Gln Ala Leu Lys
Thr Gln His 1580 1585
1590 Glu Arg Asp Leu Gln Gly Arg Asp Glu Ala Gly Glu Glu Arg Arg
1595 1600 1605 Arg Gln Leu Ala Lys Gln Leu Arg Asp Ala Glu Val Glu
Arg Asp 1610 1615 1620 Glu Glu Arg Lys Gln Arg Thr Leu Ala Val Ala
Ala Arg Lys Lys 1625 1630 1635 Leu Glu Gly Glu Leu Glu Glu Leu Lys
Ala Gln Met Ala Ser Ala 1640 1645 1650 Gly Gln Gly Lys Glu Glu Ala
Val Lys Gln Leu Arg Lys Met Gln 1655 1660 1665 Ala Gln Met Lys Glu
Leu Trp Arg Glu Val Glu Glu Thr Arg Thr 1670 1675 1680 Ser Arg Glu
Glu Ile Phe Ser Gln Asn Arg Glu Ser Glu Lys Arg 1685 1690 1695 Leu
Lys Gly Leu Glu Ala Glu Val Leu Arg Leu Gln Glu Glu Leu 1700 1705
1710 Ala Ala Ser Asp Arg Ala Arg Arg Gln Ala Gln Gln Asp Arg Asp
1715 1720 1725 Glu Met Ala Asp Glu Val Ala Asn Gly Asn Leu Ser Lys
Ala Ala 1730 1735 1740 Ile Leu Glu Glu Lys Arg Gln Leu Glu Gly Arg
Leu Gly Gln Leu 1745 1750 1755 Glu Glu Glu Leu Glu Glu Glu Gln Ser
Asn Ser Glu Leu Leu Asn 1760 1765 1770 Asp Arg Tyr Arg Lys Leu Leu
Leu Gln Val Glu Ser Leu Thr Thr 1775 1780 1785 Glu Leu Ser Ala Glu
Arg Ser Phe Ser Ala Lys Ala Glu Ser Gly 1790 1795 1800 Arg Gln Gln
Leu Glu Arg Gln Ile Gln Glu Leu Arg Gly Arg Leu 1805 1810 1815 Gly
Glu Glu Asp Ala Gly Ala Arg Ala Arg His Lys Met Thr Ile 1820 1825
1830 Ala Ala Leu Glu Ser Lys Leu Ala Gln Ala Glu Glu Gln Leu Glu
1835 1840 1845 Gln Glu Thr Arg Glu Arg Ile Leu Ser Gly Lys Leu Val
Arg Arg 1850 1855 1860 Ala Glu Lys Arg Leu Lys Glu Val Val Leu Gln
Val Glu Glu Glu 1865 1870 1875 Arg Arg Val Ala Asp Gln Leu Arg Asp
Gln Leu Glu Lys Gly Asn 1880 1885 1890 Leu Arg Val Lys Gln Leu Lys
Arg Gln Leu Glu Glu Ala Glu Glu 1895 1900 1905 Glu Ala Ser Arg Ala
Gln Ala Gly Arg Arg Arg Leu Gln Arg Glu 1910 1915 1920 Leu Glu Asp
Val Thr Glu Ser Ala Glu Ser Met Asn Arg Glu Val 1925 1930 1935 Thr
Thr Leu Arg Asn Arg Leu Arg Arg Gly Pro Leu Thr Phe Thr 1940 1945
1950 Thr Arg Thr Val Arg Gln Val Phe Arg Leu Glu Glu Gly Val Ala
1955 1960 1965 Ser Asp Glu Glu Ala Glu Glu Ala Gln Pro Gly Ser Gly
Pro Ser 1970 1975 1980 Pro Glu Pro Glu Gly Ser Pro Pro Ala His Pro
Gln 1985 1990 1995 6112PRTArtificial SequenceSynthetic peptide
61Ala Cys Gly Met Pro Tyr Val Arg Ile Pro Thr Ala 1 5 10
6212PRTArtificial SequenceSynthetic peptide 62Ala Gly Cys Met Pro
Tyr Val Arg Ile Pro Thr Ala 1 5 10 6311PRTHomo sapiens 63Leu Met
Lys Asn Met Asp Pro Leu Asn Asp Ile 1 5 10 6412PRTHomo sapiens
64Leu Met Lys Asn Met Asp Pro Leu Asn Asp Asn Val 1 5 10
6515PRTArtificial SequenceSynthetic linker peptide 65Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15
* * * * *